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Abstract
Polycystic Ovary Syndrome (PCOS) is a common disorder of chronically 
abnormal ovarian function and hyperandrogenism whose clinical effects 
include oligomenorrhoea and hirsutism. It has been determined that the 
principal underlying defect is hyperinsulinaemia secondary to insulin 
resistance. Use of insulin sensitising agents in women with PCOS is 
becoming increasingly widespread. Trials with metformin, one such agent, 
enthusiastically report a wide range of benefits in metabolic, reproductive 
and clinical measures. We have shown that metformin treatment of women 
with polycystic ovary syndrome has the following effects;
• It may be more effective than Dianette in the treatment of hirsutism.
• It is effective in reducing weight and Improves lipid profiles in obese 
women with oligomenorrhea or a raised free androgen index.
• It reduces serum mullerian inhibiting substance in the circulation 
after protracted treatment (> 4months).
• It has effects upon adrenal androgen biosynthesis manifested by a 
reduction in circulating basal concentrations of 170HP.
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Summary
Polycystic Ovary Syndrome (PCOS) is a common disorder of chronically 
abnormal ovarian function and hyperandrogenism. It has been determined that 
the principal underlying defect Is insulin resistance. Use of insulin sensitising 
agents (ISAs), in women with PCOS is becoming increasingly widespread. Trials 
with metformin, an insulin sensitising agent, enthusiastically report a wide range 
of benefits in metabolic, reproductive and clinical measures. We wished to 
determine the answer to the following questions in relation to the role of 
metformin in the treatment of women with polycystic ovary syndrome.
• The efficacy of metformin compared with Dianette in the treatment of 
hirsutism (chapter 3).
• If different doses of metformin reduce weight and improve lipid 
profiles in obese and morbidly obese women (chapter 4).
« If metformin reduces serum mullerian inhibiting substance levels 
(chapter 5).
• If metformin directly influences adrenal androgen biosynthesis 
(chapter 6).
Chapter 3: Metformin treatment results in a greater reduction of hirsutism in 
women with PCOS when compared with Dianette. In this study we tested the 
hypothesis that reduction of insulin challenge by metformin treatment may reduce 
hirsutism in women with PCOS. This was explored by: 1) does metformin have 
an effect on hirsutism in women with PCOS, and 2) is metformin more or less 
effective than the 'gold standard’ treatment of Dianette.
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Patients (n=52) were randomised to receive either metformin (500mg tds) or 
Dianette® (ethinyl estradiol, 35ug; cyproterone acetate, 2mg) treatment for a 
duration of 12 months with assessments before treatment, at 6 months, and at 12 
months. Both objective and subjective methods of evaluating hirsutism were 
used and, in addition, patient perceptions were examined. The results show that 
metformin is potentially an effective treatment for moderate to severe hirsutism in 
women with PCOS. They also suggest that, in some respects (Ferriman Gallwey 
score, and patient self-assessment), it is more efficacious than the standard 
treatment (Dianette®). The objective evaluation of hair diameter, showed that 
both treatments were moderately effective in reducing mean diameters at multiple 
anatomical sites. Dianette reduced hyperandrogenaemia significantly, and 
metformin reduced hyperinsulinaemia significantly. This suggests that hirsutism 
may be effectively treated by reducing hyperinsulinaemia.
Chapter 4: Reduction of weight and improvement of lipid profiles using 
metformin in obese and morbidly obese women with PCOS
The aim of this study was to determine whether different doses of metformin 
(1500 or 2550mg per day) could have different effects upon weight reduction, and 
circulating hormone and markers of inflammation and lipid profile parameters. 
Eighty two patients categorised as obese (Ob, BMI 30 to<37kg/m^; n= 42) and 
morbidly obeSe (Mob,"BfVII >37kg/m^; n=41) started treatment and 68 (82%) 
completed the course with assessments at the start, and at 4 and 8 months. Both 
the degree of weight reduction and the degree of suppression of circulating 
androstenedione in obese women (the Ob group) were dose related, but no 
similar relationship was established for the Mob group. Although generally 
beneficial changes in cardiovascular risk markers were recorded, there was no
23
relationship with either BMI category or metformin dose. Weight loss is a feature 
of protracted metformin therapy in women with PCOS, with greater weight 
reduction potentially achievable with higher doses of metformin.
Chapter 5: Reduction of Mullerian Inhibiting Substance using metformin in 
women with PCOS
The objective of this trial was to assess ovarian responses to metformin 
treatment in obese women with PCOS by randomization to 2 different doses of 
metformin treatment. Eighty-two obese women with polycystic ovary syndrome 
(PCOS) were recruited and markers of ovarian function were assessed after 4 
and 8 months. The main outcome measures were reproductive hormone changes 
over time, primarily being those of androgens and mullerian inhibiting substance. 
Our results showed that there was no difference in the reproductive hormone 
changes between the doses of metformin. Significant responses to treatment 
were recorded for menstrual frequency and androstenedione (reduction) within 
the first 4 months of treatment. However, suppression of the elevated circulating 
MIS concentrations required protracted treatment, as no change was observed in 
the first 4 months -  only in the second 4 month assessment period. This may be 
secondary to the development of a cohort of follicles, which underwent initial 
recruitment in an environment of reduced insulin stimulation.
Chapter 6: Adrenal androgen biosynthesis directly influenced by metformin 
treatment in women with PCOS
This study aims, by suppressing ovarian function using a gonadotrophin releasing 
hormone analogue (GnRHa), to measure adrenal steroid output alone in
24
response to a provocation test (short synacthen test) and in this way determine 
the effect of metformin on adrenal androgen output. A total of 18 
hyperandrogénie women with PCOS, and 9 controls (women without PCOS) 
completed the trial. Assessments were performed at baseline (TO), two weeks 
(T2), and four weeks (T4). The main outcome measures were reproductive 
hormone changes, primarily being those of adrenal androgens. Our results 
suggest that GnRH-A suppression of ovarian activity had little effect upon the 
responses of 170HP to standard synacthen tests or upon basal circulating 
concentrations of 170HP of adrenal origin in controls or women with PCOS. 
However, in women with PCOS, combined GnRH-A and metformin induced 
reductions in both the 170HP_AUC and also circulating basal concentrations of 
170HP. This implies that metformin treatment was responsible for suppression 
of both basal adrenal biosynthesis of 170HP and its responses to exogenous 
ACTH stimulation. This suggests that the activity P450-17a hydroxylase may be 
abnormal in women with PCOS in the adrenal as well as the ovary, and that 
excessive insulin stimulation is the underlying controlling factor.
25
Conclusion
The collection of trials contained in this thesis attempts to further elucidate the 
role of insulin sensitising agents in women with polycystic ovary syndrome. 
Metformin has been shown to be effective treatment for hirsutism, reduce serum 
mullerian inhibiting substance after protracted time, potentially have an effect of 
reducing weight in the obese when used in increased doses, and to induce 
reductions in both the 170HP__AUC and also circulating basal concentrations of 
170HP suggestive of an abnormality in the enzyme P450-17a hydroxylase in the 
adrenal gland. This is in addition to beneficial effects on menstrual cyclicity, lipids, 
and reproductive hormones possibly by amelioration of insulin resistance.
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Chapter 1
Introduction
1.0 General Introduction
1.0.1 Polycystic ovary syndrome, insulin resistance and insulin 
sensitising treatments
Polycystic Ovary Syndrome (PCOS) is a common disorder of chronically 
abnormal ovarian function and hyperandrogenism affecting 5-10% of the female 
population of reproductive age (1). The primary aetiology remains unclear and 
historically there has been no consensus on absolute defining features of the 
phenotype. At the National Institutes of Health Conference in 1990, three key 
features of PCOS were generally agreed as oligomenorrhoea, hyperandrogenism 
(clinical or laboratory evidence), and the absence of other endocrine disorders 
(congenital adrenal hyperplasia, hyperprolactinemia, thyroid dysfunction and 
androgen secreting tumours) (2). The presence of polycystic ovaries, determined 
by ultrasound evaluation, was not included in this definition but this feature is 
mandatory in many centres. More recently, at the Rotterdam ESHRE/ASRM- 
Sponsored PCOS Consensus Workshop in 2003, it was concluded that PCOS is 
a syndrome of ovarian dysfunction along with the cardinal features 
hyperandrogenism and polycystic ovary (PCO) morphology. As PCOS remains a 
syndrome, no such single diagnostic criterion (ie hyperandrogenism or PCO) is 
sufficient for clinical diagnosis (3). Correspondingly, the agreed definition now 
rests upon demonstration of at least 2 of the following 3 criteria: oligo- or 
anovulation, clinical and/ or biochemical signs of hyperandrogenism, polycystic
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ovaries determined by ultrasound examination, and exclusion of other etiologies. 
Patients with PCOS tend to present at clinics complaining of infertility, menstrual 
disturbance or hirsutism, with or without acne. They are therefore seen by 
gynaecologists, primary care physicians, endocrinologists and dermatologists.
A link between perturbed insulin action and PCOS was first highlighted in 1980 
(4). Subsequent studies over two decades have convincingly shown insulin 
resistance to be an integral pathogenic feature of PCOS, particularly in obese 
individuals (5, 6). Current data indicate insulin resistance in both adipose tissue 
and skeletal muscle in PCOS (7). The associated hyperinsulinaemia may directly 
promote ovarian androgen secretion, and abnormal follicular development, which 
ultimately leads to dysfunctional ovarian and menstrual activity (8).
Androgens are carried in the circulation bound to sex hormone binding globulin 
(SHBG) with high affinity. Conditions of increased androgen concentrations and 
hyperinsulinaemia are associated with reduced circulating SHBG, which results in 
high levels of free androgen activity (9). Thus, clinical manifestations of androgen 
activity (hirsutism, acne and alopecia) may depend upon the SHBG activity as 
well as the total circulating androgen concentrations.
Other metabolic abnormalities commonly linked to insulin resistance are also 
evident in patients with PCOS and they include dyslipidaemia (10), increased 
concentrations of tissue plasminogen activator (t-PA) (11), and low-grade chronic 
inflammation (12). In line with these metabolic features is emerging evidence that 
patients with a history of PCOS, or its surrogate marker oligomenorrhoea, have 
an increased risk of diabetes and cardiovascular disease later in life (8, 10,13, 
14).
Until recently treatments in PCOS have been targeted towards the 
symptoms/signs of the disorder: ovulation induction for infertility, and anti­
androgen therapy for hirsutism. In clinical terms, the most important consequence
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of recognising the role of insulin resistance in PCOS is the possibility of 
therapeutic intervention using insulin sensitising agents (ISAs) at a more 
fundamental level (Figure 1.1). As a result, numerous trials of ISAs in PCOS have 
been reported since 1994. Non-randomised trials with metformin enthusiastically 
report a wide range of benefits in metabolic, reproductive and clinical measures. 
However, close inspection of results from the adequately controlled studies using 
metformin in PCOS are much more modest. This is reflected in the meta-analysis 
in the Cochrane Library Review by Lord et al (15) and also our systematic review 
(16). These reviews of randomised controlled trials using insulin sensitising 
agents in women with PCOS found that metformin, an insulin sensitising agent is 
an effective treatment for anovulation in women with PCOS. This introduction is 
a summary of the data from what we consider to be the most robust trials.
1.1 insulin Sensitising Agents
Insulin sensitising agents, products that enhance tissue sensitivity to insulin 
action in vivo, have been used in type 2 diabetes for many years, and the ISA 
used most commonly in clinical practice is metformin. It is an oral biguanide 
antihyperglycaemic drug used for many years in Europe and is now also widely 
employed worldwide. Newer agents include the thiazolidinedione group of drugs 
of which the most widely used in the recent past is troglitazone. Unfortunately its 
hepatic toxicity has led to its removal, but a newer generation is now available 
including rosiglitazone (Glaxo Smith Kline (GSK)) and pioglitazone (Takeda). 
Finally, D-chiro-inositol has been used with some success as an ISA in women 
with PCOS (17) but other clinical data are lacking.
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1.1.1 Metformin
Metformin is thought to have primary effects on increasing peripheral glucose 
uptake in response to insulin, perhaps via effects at the post-receptor level, with 
some reduction in basal hepatic glucose production (18). However, it also lowers 
adipose tissue lipolysis and improves insulin sensitivity in muscle (19). Recent 
data suggest a unifying role of AMP-activated protein kinase in all the 
mechanisms of metformin action (20). It does not provoke hyperinsulinaemia and 
as such does not cause hypoglycaemia. It is now recommended as first line 
therapy in overweight patients with diabetes by most leading clinical associations 
(e.g. SIGN guidelines. Diabetes UK). It is also inexpensive.
1.1.1.1 Non-randomfsed trials of metformin In PCOS
Early ISA trials in PCOS, between 1994 and 1997 were mainly with metformin 
(21). The majority were cohort design and showed an improvement in insulin 
metabolism and a reduction in circulating androgen concentrations (22-32). In 
most cases, small reductions were seen in either BMI and/or waist-hip ratio 
measurements, and improvements in menstrual cyclicity (presumed ovulation) 
were also determined. Only one of these trials examined the effect of metformin 
on hirsutism and there were no data pertaining to acne (30). In general, the 
results were encouraging, but all trials involved small patient numbers, most were 
of short duration, and limited in design by not having a control or placebo arm 
(22-32). More importantly, none of these trials assessed ovulation incidence 
directly using frequent hormonal measurements.
More recent uncontrolled studies have confirmed the observations that metformin 
treatment effectively lowered insulin and androgen concentrations, but provided 
more specific evidence to support an improvement in menstrual cyclicity with
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metformin (33-41). The range of perceived benefits in uncontrolled studies is 
considerable, with trials achieving normal menstrual frequency from 16% (n=4 of 
24 cases) (30) to over 90% (39 of 43 cases) (34) of women with PCOS.
1.1.1.2 Results from controlled studies
Presented in this chapter are seven published metformin studies that have 
included some form of randomisation (i.e. control arm with or without placebo), of 
which five have also been double blind in design (42-48). The details of these are 
summarised in Table 1.1. Clearly, most attention should be focused on these 
studies due to the potential for bias in uncontrolled investigations. The data show 
that measures of obesity (e.g. BMI, waist to hip ratio) were reduced in 6 out 7 
studies and insulin action and the SHBG / androgen axis improved in 5 out of the 
7 studies with active treatment. Table 1.2 shows detailed analyses of the pre- and 
post- treatment data for BMI, fasting insulin concentration, SHBG and androgen 
measures in the principal studies. It demonstrates that they examined a wide 
range of patients with respect to pre-treatment fasting insulin levels and BMI. The 
most consistent findings are reductions in BMI of around 4% and in androgen 
measures of around 20% relative to placebo. The data on improvements in 
insulin level and, in particular SHBG are less convincing when considered 
together with placebo data. These observations show the potential for 
confounding effects during any prospective studies, re-emphasising the 
importance of control in study design.
1.1.1.2.1. Ovulation
With respect to ovulation, the significant observations include i) that the interval 
from start of treatment to first ovulation is significantly reduced and ii) menstrual
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or ovulation cyclicity is increased with the metformin groups compared to 
placebo, and that iii) these improvements are variable and relatively modest 
(Table 1.3). Table 1.3 shows a compilation of comparable ovulation data 
extracted from five of the seven controlled publications, all of which present their 
original data in different formats. However, they show that, on average, one 
additional ovulation is attained every five months with metformin treatment. 
Specifically, the increase is from 1 ovulation per 5-month interval to 2 in 5. It 
should be emphasised that these results relate to relatively short-term 
observations (up to 6 months), and that protracted treatment combined with 
weight loss may result in a higher frequency of normal ovarian function. Lord et 
al also found that metformin is an effective treatment for anovulation in women. In 
its ability to induce ovulation, metformin versus placebo showed an odds ratio of 
3.88 (Cl 2.25 to 6.69) (15).
1.1.1.2.2. Time-scale of responses and ovulation
Spontaneous ovulation can occur rapidly and normal menstrual rhythm can be 
achieved within 3 months of starting therapy (42, 45). In a number of studies, an 
increased ovulation rate occurred with no change in weight suggesting that this 
effect is independent of weight loss (33, 35, 38, 42, 43). More recently, a 
randomised controlled double blind trial by Baillargeon et al found an increase in 
ovulatory frequency (measured by weekly progesterone levels) and amelioration 
of hyperandrogenaemia using insulin sensitising agents (metformin 850mg bd/ 
pioglitazone 4mg bd/combination/ placebo) in nonobese women with PCOS who 
appeared to have normal insulin sensitivity (49), again suggesting that metformin 
has actions independent of those of weight loss.
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1.1,1.2.3 Metformin in infertility: alone and in conjunction with 
clomiphene, FSH and in IVF
Metformin does not require intensive monitoring and current data and logic 
indicate a negligible risk of ovarian hyperstimulation and multiple gestation when 
used alone (47). It thus has potential merit as the first line treatment for ovulation 
induction (15).
Infertile women tend to demand a rapid resolution to their problems. If ovulation 
has not occurred within 12 weeks, then the anti-estrogen clomiphene citrate 
treatment may be added. When clomiphene citrate was used after metformin pre­
treatment (42, 48) ovulation rates were higher than those achieved with placebo 
and clomiphene citrate (88% of patients, compared with 64%, respectively)
(Table 1.4). Thus, metformin as co-treatment with clomiphene citrate appears to 
be successful, perhaps by sensitising follicles to FSH. Therefore, it has been 
proposed that metformin, in the first instance alone, and subsequently in 
combination with clomiphene citrate, be used in a sequential treatment 
programme prior to the use of gonadotrophin therapy for ovulation induction in 
infertile women with PCOS (50, 51). As per Lord et al the odds ratio for metformin 
and clomiphene citrate versus clomiphene alone for induction of ovulation was 
4.41 (01 2.37-8.22) (15).
Metformin has also been shown to possibly enhance/improve responses to 
ovulation induction with exogenous FSH stimulation. De Leo et al randomised 20 
women with clomiphene-resistant PCOS to receive either FSH alone or FSH 
following 1 month pre-treatment of metformin 500mg tds (52). Compared to FSH 
alone, FSH plus metformin resulted in fewer dominant follicles (2.5 vs 4.5, 
P<0.01), a lower peak oestradiol and a lower cycle cancellation rate (0% vs 32%, 
P<0.05). Similarly, metformin treatment of PCOS patients undergoing in vitro
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fertilisation may appear to improve outcome. Forty-six women with clomiphene- 
resistant PCOS, received daily metformin (1000 to 1500 mg) in half of 60 cycles 
prior to gonadotrophin treatment. In patients treated with metformin, the total 
number of follicles on the day of hCG treatment was decreased but there were 
more mature oocytes and both the fertilisation rate and the clinical pregnancy 
rate were significantly higher (Table 1.4) (40). George et al compared sequential 
6 months combined treatment with metformin and clomiphene citrate with low 
dose gonadotrophin in clomiphene citrate-resistant PCOS women (53). Forty-five 
percent of women in the metformin group had improved menstrual and ovulatory 
function, whilst pregnancy rates were equal (16.7 vs 23.3%). However, more 
recently, Kjotrod et al in a prospective randomised double blind study found that 
pre-treatment with metformin (lOOOmg bd) prior to conventional IVF/ICSI in 73 
women with PCOS did not improve stimulation or clinical outcome (54).
Although there are issues of gonadotrophin dose and variable sensitivity in these 
observations, metformin pre-treatment may allow a more orderly follicular growth 
in response to exogenous gonadotrophins. Table 1.4 shows that the evidence 
currently supporting this proposal whilst encouraging, has significant limitations. 
Thus, future prospective definitive studies should be undertaken (Table 1.5).
In summary, metformin appears to facilitate follicular growth and maturation in 
spontaneous and induced cycles leading to improved ovulation and pregnancy 
rates, whether given alone, or in conjunction with clomiphene citrate, or 
exogenous FSH.
1.1.1.2.4 Metformin treatment continued into pregnancy
Consistent with improved ovulation rates is an improvement in the spontaneous 
pregnancy rate in several trials (35, 38, 40). With respect to pregnancy.
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metformin is a category B agent, i.e. no evidence exists of animal or human fetal 
toxicity or teratogenicity (50, 55). Current conservative practice would 
recommend removal of treatment once pregnancy has been established. Two 
retrospective analyses (56, 57) of metformin treatment continued through the first 
trimester have suggested reduced rates of pregnancy loss, but data from a more 
recent prospective study did not support this effect (58). This area requires much 
more work before any recommendations can be made.
It is not known whether this apparent beneficial effect of metformin treatment is 
due to improved oocyte / embryo developmental potential, or improved 
implantation. If the latter were the case, then continuation of therapy into 
pregnancy would be advised, while the former would lead to no change in the 
advice to withdraw treatment at establishment of pregnancy. These elements 
demand formal prospective clarification, as do a number of clinical issues 
associated with metformin and pregnancy, including the well-being of the mother 
through pregnancy, and also the neonate (Table 1.5). Metformin has been used 
to treat diabetes in the second and third trimester in pregnancy (after the principal 
teratogenic period) and have suggested no increased perinatal morbidity 
although an increase in the incidence of neonatal jaundice was noted (59). A 
recent report of 118 diabetic pregnancies that involved use of an oral 
hypoglycaemic agent suggested an association of metformin treatment in the 
third trimester with a significantly higher perinatal mortality and prevalence of pre­
eclampsia (60). However, compared to the reference group of women treated 
with insulin or sulphonylurea, women given metformin had significantly higher 
pre-pregnancy BMI (24.8 & 22.8 vs 31.2 kg/m^, respectively) and were older. This 
difference in baseline characteristics, rather than metformin per se, might have 
accounted for the study findings.
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1.1.1.2.5 Caveat: metformin and pregnancy in obese women
Many patients with PCOS are obese, and pregnancy complications are linked to 
maternal obesity. Therefore pregnancies achieved in women with PCOS using 
metformin may lead to a greater proportion of adverse obesity-related pregnancy 
complications. If metformin is used prior to and continued through pregnancy, 
then carefully designed prospective and ideally randomised trials of metformin in 
pregnancy are required to determine pregnancy outcomes in mother and 
neonates (Table 1.5). There is also the ethical issue of assisting grossly obese 
women to achieve pregnancy when the mother and baby are at increased risk 
under normal circumstances (61) in the absence of a weight loss programme 
prior to conception.
1.1.1.2.6 Metformin and ovulation: prediction of who will benefit
There is little published evidence concerning this important issue. It is predicted 
that metformin should have best results on ovulation rates in infertile women who 
are most insulin resistant (provided the dose schedule Is satisfactory). However, 
the picture is not entirely clear. Moghetti et al found that higher BMI, plasma 
insulin, lower serum androstenedione, and less severe menstrual abnormalities 
were baseline predictors of clinical efficacy measured by improved menstrual 
cyclicity (43). In contrast, sub-group analysis in the large randomised study by 
Fleming et al revealed that BMI and insulin measures did not predict the ability to 
establish normal ovarian function, but high SHBG and lower free androgen index 
did (47). However, in the meta-analysis by Lord et al, it is suggested that it would 
be potentially beneficial to investigate those who have the greatest initial 
hyperandrogenaemia and/or hyperinsulinaemia, as the review found no effect on 
weight loss or change in body fat distribution as assessed by waist:hip ratio (15).
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One of the factors to be resolved at this stage is the relationship between dose 
and body mass. It is also not correct to assume that lean women with PCOS will 
not respond to metformin treatment. Nestler and Jakubowicz have shown 
significant reductions in insulin response to glucose load and androgen levels in 
lean PCOS women (mean BMI of 21.7 kg/m^) with metformin 500mg tds despite 
no change in BMI but WHR was reduced in the active group alone (6). More 
recently this is supported by Maciel et al in a randomised controlled study of 29 
obese and non-obese patients with PCOS treated with metformin (1.5g/day) for 6 
months (62). In this trial, non-obese women demonstrated increased 
responsiveness with regard to androgen levels, menstrual cyclicity, and metabolic 
features. However, they did not employ interval progesterone levels to objectively 
assess ovulation.
1.1.1.2.7 Metformin use for women wishing cycle regulation but not 
pregnancy?
The data discussed above indicates that metformin alone will not restore normal 
menstrual cyclicity in every woman with PCOS, at least in the short term. In fact, 
achieving normal ovarian function appears to occur in less than half of those 
women prescribed metformin at current doses. Thus, in women not wishing to 
become pregnant, the oral contraceptive pill may be a better agent to regulate 
cycles. However, these women tend to be insulin resistant, which is a state that 
is exacerbated by oral contraception (63), although the clinical relevance of such 
effects requires clarification. The use of the combined oral contraceptive is 
cautioned in obese women (BMI>30kg/m^) and contraindicated in morbidly obese 
women (BMI>37kg/m^). This should be taken into account when addressing this 
issue.
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1.1.1.2.8 Ovarian function, metformin and mullerian inhibiting 
substance
Mullerian Inhibiting Substance (MIS), a dimeric glycoprotein of the TGFp super­
family, is believed to act in a paracrine fashion after birth to regulate granulosa 
cell and oocyte function, and it may be an important regulator of follicular 
recruitment. Maximal expression is seen at the small antral follicle stage where 
there are also a large number of granulosa cells. Correspondingly, MIS has been 
found to be raised in the circulation of women with PCOS. A recent small trial by 
la Marca et al found that the HOMA score (a measure of insulin resistance) was 
positively related to serum MIS levels (64). However, there exists no other current 
data relating insulin and MIS levels. The effect of ISAs on circulating 
concentrations of MIS in PCOS has so far not been explored. In this thesis we 
undertook a trial to determine the effect of metformin on the relationship between 
MIS and other reproductive parameters in obese women with PCOS.
1.1.1.2.9 Metformin and adrenal androgens
High circulating androgen concentrations may be produced by either the ovary or 
by the adrenal gland. About 25% to 60% of women with hyperandrogenism 
display excessive adrenal androgen levels (65, 66). One of the effects of 
metformin (in the majority of studies) is to reduce the circulating androgen 
concentrations. However, it is difficult to detect by analysing serum androgen 
concentrations whether metformin is exerting its effects at the level of the ovary 
or the adrenal gland, or both. It has been hypothesized that the dysregulation of 
cytochrome P450-17a hydroxylase activity may be responsible for the 
abnormalities seen in both the ovary and the adrenal gland (67). Studies have 
shown that metformin treatment can influence the ovarian production of 17
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hydroxyprogesterone (170HP) through the activity of cytochrome P450-17a 
hydroxylase activity in women with PCOS (24, 67). However, the possibility of a 
contributory effect of adrenal origin was not explored. The study contained in this 
thesis attempts to examine whether suppression of ovarian function using a 
gonadotrophin releasing hormone agonist (GnRHa), and provoking adrenal 
function in the absence and presence of metformin, may reveal an effect of 
metformin upon adrenal steroid output.
1.1.1.2.10 Metformin and hirsutism
Six trials, other than our own have examined the treatment of hirsutism with 
metformin (1.5g to 1.7g daily) (30, 33, 36, 43, 45, 68). In only one of these was 
hirsutism the primary end-point (68). Three of the studies showed no change 
(30,33,43) and three demonstrated modest but statistically significant reductions 
in the Ferriman Gallwey (FG) score after metformin treatment. It is important to 
note that most of the trials were only of 3-6 months duration, and included 
relatively small numbers. In addition, no breakdown of anatomical site was 
included. Because of the duration of the average hair growth cycle, a response to 
any treatment is generally not seen within 6 months. At least 12 months should 
be allowed to optimise potential effects of treatment upon hair growth, so future 
trials need to be more focused, and of considerably longer duration. It is also 
important to point out that the mean FG scores pre-treatment in the studies 
published so far represented only moderate hirsutism (between 8 and 15). It may 
be that a larger effect may be seen with higher pre-treatment scores consistent 
with more severe hirsutism. In this thesis are presented the results of a trial we 
undertook to compare metformin with an established therapy. This was 
performed in a randomised manner, and an objective method of hair growth was 
employed.
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Prior to our study being undertaken, there was no evidence to support a clinically 
significant effect of metformin on hirsutism.
1.1.1.2.11 Metformin and acne
Other than our own study, described in detail later in this thesis, to date there is 
only one trial published addressing acne as a specific end-point. Kolodziejczyk et 
al found a statistically significant decrease in acne score from 1.45 to 1.14 
(p<0.001) (36). However, this trial was not placebo-controlled and the clinical 
significance of the decrease is uncertain. More data are required (Table 1.6).
1.1.1.2.12 Metformin in adolescents
A recent small (n=11) non-randomised study suggests that metformin (1.5 to 2.55 
g/day) can achieve normal menstrual frequency in teenage girls in association 
with weight loss and reductions in testosterone concentration (69). The data are 
consistent with results in adult women with PCOS, but more rigorous, 
randomised studies are required.
1.1.1.2.13 Cardiovascular risk factors
Women with PCOS show increased cardiovascular risk factors compared to 
weight matched controls with normal ovarian function (10). The evidence is 
broadly consistent for deranged lipids and greater glucose intolerance in women 
with PCOS. Evidence of hypertension was less consistent. There are also 
preliminary data now for altered haemostatic (tissue plasminogen activator 
antigen) (11) and inflammatory (C-reactive protein concentrations) (13) factors. A 
recent trial by Boulman et al found that 36.8% women with PCOS had C-reactive 
protein (CRP) levels above 5mg/liter, and only 9.6% of controls exhibited high
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CRP levels (70). These subjects included 116 PCOS patients and 94 body mass 
index-matched controls. CRP is a strong independent predictor of future 
cardiovascular disease and/ or stroke. In line with such data, invasive and non- 
invasive tests have reported greater atherosclerotic burden in PCOS, in different 
vascular beds (12). Moreover, a recent prospective study has linked menstrual 
irregularity, approximately 80% of which is due to PCOS, to elevated risk of fatal 
CHD (14).
In clinical terms, all women with PCOS should have an assessment of fasting 
glucose to screen for diabetes. However, determination of lipid profiles will not 
alter management, according to current data, until these women reach the age of 
35 - 50, unless there are significant other risk factors, such as obesity or family 
history.
1.1.1.2.14 Cardiovascular parameters and metformin
Four of the studies in Table 1.1 (43, 44, 46, 47) examined circulating lipid profiles 
before and after 4 to 6 months treatment, and in comparison with controls. Two 
showed an increase in HDL-cholesterol concentration of around 0.10 mmol/L with 
metformin, and a trend towards lower LDL-cholesterol levels was also noted in 
one. One reported a significant reduction in free fatty acid concentrations (44). 
These changes are in keeping with improvements in insulin sensitivity and also 
reduced body mass. Lord et al found that metformin had a significant effect on 
not only fasting insulin levels but also blood pressure and low density lipoprotein 
cholesterol (LDL) (15). However, larger and more focused studies are needed, 
examining established and novel risk factors for coronary heart disease in women 
with PCOS, such as inflammatory and clotting parameters. The potential effect of 
metformin on factors associated with chronic inflammation would be particularly
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important to establish, since a pro-inflammatory phenotype has now been linked 
to risk for diabetes and coronary heart disease in men and women (71, 72). 
Presented in this thesis are the results of a randomised trial we undertook, 
employing two differing doses of metformin to examine the effects on not only 
weight loss but also a variety of parameters designed to examine risk factors 
including lipids and C-reactive protein.
If women with PCOS are proven to be at excess risk for CHD and type 2 
diabetes, then there may be a case for long term treatment with metformin. The 
United Kingdom prospective diabetes study (73) showed that metformin 
treatment was more effective in reducing CHD risk than either insulin or 
sulphonylurea. More recently, the Diabetes Prevention Program Research Group 
examined the effects of metformin, life-style modification or placebo, during a 4 
year prospective programme, upon the incidence of onset of type 2 diabetes in 
non-diabetic persons with elevated glucose concentrations (74). They showed 
that metformin treatment resulted in a 31% reduction in the incidence of diabetes, 
compared with placebo. Interestingly, they demonstrated that intensive life-style 
intervention, involving at least a 7% weight loss and at least 150 minutes of 
physical activity per week, was associated with a much greater (58%) reduction 
in the incidence of diabetes onset. A similar reduction in BMI in PCOS women 
can improve ovarian function and fertility (75, 76) and thus, there is a strong basis 
to emphasise the enormous benefits women with PCOS could achieve with 
lifestyle measures alone. In particular, the fact that such benefits can exceed 
effects of any pharmaceutical intervention should be strongly stressed.
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1.1.1.2.15 Side effects with metformin
Side effects of metformin like nausea, vomiting, and diarrhoea may cause 
difficulties initially, leading to problems with compliance (47). Many physicians 
use a graduated dosing system, increasing dose on a weekly basis to attempt to 
ameliorate this problem. A reduced frequency of dosing may be preferred when 
attempting to optimise patient compliance and as a result some advocate 
switching from a dosage regimen of 500mg tds to 850mg bd. However, the use of 
850mg tablets in the study by Fleming et al (47) showed a three-fold higher 
dropout rate in the metformin group compared to placebo. This drawback has not 
been reported in other studies. Finally, a sustained release form of metformin 
(Glucophage XR) is now available with a reported side effect profile similar to 
placebo.
1.1.1.2.16 Contraindications to metformin treatment
As metformin is contraindicated in patients with hepatic or renal impairment 
caution must be taken prior to commencing patients on this treatment. Thus, liver 
and renal function testing is necessary in advance of prescription and thereafter 
yearly testing on treatment in indicated. Treatment is also contraindicated in 
conditions that predispose to lactic acidosis.
1.1.2 Thiazolidinediones
The thiazolidinediones sensitize peripheral tissues to insulin. They are synthetic 
ligands that bind to an orphan nuclear receptor called peroxisome proliterator- 
activated receptor gamma (PPARy) and affect the expression of a number of 
genes. Thiazolidinediones bind to the orphan nucleotide receptor PPAR gamma 
which after dimérisation with the retinoid X Receptor (RXR) enters the nucleus.
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The complex of receptors interacts with peroxisome proliferator responsive 
elements (PPRE) which activate the transcription of a number of genes involved 
in lipid and glucose metabolism. Observed effects of thiazolidinediones include 
increased glucose transporter expression (GLUT 1 and GLUT 4), decreased 
hepatic glucose output, decreased free fatty acid levels, and increased 
differentiation of preadipocytes into adipocytes. Troglitazone, which is now 
unavailable, due to reports of hepatic toxicity, is the most researched agent of the 
thiazolidinediones in the context of PCOS.
Initial trials with this agent by Dunaif et al (22) and Ehrmann et al (23) showed 
improvements in insulin metabolism, androgen, SHBG, LH, and oestrogen 
concentrations, and an improvement in reproductive function in women with 
PCOS.
As a follow up to the above data, an exemplary, large multicentre, dose- 
determining study with troglitazone has been carried out (77). The trial included 
410 women with PCOS in a multicentre, double blind study over a 44-week 
period randomised to either placebo or 3 different dosages of troglitazone. Three 
hundred and five (74.4%) patients completed the study. They found that ovulation 
rates were significantly higher for patients treated with SOOmg and 600mg 
troglitazone daily than for those receiving placebo. Fifty seven percent ovulated 
over 50% of the time in the 600mg troglitazone arm compared with 12% of 
placebo treated patients. Although not an entry criterion to this study, it was found 
that approximately 50% of the patients had a Ferriman Gallwey (FG) score of 6 or 
more prior to treatment, representing normal to moderate hirsutism. The mean 
basal FG scores were of the order of 14 in each arm. There was a dose-related 
decrease of 15% in the FG score by 20 weeks therapy that was only statistically 
significant with a dose of troglitazone 600mg. The authors also found that 600mg 
troglitazone reduced circulating insulin by 53%, and the insulin response to an
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oral glucose challenge by 45%. There was also a decrease in circulating free 
testosterone concentrations, and a rise in SHBG.
Clearly, the above data pave the way for studies with newer PPARy activators, 
such as rosiglitazone and pioglitazone in women with PCOS. These agents 
appear to avoid the hepatic side effects reported for troglitazone and are 
increasingly used in the management of patients with type 2 diabetes. They also 
appear to reduce surrogate risk factors for vascular disease and large 
prospective multicentre trials are underway to determine whether they lessen 
CHD risk and incidence of diabetes type 2. More recently, Legro et al studied 398 
women with polycystic ovary syndrome and dyslipidaemia associated with insulin 
resistance (78). Troglitazone (3 different doses) or placebo were randomly 
assigned and taken for 44 weeks. There was no significant response of any of 
the circulating lipids to treatment with either placebo or one of the troglitazone 
arms. Further treatment and surveillance may be required.
1.1,2.1 Caveats of thiazolidinedione treatment
There are two notes of caution when considering the use of these agents in 
PCOS, however. Firstly, like troglitazone, they tend to increase body mass, and 
as many women with PCOS are already overweight then this can be an 
unwelcome effect. Secondly, and more importantly, although pregnancy has 
been reported in a woman with PCOS following treatment with rosiglitazone (79) 
these are pregnancy class C drugs which means that there is evidence of 
teratogenicity in animal studies including lethality. Specifically, fetal growth 
restriction has been noted and attributed to a reduction in the maternal 
hyperinsulinaemia and insulin resistance that occurs during pregnancy thereby
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reducing the availability of metabolic substrates for fetal growth. Clearly, these 
findings mean that extreme caution must be taken with human studies.
1.2 Conclusion
We performed our own review of what we considered the best available evidence 
on the use of metformin in women with PCOS (Table 1.6 presents a summary of 
findings). There was considerable variation in the patients examined and the 
methods of assessment used, but a consistent yet moderate improvement in 
ovarian function was established. It is evident, that on average, women treated 
with metformin have one more ovulatory event and menstrual period In every five 
months -  from one ovulation per five months to two. Thus, ovulation frequency is 
by no means restored to normal in every woman with metformin use. The 
accumulated data also suggests that metformin reduces weight by around 4% in 
women with PCOS. Lord et al found no effect on body mass index or waist:hip 
ratio.
Patients with symptoms related to PCOS are increasingly demanding treatment 
with metformin, regarding it as the panacea for their symptoms. They are 
receiving treatment for unlicensed indications, and often outside the research 
environment. The knowledge base supporting these actions does not exist, with 
the exception of ovulation induction.
To date, all studies reported have been investigator led, and existing evidence is 
of insufficient validity for pharmaceutical companies to proceed to licensing 
procedures. Therefore, it is important that clinicians counsel women 
appropriately prior to commencement of metformin therapy.
Many aspects of ISAs and PCOS remain to be determined definitively including 
those of ovulation induction and infertility treatment. These include the
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complications and outcomes of pregnancy in obese women, and metformin dose 
and its relation to body mass. Prior to this thesis data on effects on hirsutism and 
acne were limited, such that no recommendations could be made. In this thesis 
we have attempted to address the existing knowledge base to provide some 
answers to further elucidate the action of metformin in women with PCOS.
The aims of this thesis were to address the dearth of information in the 
following areas;
1) To determine the efficacy of metformin compared to Dianette in the 
treatment of hirsutism in women with polycystic ovary syndrome.
2) To examine the effects of different doses of metformin in obese women 
with PCOS: roles in weight reduction and improvement in lipid profiles.
3) To investigate the role of Mullerian Inhibiting Substance in obese women 
with PCOS, and to determine the effects of metformin treatment.
4) To determine if metformin directly influences adrenal androgen 
biosynthesis in women with polycystic ovary syndrome.
These examinations were all intended to provide more substantial evidence in the 
area of insulin metabolism and PCOS, at the same time as compounding the 
information regarding the use of metformin in PCOS. We would have expected 
to produce many questions from these explorations, and indeed they have been 
forthcoming, but at the same time, I believe that some important questions have 
been answered.
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Figure 1.1
The postulated role for insulin sensitising agents in the scheme describing the 
range of consequences linked to insulin resistance in women with PCOS.
Insulin resistance 
Obesity
Role for insulin sensitising agents?...
E n d o c r i n e
m a n i f e s t a t i o n s i ; M e t a b o l i cm a n i f e s t a t i o n s
tlns.ulln
Ovary AdrenalsLiver
iSHBG
Î Androgen activity
C l i n i c a l
p r e s e n t a t i o n
Glucose intolerance
Dyslipidaemia
Vascular dysfunction
i L o n g  t e r m  s e q u e l a e
Infertility/ Menstrual 
disturbance
Hirsutism
Vascular disease
48
(0
ÛXi.—
IIIEI
COIICO9
f
oi
1
ÿ.LU
üI
I
z
COÜ
k
gI
Ü
Ë= )
CO
cI
IQ
c.e8Q
0!i
s
s s
I I
II
Is
>
Pi
CO3og
(0
I
I
IÎ
Ü
04
§O)Eog
Saa:
g
I
E
<D
lO
N
I
S8lO
g
E
D)
I
mI a
I
E
(O
I 1
Oz mCO
a Pi
Ii2
TOeE
(O
_0)8z IS’
49
< I
c
8
0)
m
0
1 1S
8 2
<0 0
< 3  0 E
fi
I
I
c
I
oz
<  E
| s
> -
00
s
s
E
§
ia: Ii(O
05P OTCI
z
S
S
(O
3
E§
CH
(Q
%
O )
00
à
ico
:X<r~ I
oo
g
2O)E§
:a:
S
I
Ë
> -
CD
cô
■OJQ
CDE§
ca
OÉ
CH
g
g
CL
0Co
0&
8
&
CM
I
CM I
O
1
I
0  
8î1ff
îjQ
_ 01X>
IIg
8It1I§II
I
0%
81E
0T3C
21
I
iIIIa
wc
êXIi
cI
II
il
50
cy
T—
.Q
[2
8■a
ÎE
8CL
0
8
C
1
mT3
i
S
I
■8
1
Î1Ec
&2 T5
<
I
I
<3JQ0O0 0CL CL
c <Ê1»o
1 2s Q.
<3OX0OisCL 2CL
c <3
Êi.o
1 2s CL
<.20o0 0CL CL
C <]
E ssh.o
1 2S (L
s0Û
a
00
Ô
R
o
+
CM
+
tp
CM
I
a
<3OJQ0Ujg 0CL cCL
.£ <1
o
5 2E CL
a>
0
0I
CO
h-
ô
CD
CO+
lO
8
+
CO
Î
CMto
CM
CM CO
O
t
in
CO m
01
§>
Z
I
g
CO
CO
CO m
CM CMCO CM CO
c
to 0CO "cô c
00
in
Ô
ocb
CO
+
in
00
o
CO
h -
ob
CO
in
8
9
9
O
t
CDà)CO
in
ob
oo
0  
0
1
-  ^  O ^
R
Î
N
cb
in
CO
CD
U>+
?
CM
%
S  5  % a .
0
0
z
o
CO
in
I
Z
«? in+
'M' CO
CM 00 CM
CO 00
CD cb R
op q> CD
4* CD+ +
h - CO 00
N inCO 5
N CD x t
t
CM CR
È CO
9
0 5
0
g1LL
0
0I
CM
CM
Î
m+
CO
CM
ID
Ô
0 
0 cI!
3I0a.
0  c
1
0
. i
QIII1§XI
0
"SÎICL
Î
E
1I
III0
CL
a
I
I
§CDI0I1
01IjQ
0CIii
II
j )gI
oc
Î
I!
Z
a  «I
£
I
ECL
0ÜCITO
5j
sIjgI:>
a
I
51
Table 1.3
Examination of ovulation/cyclicity data in relevant trials including, where 
possible, extraction of cycles per hundred patient months during placebo and 
metformin phases.
Cycles per hundred patient 
months
A in ovulation parameters Placebo Metfoimin Difference
rates rates
Nestler et al^ ® ovulation 34% M, 4% P 4 34 30
+ clomiphene: 90% M, 8% P
Moghetti et al®® tO.35 cycles/month 22 59 37
tcycles 50% women (M), no 
AP
Morin-Papunen time between periods 32* 44 12
et al'*® M=98 to 69 days, D=88 to 28
Pasquali et al^  ^ tcycle frequency 29 39 10
M>P
Ng et al'^  ^ Median ovulation rates 0% NA NA NA
in both M and P groups
Fleming et ai"^ ® normalised cycles M=30%, 18 30 12
P=18%
Days to ovulation M=23,
P=42
Kocak et al'^ Ovulations over 2 cycles: NA NA NA
M 78%, P 14%
Averages 21 41 20
M=metformin; P=placebo; D=Diane Nova
For a normally menstruating woman the cycles per hundred patient months 
column would =100.
*compared to baseline pre-treatment value as no placebo group.
NA -  data not available as either effect of metformin use alone'*'^  or mean 
ovulation rates'*  ^were not reported.
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Table 1.4
Summaiy of benefits of metformin use in ovulation induction and early pregnancy
Strength
of
Evidence
Spontaneous ovulation
With clomiphene
With FSH and Prior to 
IVF
Pregnancy Loss + /-
Magnitude Of Benefit Noted
Non-randomised trials; up to 90% 
improvement 
Randomised trials: 0-35% 
improvement
Ovulation rates 64-88% of cases 
higher than placebo
(compared with FSH alone) 
i  dominant follicles 
i  peak oestradiol 
>Lcycle cancellation rate (0% vs 32%)
more mature oocytes 
tfertilisation rate (64% vs 43%) 
tclinical pregnancy rate (70% vs 
30%)
73% prior to treatment Vs 10% with 
metformin
42% control group Vs 13% with 
metformin
35% spontaneous abortion rate in 
series of PCOS women given 
metformin up to 12 weeks gestations
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Table 1.5
Areas where more (prospective) data is required 
Areas for future studies
Dose studies and effects on ovulation 
Effects on stimulated ovarian function 
Lean women with PCOS 
Ethnic variability of response 
Compliance issues 
Acne and Hirsutism 
Early pregnancy loss 
Pregnancy outcome 
Neonatal outcome
Effects on surrogate risk factors for CHD
Longer term risk for diabetes & CHD
Effects of prolonged treatment
New insulin sensitising agents (ISAs)
Determination of baseline factors 
predicting benefit to ISAs
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Table 1.6
Summary of evidence for benefit in key areas
Key area Summary of evidence
Ovulation
Ovulation induction
Metformin treatment achieves only a modest 
improvement in ovulation rate; on average increasing 
from a baseline of one ovulation every five months to 
two.
Metformin enhances ovarian function when used in 
conjunction with clomiphene, but more data are 
needed.
Weight and androgens Metformin achieves modest reductions in body mass
and androgenicity.
Pregnancy
Hirsutism and acne
More precise controlled data are required on 
pregnancy and neonatal outcome. In particular, 
caution may need to be taken with ovulation induction 
in obese women with PCOS.
There exists insufficient evidence to warrant metformin 
for first line therapy for treatment of hirsutism and 
acne.
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Chapter 2
Patients and Methods
2.0 Summary
This chapter provides a description of the general protocols for the clinical and 
laboratory techniques used in the studies described in this thesis. All patient 
information sheets and data recruitment forms for the relevant trials are Included 
in the Appendix.
2.1 Location
Studies were performed at the Royal Infirmary (Glasgow) in the areas of Ward 
33, the Assisted Conception Unit, and the University Department of Obstetrics 
and Gynaecology, Division of Developmental Medicine.
2.2 Patients
Patients with PCOS and controls were recruited from the Reproductive 
Endocrinology and Assisted Conception Unit clinics at the Royal Infirmary, North 
Glasgow University NHS Trusts. The North Glasgow University Trust Ethics 
Committee approved all studies. All patients gave informed consent for inclusion 
in each respective trial.
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2.2.1 Patients with PCOS
All patients with PCOS met the criteria defined below, and those who also had 
co-morbidities, including the specific disorders of adult onset congenital adrenal 
hyperplasia, hyperprolactlnaemia, thyroid dysfunction, diabetes mellitus and 
androgen secreting tumours were excluded. The tests for these were performed 
using standard laboratory testing for 17ahydroxyprogesterone, thyroid function 
tests, fasting glucose, and total testosterone. Other exclusion criteria were those 
of medication for treatment of dyslipidaemia, hirsutism, or reproductive causes. 
Patients were required to fulfil all entry criteria prior to providing informed 
consent. Organisation, recruitment, clinical assessments and blood sampling for 
all trials were performed by myself, while the hormone assays were carried out by 
MM, DL, EM, and NS in the university department gynaecology laboratory, and 
the university department of vascular biochemistry. Statistical advice and 
analyses were performed by RF and NS (see acknowledgements).
2.2.2 Definition of PCOS
The parameters used in this thesis are based on the criteria set by the National 
Institutes of Health conference held in Bethseda, Maryland, USA in 1990, with the 
addition of ultrasound criteria. At this conference the following diagnostic criteria 
were put forth; clinical or biochemical evidence of hyperandrogenlsm, chronic 
anovulation, and exclusion of other known disorders (2). The patients included in 
this thesis were defined as having polycystic ovary syndrome based on the 
following: raised free androgen index (>7.9) +/- oligo/amenorrhea (<6 
cycles/year), +/- polycystic ovaries on ultrasound (80).
Subsequent to the finalisation of work included in this thesis was the 
ESHRE/ASRM-sponsored PCOS consensus workshop group conference held in
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Rotterdam, The Netherlands, In 2003. The consensus on defining criteria from 
this international conference are as follows (2 out of 3): oligo- or anovulation, 
clinical and/or biochemical signs of hyperandrogenism, polycystic ovaries 
determined by ultrasound examination, and exclusion of other etiologies (3). Our 
defining parameters for PCOS included in this thesis are consistent with this most 
recent consensus.
2.2.3 Definition of PCO
Echographic diagnosis of polycystic ovaries in this thesis was carried out 
according to the published criteria by Adams et al (80). Measured were follicular 
diameter of the largest follicle present and total number of follicles (TFN) (at least 
10 follicles) present in one mid-point 'slice' through each ovary, with diameters 
(FD) of 2 - 9mm. An ovarian volume of >10cm® was deemed as being consistent 
with PCO.
Following finalisation of the work included in this thesis a description of the 
morphology of the PCO was generated by the ESHRE/ASRM-sponsored PCOS 
consensus workshop group conference held in Rotterdam, The Netherlands, 
2003 (81). It was decided that the criteria fulfilling sufficient specificity and 
sensitivity to encompass this definition should have at least one of the following: 
either 12 or more follicles measuring 2-9mm in diameter, or increased ovarian 
volume (>10cm®). Thus, our ultrasound criteria for PCO included in this thesis 
corresponds to this most recent definition, the only difference being the TFN 
consistent with PCO (>10 in this thesis, as opposed to 12 or more in most recent 
published definition).
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2.2.4 Body weight
Body weight was measured in kilograms to the nearest 0.1kg of weight. All 
patients had heavy clothing and shoes removed. The same set of scales was 
used for all studies (Weylux Scales; Model 424; England, UK)). The scales were 
maintained and calibrated by the hospital’s medical physics department.
2.2.5 Body height
Height was measured in centimetres to the nearest 0.5cm (Weylux Scales; Model 
424; England). All patients removed their shoes.
2.2.6 Body mass index
Body mass Index (BMI) was calculated using the equation;
Body weight (kg)
BMI = ------   —
(Height (m))^
2.2.7 Waist/ hip ratio
Waist and hip circumferences were measured to the nearest centimetre with a 
soft 1cm wide tape as per WHO criteria. Generally, the waist measurement was 
ascertained as being the minimum value between the iliac crest and the lateral 
costal margin, and the hip circumference was determined to be the maximum 
area around the buttock region.
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2.2.8 Blood pressure
All blood pressure measurements (both systolic and diastolic) were performed 
with a manual sphygmomanometer in a standard clinical method. The heart 
sound Korotkoff 4 was taken to ascertain diastolic measurement. Where 
appropriate a targe cuff was used. This was to ensure that the cuff had a width 
approximately 40% of the circumference of the arm and the inflation bladder 
encircled the arm to apply even occlusive pressure over the brachial artery. All 
measurements were performed with the patient in a semi- recumbent position 
after 10 minutes rest.
2.3 Hair measurement
2.3.1 Ferriman-Gallwey score
Hirsutism was assessed by measurement with the modified Ferriman-Gallwey 
score (FG score) (82) (see Appendix). Specifically, the eleven body sites 
containing hormone-sensitive hairs are graded from 1 (minimal terminal hair) to 4 
(frank virilization), and the grades in each of these areas are summed. A score of 
8 or more indicates hirsutism. Hirsutism was classified as mild, moderate and 
severe when the FG score was 7-9, 10-14 and >15 respectively. The FG score is 
semi-quantitative, with inter-observer and some Intra observer variation.
However, it has been shown to be reproducible to a level of 3 points (83). FG 
score was always evaluated by the same physician (LH). On calculating the FG 
score for an individual patient’s hirsutism on 4 separate occasions there was no 
difference noted for intra-measure coefficient of variance.
60
2.4 Transvaginal ultrasound
Transvaginal ultrasound was performed with an ultrasound imaging system 
(Sonoline Sienna; Siemens Medical Systems Inc.) and a 6.5MHz vaginal 
transducer (6.5EV13) with 160 degrees sector angle focused at 3cm. The value 
for ovarian volume was calculated automatically by the ultrasound system after 
the measurements for length, width, and depth were entered. Ail examinations 
were performed using the same ultrasound system. The formula for ovarian 
volume as set on this particular system used the simplified formula for ellipsoids: 
0.5233 X length x width x depth (84).
2.5 Questionnaires
In the hirsutism trial, patients were asked to assess their own status of hirsutism 
and acne, and the effects of treatment at baseline (TO), 6 months (T6) and 12 
months (T12). This was estimated in a quantitative manner using a mark on a 
visual analogue sliding scale. In the same questionnaire, they were asked to 
assess change in hair quality, and their need for use of cosmesis (ie methods of 
hair removal) at T6 and T12, using Boolean operators (see Appendix).
As part of the weight loss trial, patients were required to complete a 
comprehensive diet and exercise questionnaire obtained from the Department of 
Dietetics and Nutrition at the Royal Infirmary, Glasgow. This was in an attempt to 
ascertain if the effect of weight loss was independent of the factors of diet and/or 
exercise thus being wholly due to metformin treatment alone. Patients were 
asked to complete these questionnaires at baseline (TO), 4 months (T4), and 8 
months (T8) (see Appendix).
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2.6 Side Effect Profiles
In the hirsutism trial, a side effect profile questionnaire was completed after 2 
months (T2), at 6 months (T6) and 12 months (T12), and in the weight loss trial at 
1 month (T1), 2 months (T2), 4 months (T4) and 8 months (T8) to assess 
worsening of symptoms compared with baseline, using Boolean operators.
Issues covered included, reduced appetite, nausea, vomiting, diarrhoea, 
headache, breast tenderness and depression (see Appendix).
2.7 Laboratory Methods
Hormone concentrations were assayed in plasma or serum that were separated 
from blood cells by centrifugation within 45 minutes of collection. Samples were 
stored at -20°C and in most cases they were assayed in patient-specific batches 
to eliminate the effect of inter assay drift.
2.7.1 Reproductive Hormones
Testosterone was assessed using the semi-automated ‘Immulite’ technology 
(DPC, Los Angeles, USA) (intra-assay CV<7.5%), while sex hormone binding 
globulin, and DHEAS were assessed by the Immulite 2000 analyser (DPC, Los 
Angeles, USA) (intra-assay CV <6% and <12% respectively).
Free androgen index was calculated as total testosterone divided by the 
concentration of sex hormone binding globulin x 100. The upper limit of normal 
for FAl was 7.9.
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Estradiol, progesterone, LH, and FSH were assessed using the semi-automated 
‘Immulite’ technology (DPC, Los Angeles, USA) (their intra-assay coefficient 
variants were < 10%, 8%, 6%, and 7% respectively).
Androstenedione and 170HP were measured by ‘Coat-A-Count’ technology 
(DPC, Los Angeles, USA) (intra-assay CV<5% and <7% respectively) for the 
adrenal androgen trials. However, for the MIS and weight loss trials, 
androstenedione was assayed using the semi-automated 'Immulite' technology 
(DPC, Los Angeles, USA). Intra assay coefficient of variation was < 8%.
For the hirsutism and weight loss trials the ‘in house’ radioimmunoassay for 
170HP (intra assay CVs <12%) was used. For androstenedione the 
radioimmunoassay was used as described in (85). Reference range in women 
aged 18-40 yrs was 0.6 -8.8 nmol/l. The within batch and between batch CVs are 
consistently below 10% for low, medium and high concentration serum pools (3,9 
and 16nmol/l.)
IGF-1 was assessed using the semi-automated ‘Immulite’ technology (DPC, Los 
Angeles, USA) (the intra-assay coefficient variant was <7%). IGFBP-3 was 
assessed using the semi-automated ‘Immulite’ technology (DPC, Los Angeles, 
USA) (the intra-assay coefficient variant was <9%). IGFBP-1 was assessed using 
the ‘Bridge’ technology (BioChem ImmunoSystems Italia S.P.A., Bologna, Italy) 
(the intra-assay coefficient variant was <5%). Inhibin-B was measured using a 
solid phase sandwich enzyme-linked immunosorbent assay (ELISA) (Oxford Bio- 
Innovation Ltd.,Upper Heyford, Oxfordshire, UK). The inter plate and intra plate 
coefficient of variations were <7%, and the limit of sensitivity was 15pg/ml. 
Vascular endothelial growth factor (VEGF) was performed using Quantikine 
(Human VEGF Immunoassay) (R&D Systems Europe Ltd., Abingdon, Oxon, UK).
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The intra assay coefficient variant was<6.5%, and the inter assay coefficient 
variant <5.8%. For MIS assay details see Chapter 5.
Plasma leptin was measured by an in-house radioimmunoassay validated 
thoroughly against the commercially available Linco assay (86). The intra assay 
and inter assay coefficient variations were <7% and <10% respectively over the 
sample range. The detection limit of the assay was O.Sng/ml.
2.7.2 Glucose and Insulin
Fasting plasma glucose was measured using the glucose oxidase method (Bayer 
Advla 1650 Chemistry System) (Bayer Corporation, Tarrytown NY, USA), intra­
assay CV <2%).
Insulin was measured using two different assays. For the chapters concerned 
with the weight loss during metformin treatment and also the dynamics of MIS 
concentrations, a competitive radioimmunoassay (Coat-A-Count® I, DPC, Los 
Angeles, USA) (the intra-assay coefficient of variant < 6%) was used. Fasting 
plasma insulin was measured using a competitive radioimmunoassay (‘in house’; 
intra-assay CV<8%) for the hirsutism, and adrenal androgen trials. Following 
immediate collection the insulin sample was placed in crushed ice for 
transportation to the laboratory and then centrifuged at SOOOrpm at 4 degrees 
Celsius for lOminutes.
The homeostasis model assessment of insulin resistance (HOMA-IR) was 
calculated from the fasting concentrations of insulin and glucose using the 
following formula: HOMA-IR = fasting serum insulin (pU/ml) x fasting plasma 
glucose (mmol/liter) / 22.5.
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Glycosylated hemoglobin (HbA1C) was measured using high performance liquid 
chromatography (HA8121 analyser; Menarini Diagnostics, Berkshire, UK).
2.7.3 Lipids
Venous blood was taken after an overnight fast for analysis of lipids and 
lipoproteins. Plasma total cholesterol, triglyceride, LDL-cholesterol and HDL- 
cholesterol were determined by a modification of the standard Lipid Research 
Clinics Protocol (87) using the Bayer Advia 1650 Chemistry System (Bayer 
Corporation, Tarrytown NY, USA) the intra assay and inter assay coefficients of 
variation for all lipid measures were <3%.
2.7.4 Inflammatory Markers
C-reactive protein (CRP) concentrations were measured using an in-house 
sensitive double antibody sandwich ELISA as described previously by (88). The 
assay was linear up to 5mg/l and logarithmic thereafter, and had a lower 
detection limit of 0.10 mg/l. The inter- and intra-assay coefficients of variation 
were less than 10% across the range of measured results.
2.7.5 Screening Tests
Standard ‘in-house assays’ for urea, creatinine and electrolytes, thyroid function 
tests, prolactin, liver function tests, and urate were performed in the routine 
hospital laboratories prior to recruitment to the respective studies.
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2.8 Medications
2.8.1 Metformin Hydrochloride BP
Also known by the trade name Glucophage™. This insulin sensitising agent is 
marketed by Merck, West Drayton, Middlesex UB7 7QG, UK. In the trials 
included in this thesis two doses of 500mg and 850mg tablets were used. All 
patients were screened as to absolute and relative contra-indications and advised 
about side effects/ potential adverse outcomes. Patients were then recruited 
accordingly. Patient information leaflet was also provided. Medication was 
obtained through the pharmacy at the Royal Infirmary. Contact was made to 
ascertain side effects on the medication.
2.8.2 Cyproterone acetate and ethinylestradiol
This medication was used in the hirsutism trial. It is marketed by Sobering Health 
Care Limited, Burgess Hill, West Sussex RH15 9NE, UK. The trade name is 
known as Dianette™, and comprised cyproterone acetate 2mg and 
ethinylestradiol 35mcg. All patients were screened as to absolute and relative 
contraindications and advised about side effects/ potential adverse outcomes. 
Patients were then recruited accordingly. Also specifically, patients with a BMI 
(kg/m^) >38 were excluded from recruitment. Patients included in the hirsutism 
trial were also provided a patient information booklet. Medication was obtained 
through the pharmacy at the Royal Infirmary. Contact was made to ascertain side 
effects on the medication.
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2.8.3 Tetracosactrin
This medication was used in the adrenal androgen trial. It is also known as 
Synacthen™ (Alliance). Intravenous administration of Tetracosactrin 250mcg 
occurred each 2 and 4 week patient visit after obtaining informed consent for the 
study on adrenal androgens. This medication was the normal ward stock of the 
Assisted Conception Unit, Royal Infirmary, Glasgow.
Patients were informed of possible side effects prior to administration of the 
medication. Administration was via a Venflon™ inserted into the cubital fossa of 
each patient recruited as per product administration recommendations. Samples 
of serum for hormonal testing were obtained at baseline (TO), SOminutes (T30), 
60 minutes (T60), and 90 minutes (T90).
2.8.4 Leuprorelin acetate
This medication was used in the adrenal androgen trial. Also known as Prostap 
(Wyeth), this GnRH analogue was administered to the patients in the adrenal 
androgen trial in order to down regulate ovarian reproductive hormonal output so 
that only adrenal hormonal production could be measured. Dosage was 3.75mg 
by intramuscular injection.
2.8.5 Menotrophin
This medication was used in Chapter 8. Also known as Menogon (follicle 
stimulating hormone purified from human urine) (Ferring) this was used for 
ovarian stimulation treatment as part of an assisted conception cycle.
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Chapter 3
Metformin compared with Dianette 
in the treatment of hirsutism 
in women with PCOS
3.0 Summary
Hirsutism is a common and distressing symptom frequently encountered In 
women with polycystic ovary syndrome (PCOS), who also show relative insulin 
resistance. The aim of this trial, where treatment of hirsutism was the primary 
endpoint, was to compare the efficacy of the insulin sensitising agent metformin 
with an established treatment, combined ethinyl estradiol and cyproterone 
acetate.
Patients (n=52) were randomised to receive either metformin (500mg tds) or 
Dianette® (ethinyl estradiol, 35pg; cyproterone acetate, 2mg) treatment for a 
duration of 12 months with assessments before treatment, at 6 months and at 12 
months. Both objective and subjective methods of evaluating hirsutism were 
used and, in addition, patient perceptions of their own condition were examined.
The results show that metformin is potentially an effective treatment for moderate 
to severe hirsutism in women with PCOS. They also suggest that, in some 
respects (Ferriman Gallwey score, and patient self-assessment), it is more 
efficacious than the standard treatment (Dianette®). The objective evaluation of 
hair diameter, showed that both treatments were moderately effective in reducing 
mean diameters at multiple anatomical sites.
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Dianette®treatment was responsible for profound suppression of androgen 
activity, in contrast to metformin, which induced negligible change. However 
metformin did reduce markers of insulin resistance. The data suggest that 
hirsutism may be effectively treated by reducing hyperinsulinaemia. 
Correspondingly, the efficacy of a combined approach should be explored.
3.1 Introduction
Hirsutism is excessive hair growth in a male pattern distribution in women. It is 
not only distressing to patients, but also presents a challenging clinical 
management dilemma. In approximately 90% of women with hirsutism, the 
underlying disorder is either polycystic ovary syndrome (PCOS) with its intrinsic 
hyperandrogenism, or it is idiopathic, probably related to increased tissue 
sensitivity to androgens (89). In fact, a high proportion of patients with idiopathic 
hirsutism demonstrate polycystic ovaries (90), suggesting that these 2 forms may 
not be easily distinguished.
Polycystic ovary syndrome (PCOS) Is a heterogeneous disorder characterised by 
chronic anovulation, hyperandrogenism and hyperinsulinaemia, secondary to 
reduced insulin sensitivity. The increased secretion of ovarian androgens is 
considered to be due to increased insulin stimulation of ovarian steroid secreting 
cells (mainly thecal cells) by LH promoted by insulin, and also insulin stimulated 
growth factors, including insulin-like growth factor (IGF-1), and perhaps 
decreased IGF-binding protein activity (91). Hyperandrogenism commonly 
manifests itself as hirsutism (60-83%), acne (11-43%) (92), seborrhoea and 
alopecia.
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Androgens have been shown to be at least partly responsible for promoting the 
anagen phase (growth phase) of the hair cycle, leading to larger hair follicles 
(93), and bringing about a change from vellus to terminal hair status. In vitro 
studies show that the active androgen is Sadîhydrotestosterone, produced locally 
by the action of 5a reductase enzyme on testosterone (89). The anagen phase 
has also been shown to be influenced by the growth factor, IGF-1. IGF-1 is 
carried in the circulation, predominantly by specific IGF binding proteins, but it is 
also produced locally by the dermal papilla where it acts on both the dermis and 
epidermis (94, 95). The activity of these growth factors depends on a number of 
factors, including local and circulating binding proteins, which in turn are also 
influenced by the actions of Insulin. Thus, women with PCOS may demonstrate 
abnormalities in the metabolism of both the major factors responsible for 
hirsutism- androgens and insulin / growth factors.
Women with PCOS also suffer from a high incidence of acne, which has also 
been linked with raised serum androgen (96), insulin (97), and free IGF-1 (98, 99) 
concentrations in the circulation.
The use of insulin sensitising agents (ISAs), predominantly metformin and the 
thiazolidinediones, in the treatment of women with PCOS, has been shown to 
improve insulin sensitivity and ovarian function (16). Treatment with the ISA 
metformin reduced circulating insulin, luteinising hormone, androstenedione, and 
testosterone concentrations in a number of studies, and protracted treatment has 
resulted in improvements in BMI, menstrual cycle regulation, spontaneous 
ovulation rates, and spontaneous and assisted pregnancy rates (16, 42, 48). It 
has been hypothesised that by reducing circulating insulin concentrations, 
leading to decreased free androgen concentrations, ISAs may ameliorate 
hirsutism. In fact, examination of the literature shows that most, but not all.
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controlled studies achieved modest reductions in circulating free androgens using 
metformin (16). A recent study in lean women with PCOS showed significant 
reductions of circulating testosterone, even though they were only modestly 
elevated prior to treatment (100). However, changes in insulin and possibly IGF 
metabolism, justify further examination of this therapeutic approach, since, as 
described above, changes in the growth factor environment may also be 
important in the treatment of hirsutism.
Some recent reports have addressed the use of ISAs in hirsutism (36, 43-45, 77, 
101). However, in none of them was hirsutism a primary outcome measure, and 
no objective measure of hair growth was undertaken. There has been one very 
small study reporting the effect of metformin upon hirsutism as a primary end­
point measure, and using an objective measure of hair growth (68). The results 
suggested that metformin may show benefit compared with placebo.
The aim of this trial, where hirsutism is the primary endpoint, was to firstly 
elucidate if metformin does have an effect on hirsutism in women with PCOS, 
and secondly, to compare its efficacy with an established treatment for hirsutism, 
combined ethinylestradiol and cyproterone acetate. In doing so we have used 
objective techniques and also validated subjective methods of assessment of 
hirsutism, and also incorporated patient perception measures.
3.2 Subjects and methods
3.2.1 Study population
Women with PCOS (n=52), whose primary complaint was hirsutism (Ferriman- 
Gallwey score >8) were recruited from the Reproductive Endocrinology clinic at
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the Royal Infirmary, Glasgow, UK. The diagnosis of PCOS was described in 
chapter 2. Exclusion criteria included; contraindications to either metformin or 
Dianette (including BMI >38kg/m=*), and use of COCP or metformin within the 
previous 3 months. Thyroid dysfunction, hyperprolactinaemia, diabetes mellitus, 
or late-onset congenital adrenal hyperplasia were excluded as described. Women 
taking medication known to affect gonadal or adrenal function, or carbohydrate or 
lipid metabolism were also excluded. Women were also advised to use barrier 
contraception if randomised to metformin.
The study was conducted at the Royal Infirmary, Glasgow, UK, following approval 
from the ethics committee of the North Glasgow Hospitals University NHS Trust, 
and informed consent was obtained from each woman.
3.2.2 Study design
3.2.2.1 Treatments
Patients were block (n=10 per block) randomised in a 1:1 ratio to receive either 
ethinyl estradiol 35meg and cyproterone acetate 2mg (Dianette; Schering AG, 
Germany) or metformin (Glucophage; Merck, West Drayton, UK) for a 12 month 
treatment course. Randomisation was by random number tables. The patient 
number treatment codes were held by a third party and were allocated 
individually following written consent. A list of codes was kept by a third party and 
patient names were checked after completion of the trial. Medication was 
commenced one week following written consent. The Dianette was administered 
in the recommended regime (ethinyl estradiol 35mcg + CPA 2mg; 21 days/month 
followed by a 7-day pill-free period). Metformin (metformin hydrochloride) was 
administered orally at a dose of 500mg tds.
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3 2.2.2 Assessment programme
At baseline (TO), 6 months (T6), and 12 months (T12) all patients underwent 
clinical and hormonal assessments. These included anthropometric 
measurements of height, weight, BMI, waist and hip (WHR), blood pressure, and 
hirsutism using the Ferriman-Gallwey score and hair diameter measurements. 
These assessments were performed by the same observer (LH), Sebum 
excretion rate (SER) was also assessed at each time point, and a side effect 
profile was also performed at 2, 6 and 12 months. Assessment of patient 
perception was recorded at 0, 6 and 12 months for hirsutism and acne.
Circulating concentrations of insulin, glucose, testosterone, SHBG, 
androstenedione, DHEAS, 17aOH progesterone, total cholesterol, triglycerides, 
low density lipoprotein cholesterol (LDL), high density lipoprotein cholesterol 
(HDL), IGF-1 and IGFBP-3 were also determined in a fasting blood sample taken 
at the TO, T6 and T12.
3.2.3 Methods
Most of the methods used were described in Chapter 2, but those specific to this 
study are described below. All patients completed assessments for side effects of 
medication, Ferriman Gallwey score, visual analogue scales for hirsutism and 
acne and a qualitative assessment of hirsutism (see Appendix).
3.2.3.1 Hair diameter
Samples of terminal hair were collected from each patient from anatomical sites 
of the chin, lower abdomen, anterior mid-thigh and forearm at baseline (TO), T6
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and T12 for measurement of hair diameter. This method was described by 
Falsetti et at (102). Women were asked to allow at least 3 days growth of hair 
prior to removal. This time period was determined as subjects were unwilling to 
allow a longer hair growth interval for the face. The samples were removed using 
a stitch cutter blade (Swann-Morton™; Swann-Morton Ltd, Sheffield, UK) to cut 
the cutaneous base. Hair samples were then aligned on a microscopy slide with 
the hair base towards the frosted end, and all were fixed using the same roll of 
selotape™ placed over the hair. Thus, the area of most recent growth was 
adjacent to the frosted end of the microscopy slide.
Hairs were examined with a bright field microscope set up precisely for Koehler 
illumination. All condenser and illumination settings were kept constant. Digital 
images of hairs were captured with a three chip analogue camera (SBCKY55, 
JVC, London) connected to a frame grabber (Snapper, Data Cell,
Finchampstead, UK).
Hair diameter was determined using digital image analysis software (Image Pro 
Plus, Media Cybernetics, Silverspring MD). One investigator (LH), made all hair 
diameter measurements whilst blind to the treatment group.
An objective lens was used (x40) (field width = 242.32 pm), with the exception of 
certain hairs that were too large to be viewed at this magnification and in these 
cases a x20 objective lens was used (field width = 487.50pm). The system was 
calibrated using a 10pm stage micrometer (Graticules Ltd UK, Tonbridge).
Hairs were aligned horizontally on screen and with the segment immediately next 
to the cut end in view. The hair diameters were measured by drawing a single 
line across the hair shaft perpendicular to the long axis of the hair. The optical 
measurement was effected immediately adjacent to the cut end in order to
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estimate the diameter of most recent growth. Hair diameter measurements were 
calibrated in micrometers to 2 decimal points, and repeated measurements 
(n=18) of the same hair demonstrated that the technology was consistent and 
precise to <2% variation.
Initially, as the precision of the method was deemed to be precise, one terminal 
hair from each site was measured. However, the protocol was changed part way 
through the trial, after testing revealed significant biological variation between 
terminal hairs within the same location. Thereafter, six hairs from each site were 
measured and a mean value calculated. Table 3.1 shows the variation in hair 
diameters according to location.
The numbers of patients who had 6 hairs obtained at TO, T6 and T12 were 14 
(includes one patient who withdrew prior to T12), at T6 and T12 were 4, and only 
at T12 were 6. All other patients had only one hair obtained from each anatomical 
site (n=14).
3.2 3.2 Sebum excretion rate
The method of SER was performed as described by Rademaker et al (103). An 
area on the forehead was wiped clean with 4 absorbent papers (Rizla™cigarette 
papers), each of 7.0cm x 2.5cm=17.5cm^. A pad of 4 papers were prepared and 
placed on the delineated forehead, and held in place by gauze sponges and a 
bandana. After 15 mins, another pad of 4 papers and gauze sponges was 
prepared and placed in situ for 1.5 hours. The papers were then removed and 
placed on tin foil for laboratory processing. All handling of the papers was by 
sterilised forceps. In the laboratory the papers were triple extracted with analar 
grade diethyl ether (20ml). Volumes used were 8ml, 6ml, and 6ml. The weighed
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boats were evaporated to dryness and reweighed. Control papers (same size) 
were extracted as well. Results are expressed in mg sebum excreted per sq cm 
per hour, and the limit of sensitivity was 0.01mg/sqm/h.
3.2.3.3 Statistics
Changes in parameters over time within patients were assessed using repeated 
measures analyses of variance (ANOVA), and differences between groups were 
evaluated using a non-parametric test (Mann-Whitney). Comparisons between 2 
time points within the same patient were effected using paired t tests.
Proportions of patients responding were compared using contingency table 
analyses. Statistical analyses were performed using GraphPad Prism (San 
Diego, CA) software.
3.3 Results
3.3.1 Patients and randomisation
The baseline characteristics of the two treatment groups were similar. Means of 
the base line characteristics are shown in table 3.2. They showed similar ages 
and degrees of hirsutism. Normal (non-hirsute) values for the Ferriman-Gallwey 
score lie below 8, so the degree of hirsutism in both groups was considerable. 
The patients were generally obese and the proportions of patients in each group 
with BMI >29 kg/m^ were; Dianette, 20 of 26 and metformin, 14 of 26. Elevated 
fasting insulin concentrations in the circulation were also observed (laboratory 
upper limit of normal = 13.9mU/L: and the proportions of patients showing 
elevated fasting insulin were: Dianette, 8 of 26, and metformin, 9 of 26. Fasting
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glucose concentrations were within the normal range. The free androgen index 
(normal upper limit = 7.9) was elevated in both groups, and the proportions of 
patients in each group with F AI >7.9 were: Dianette, 16 of 26 (62%) and 
metformin, 14 of 26 (54%). Acne was generally not a profound problem amongst 
the groups.
Figure 3.1 shows the process of patients from recruitment and randomisation and 
through the 12 month treatment programme. Ten patients discontinued Dianette, 
while 8 stopped taking metformin (including 3 pregnancies).
3.3.2 Hirsutism
Figure 3.2 shows that Ferriman Gallwey score was significantly reduced following 
treatment in both groups, using repeated measures ANOVA. The degree of 
reduction in FG score was significantly greater (p<0.01, Mann-Whitney test) in 
the metformin group (approximately 25%) compared with the Dianette group 
(approximately 5%). Twelve months treatment with metformin resulted in 5 
patients with severe hirsutism (FG score >15, at TO) achieving a FG score of <15 
(ie ‘moderate / mild’ hirsutism) out of a total of 22, while only 1 did so after 
Dianette treatment (out of n = 25: Chi-square, p=0.08).
The mean hair diameters were significantly reduced (P<0.001 ; repeated 
measures ANOVA) in both groups during the treatment programme (figure 3.3), 
and to a similar degree (Dianette, 17% reduction; metformin, 12%; difference 
between groups, p = 0.15). Table 3.3 shows changes in hair diameter according 
to anatomical site. In fact, the changes in hair diameter appeared to be 
dependent upon either anatomical site and / or baseline hair diameter in both 
treatment groups. It can be seen that hairs on the forearm were relatively fine at
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TO and underwent negligible change, while hairs on the chin and abdomen were 
relatively coarse at TO and apparently underwent considerable change (both 
groups).
3.3.3 Patient self assessments
Table 3.4 shows that patient self assessment (visual analogue scale) of both 
hirsutism (figure 3.4) and acne underwent significant reduction in both groups 
(ANOVA). There was no difference between the treatment groups at TO, but at 
T12 the metformin patients scored their hirsutism significantly lower than the 
Dianette group (Mann Whitney, p = 0.01 ).
Table 3.5 demonstrates changes in patient perception of specific qualitative 
aspects of their hirsutism. More than half the patients in both treatment groups 
assessed their hair quality to be ‘finer’ after treatment, and there was no 
difference between the treatments in this parameter. Approximately half of the 
metformin group recorded that their hair growth rate was reduced at T6. This 
proportion was significantly (p<0.05) greater than in the Dianette group. Half the 
metformin treated patients responded with a reduced requirement for the use of 
cosmesis (T6 and T12). This proportion was not significantly greater than the 
Dianette group at either time point. The overall appearance' as a description 
specific to hirsutism was improved in more than 50% at both T6 and T12 in the 
metformin group. This was a significantly greater proportion than the Dianette 
group at both time points.
3.3.4 Acne and sebum excretion
The degree of acne in general was low (secondary outcome measure), but both 
groups considered that acne improved significantly (table 3.4) by self
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assessment. There was no difference between the treatment groups in the 
responses recorded (p=0.36).
The sebum excretion rates underwent modest improvement (p<0.05) during 
Dianette treatment, but no change during metformin treatment. (Dianette, from 
0.14 (+/- 0.11 sd) pg/m^/h at TO to 0.08 (+/- 0.04 sd) at T12, p = 0.04; metformin, 
0.15 (+/- 0.08 sd) pg/m^/h at TO to 0.12 (+/- 0.08 sd) at T12, p=0.18).
3.3.5 Hormone changes
The effects of Dianette treatment upon hormone profiles at 6 months and 12 
months were profound (table 3.6), with reduced total androgens in the circulation 
and an increase in the SHBG, effectively reducing free androgens to values 
below the normal range. Similar changes were recorded in circulating 17aOH- 
progesterone and DHEAS. However there was no effect upon glycaemic 
parameters, and the BMI did not change over the 12 month course of treatment. 
In contrast, metformin treatment showed negligible effects upon circulating total 
androgens, SHBG, or free androgen index, or 17aOH-progesterone. Although a 
significant (p=0.02) increase in the circulating DHEAS was observed. However, 
metformin treatment resulted in a significant decrease in the glucose/insulin ratio 
and the logHOMA-IR (log transformed to normalise the distribution), suggesting 
improved efficiency of utilisation of glucose, secondary to improved insulin 
sensitivity. There was no change in the circulating IGF1, IGF-BP1 or IGF-BP3 
during metformin treatment.
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3.3.6 Blood pressure and circulating lipid profiles 
during metformin treatment
Table 3.6 shows that Dianette treatment was not associated with changes in 
blood pressure, while the patients treated with metformin showed a clinically 
insignificant increase in diastolic blood pressure. There was no change in the 
systolic blood pressure in either treatment group. The circulating lipid profiles 
were normal and showed non-significant improvements during treatment with 
metformin (table 3.6).
3.3.7 Changes in hirsutism and metformin treatment
Metformin treatment was associated with changes in the FG scores, BMI, and 
improved indices of insulin action. There was little correlation between these 
specific changes. Those individuals who lost more than 1 kg/m=^  in BMI (n=11 ) 
showed no greater reduction in FG score (reduction of 3.8 FG units) compared 
with those who lost less weight (n=7, reduction of 6.6 FG units: P = 0.13). Similar 
analyses with the glucose / insulin ratio showed that those showing the greatest 
improvement in the ratio reduced their FG scores to the same degree as those 
showing a relatively inferior response (mean FG reductions, 4.8 and 5.0 
respectively).
The changes in FG score showed poor correlations with changes in 
glucose/insulin ratio and logHOMA-IR value (Glu/lns, r^  = 0.01; change in HOMA- 
!R, 1^  = 0.004) indicating that changes in hirsutism were relatively Independent of 
changes in both measures of insulin sensitivity. The correlation of change in FG 
score with change in BMI (r  ^= 0.17) was not significant (p = 0.08).
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The population median BMI was 34 kg/m^, and responses were examined 
according to the 2 BMI subgroups (n = 9, each) lying either side of this value. The 
data suggest that BMI may be a relevant factor with respect to treatment efficacy 
as the leaner sub-group showed a tendency (p = 0.08) to greater improvement in 
FG score (6.8 units, 95%CL, 3.3 -  10.3) than the more obese sub-group (3.0 
units, 95%CL, 0.2 -  6.2). The same sub-grouping revealed that the change in 
the free androgen index was significantly greater (p = 0.03) in the leaner sub­
group.
A similar examination of changes in FG score in relation to hyperandrogenaemia 
prior to treatment (FAI > 7.9) failed to establish any relationship, as both groups 
showed similar FG scores at TO and T12, with similar degrees of benefit.
3.3.8 Side effects
Table 3.7 shows the results of side-effect recordings by those patients who 
continued on each treatment, despite side effects. It shows that the side effect 
profiles of both treatments were moderate, and there was little difference 
between the treatment groups. Gastro-intestinal problems (including reduced 
appetite) affected approximately half of the patients on metformin in the first 6 
months, contrasting with the Dianette group. Headache and breast tenderness 
were features in both treatment groups, but there was no difference between 
them.
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3.4 Discussion
The results of this prospective randomised, study show that metformin is an 
effective treatment for moderate to severe hirsutism in women with PCOS. The 
data also suggest that, in some respects (FG score, and patient self- 
assessment), it is more efficacious than the 'gold standard’ treatment, combined 
estrogen and anti-androgen (cyproterone acetate), Dianette®. The objective 
evaluation of one component of hirsutism, hair diameter, showed that both 
treatments were effective in reducing mean diameters at multiple anatomical 
sites. However, this reduction was modest and probably within the known 
biological variation in both treatment groups.
To my knowledge, this is the first comparative, randomised, controlled trial of 
sufficient duration and patient numbers to address the issue of efficacy and 
acceptability of metformin, in the treatment of hirsutism in women with PCOS, as 
a primary outcome measure. Furthermore, the use of an objective measure of 
one aspect of hair growth is an important addition to the assessment, since 
subjective evaluations may be influenced by many factors.
Previous trials addressing the use of ISAs for the treatment of hirsutism in women 
with PCOS, were not unanimous, but four of them suggested that metformin 
treatment would be efficacious if addressed directly. However, the studies 
generally suffered from small patient numbers, patients who were only mild- 
moderately hirsute (assessed by FG score), short therapeutic duration, and only 
one study employed an objective measure of hair analysis. In none of the trials 
was treatment acceptability or assessment of response explored.
Our trial indicates that the recorded improvement in hirsutism also equated with 
patient perception of improvement, which was strongly in favour of metformin
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compared with Dianette. The acceptability of metformin as a treatment for 
hirsutism appeared to be high. In addition, although side effects were similar in 
the two treatment groups there was a trend towards increased compliance in the 
metformin group as evidenced by a lower side-effect motivated dropout rate 
(excluding pregnancies). This is important, as high patient compliance is 
essential for optimal treatment effect, given the length of time of the hair bio­
cycle.
Overall, the results present a counter-intuitive profile in the observations of a 
limited change in circulating total and free androgens at the same time as 
considerable improvements in hirsutism. Hirsutism is a result of end-organ 
sensitivity as well as direct androgen stimulation, and this tissue sensitivity is 
known to be controlled by factors other than androgens, such as insulin and IGF- 
1 activity. In our study, metformin treatment showed significant improvement in 
the glucose / insulin ratio and the logHOMA-IR, but it had negligible impact upon 
circulating androgens. In contrast, Dianette virtually eliminated free androgens 
from the circulation, but in fact showed little effect upon severe hirsutism, as has 
been recorded previously (92). Taken together, these data suggest that 
addressing insulin insensitivity may be a more effective therapeutic approach to 
hirsutism in women with PCOS, than aggressive suppression of androgens, in 
the form of anti-androgen therapy. Thus hirsutism and hyperandrogenism may 
be related through a common underlying mechanism, in addition to a direct 
androgen stimulant -  response aetiology.
The activity of IGF1 is related to both absolute circulating concentrations and also 
those of its carrier proteins, such as IGF-BP3, which effectively reduce IGF 
potency. Women with PCOS may have raised circulating free IGF1, mediated 
mainly through reduced IGF-BPs, suggesting increased growth factor stimulation
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(104, 105). However, we did not demonstrate any change in the circulating 
concentrations of either IGF1 or 1GF-BP3 or IGF-BP1 after metformin treatment, 
thus we may hypothesise that the beneficial effect of metformin is unlikely to be 
due to an effect upon circulating growth factor stimulation. Correspondingly, 
benefit may be due to a mechanism involving local growth factor action at the 
dermal papillae. The inability of metformin to modify serum IGF-1 concentrations 
has been reported previously (40, 106).
The failure of metformin to influence circulating SHBG concentrations beyond 
placebo or control, is another surprising observation which has been recorded 
previously (16). The pre-treatment values would be considered low and 
representative of a cohort of obese women with PCOS. The failure to 
significantly change these values with protracted treatment may reflect the 
confounding effect of obesity in the patient cohort, and the complex nature of 
SHBG control mechanisms. Body mass has a profound influence upon SHBG 
secretion, and the weight loss during the programme was modest, and the 
patients remained generally obese. It may be that a greater degree of weight 
loss is needed to effect a substantial increase in SHBG, such that higher doses of 
metformin should be used in obese women.
We observed poor correlations between reduction in FG score and changes in 
BMI, or measures of insulin sensitivity, suggesting that neither of these changes 
is directly responsible for improvement in FG score. Further suggesting that 
beneficial effects may be due to endocrine changes not so far determined, such 
as the evolution of growth factor and binding protein complexes at local tissue 
level, secondary to induced changes in insulin sensitivity.
The degree of acne in our patient cohort was generally low, and it is difficult to 
extract useful conclusions from the data, as there was no absolute difference
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between the two treatment groups for sebum excretion over the 12 months. This 
is probably related to the fact that acne was not a primary complaint in our study.
The examination of the impact of morbid obesity upon the responses to 
metformin therapy suggest that in such women metformin at a dose of 500mg tds 
may have reduced efficacy, compared with leaner women. A similar observation 
was recorded with morbidly obese women with PCOS in aspects of improving 
ovarian function, weight reduction and circulating lipids (47). This observation 
suggests that either morbidly obese women are refractory to metformin therapy 
or quite simply that the current dose is insufficient.
Life-style change and weight loss have been shown to be effective means of 
treating many of the abnormalities associated with PCOS (76,107), and hirsutism 
may also respond to this approach. Crave et al (30) suggested that metformin 
may confer no additional advantage over weight loss, which contrasts with the 
analyses presented above.
In summary, the results of this study open the prospect of a realistic treatment for 
a large number of women with hirsutism and PCOS, and possibly also idiopathic 
hirsutism, a large proportion of whom (>90%) have polycystic ovaries (90). The 
beneficial effects do not appear to be mediated by suppression of circulating 
androgens, which opens the possibility that hyperinsulinaemia or related 
metabolic pathways may be important determinants of end-organ responses at 
the level of the hair follicle. Future work should address this therapeutic 
approach through examining optimal doses of ISAs, either alone or in 
combination with anti-androgen treatment.
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Table 3.1
Mean biological variation and standard deviations in hair diameters recorded 
within a single site
Mean Diameter 
(pm)
Standard 
Deviation (pm)
Variation
(%)
Abdomen 87.9 15.1 19.4
Chin 103.7 16.6 23.3
Forearm 58.8 8.7 14.9
Thigh 73.5 11.9 16.2
Table 3.2
Standard deviations (in parentheses) and means of baseline characteristics 
between the two treatment groups.
Dianette Metformin P
Values
Age (yrs) 31.65 31.30 0 88
(8.2) (6.9)
Hirsutism (FG score>8) 22.8 20.3 0.24
(5.9) (5.0)
BMI (kg/m^) 31.8 31.7 0.86
(5.6) (6.0)
WHR 0.81 0.85 0.17
(0.051) (0.067)
Fasting insulin (mU/ml) 19.0 15.8 0.92
(23.7) (11.1)
Fasting glucose (mmol/L) 5.0 5.4 0.36
(0.55) (1.4)
Gluc/lnsulin 0.4 0.45 0.73
(0.16) (0.21)
Testosterone (nmol/L) 3.5 3.2 0.65
(1.4) (1.7)
FAI (>7.9) 15.8 14.1 0.46
(13.5) (13.1)
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Table 3.3.
Changes in mean hair diameters and standard deviations (in parentheses) 
according to anatomical site during 12 months treatment with Dianette or 
metformin. The data were compared using paired t test analyses.
Dianette Metformin
TO T12 % P TO T12 % P
Chin (pm) 115
(41)
102
(42)
11.3 0.06 103
(41)
91
(37)
12 0.09
Abdomen (pm) 100
(18)
75
(19)
25.0 0.0004 93
(22)
72
(24)
22 0.002
Mid-thigh (pm) 89
(21)
71
(21)
20.0 0.0001 67
(23)
62
(19)
7.5 0.10
Forearm (pm) 63
(10)
58
(9.2)
7.9 0.03 53
(13)
52
(11)
1.9 0.38
Combined
(pm)
92
(16)
76
(15)
17 0.001 79
(18)
69
(17)
13 0.004
Table 3.4
Comparison of patient own quantitative self-assessments of hirsutism and acne 
through and at the end of 12 months treatment with either Dianette or metformin. 
(Standard deviations are in parentheses.)
Dianette Metformin Mann^
Whitney
TO T6 T12 ANOVA
(P)
TO T6 T12 ANOVA
(P)
Rx
Groups
T12
Hirsutism 7.4
(1.8)
7.1
(1.7)
6.6
(1.9)
0.005 7.0
(2.1)
5.0
(2.)
3.9
(3.1)
<0.0001 0.01
Acne 2.0
(2.3)
1.2
(1.9)
1.0
(1.3)
0.002 3.4
(2.5)
2.9
(2.6)
1.9
(2.4)
0.005 0.36
Footnote to table 3.4
The values derive from patients own assessment of their degree of hirsutism and 
acne according to a visual analogue scale graded from 0 (nil) to 10 (grossly 
abnormal). See appendix.
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Table 3.5
Numbers of patients (proportions presented as %) reporting changes in 
qualitative aspects of hirsutism after 6 months (T6) and 12 months (T12) 
treatment with Dianette or metformin.
16
Nos. of patients (%)
T12
Nos. of patients (%)
Dianette Metformin P Dianette Metformin P
Finer hair quality 10/17 (59) 13/20 (65) ns 9/16 (65) 11/18(61) ns
Reduced rate of 
hair growth
4/17(24) 13/20 (65) 0.02 9/16 (56) 8/18 (44) ns
Reduced need 
for cosmesis
3/17(18) 10/20 (50) 0.08 4/16 (25) 9/18 (50) ns
Overall improved
appearance
(hirsutism)
1/17(6) 11/20 (55) 0.002 4/16 (25) 11/18(61) 0.002
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Table 3.6
Changes in mean (SDs) circulating hormone concentrations and 
anthropomorphic features over 6 and 12 months' treatment with either Dianette or 
metformin. The statistical power (P) represents changes within each group 
assessed by repeated measures ANOVA.
Dianette Metformin
TO T6 T12 P TO T6 T12 P
Fasting Insulin 
(mU/L)
16.5
(23.1)
14.5
(10.7)
15.0
(8.9)
0.7 15.8
(111)
12.0
(7.8)
11.3
(8.8)
0.07
Glucose
(mmol/L)
5.0
(0.55)
4.8
(0.36)
4.8
(0.39)
0.3 5.4
(1.38)
5.2
(114)
5.3
(1.42)
0.5
HOMA-IR 0.49
(0.32)
0.39
(0.32)
0.44
(0.34)
0.35 0.49
(0.30)
0.37
(0.26)
0.32
(0.32)
0.03
Gluc/lnsulin 0.40
(0.16)
0.50
(0.31)
0.40
(0.16)
0.2 0.45
(0.21)
0.55
(0.26)
0.68
(0.40)
0.004
Testosterone
(nmol/L)
3.52
(1.4)
2.38
(1.3)
2.68
(1.3)
0.006 3.19
(1.7)
3.34
(1.9)
2.82
(1.3)
0.39
SHBG
(nmol/L)
31.4
(17.9)
141.1
(63)
117.4
(72)
<0.0001 30.4
(15.6)
29.6
(11.9)
28.8
(11.5)
0.90
FAI 15.5
(12.7)
2.0
(1.1)
3.2
(2.2)
<0.0001 14.1
(12.8)
15.5
(16.7)
12.9
(12.0)
0.4
DHEAS
(pmol/L)
7.2
(3.7)
4.8
(2.3)
4.4
(1.9)
0.0002 6.8
(3.6)
7.9
(3.6)
7.4
(3.4)
0.02
Androstene
dione
(ng/ml)
11.6
(3.5)
7.7
(3.0)
8.2
(3.7)
0.0001 11.6
(6.6)
11.5
7.9()
10.4
(6.2)
0.3
17aOH
Progesterone
(nmol/L)
5.4
(3.3)
2.3
(0.9)
3.1
(2.4)
0.0008 4.2
(2.2)
5.2
(2.7)
5.8
(2.9)
0.2
BMI (kg/m^) 31.8
(5.6)
31.1
(5.6)
31.3
(5.8)
0.15 31.7
(6.0)
30.3
(6.2)
30.1
(6.0)
0.001
WHR 0.81
(0.051)
0.81
(0.059)
0.81
(0.060)
0.69 0.85
(0.067)
0.84
(0.053)
0.85
(0.057)
0.59
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(Table 3.6 cont)
Dianette Metformin
TO T6 T12 P TO T6 T12 P
BP; diastolic 
(mmHg)
73.1
(10.1)
73.4
(10.0)
72.8
(9.3)
0.97 74.4
(10.6)
76.4
(10.4)
80.3
(9.3)
0.01
BP: systolic 
(mmHg)
118.8
(14.1)
116.3
(17.5)
116.3
(15.3)
0.58 119.1
(19.4)
117.2
(17.3)
120.4
(20.6)
0.71
Cholesterol 
(Total: mmol/L)
4.90
(1.1)
5.05
(1.0)
4.75
(1.4)
0 35 4.98
(0.9)
4.87
(0.7)
4.79
(0.8)
0.32
Triglycerides
(mmol/L)
1.68
(1.2)
1.68
(0.9)
1.54
(0.9)
0.72 1.48
(0.6)
1.24
(0.6)
1.27
(0.6)
0.19
LDL Cholesterol 
(mmol/L)
2.81
(0.6)
2.43
(1.2)
2.55
(1.2)
0.40 3.08
(0.9)
2.94
(1.2)
2.86
(1.0)
0.39
HDL Cholesterol 
(mmol/L)
1.41
(0.30)
1.64
(0.33)
1.51
(0.51)
0.01 1.29
(0.31)
1.27
(0.27)
1.31
(0.27)
0.52
IGF-1
(ng/ml)
267
(117)
250
(75)
250
(98)
0.90
IGF-BP1
(ng/ml)
21.6
(19.6)
32.2
(35.5)
25.9
(29.6)
0.30
IGF-BP3
(ng/ml)
6.6
(1.4)
6.6
(1.1)
6.4
(1.2)
0.50
Table 3.7
Record of side effects considered attributable to either treatment with Dianette or 
metformin at 2 months (T2), 6 months (T6) and 12 months (T12).
Time Dianette 
N (%)
Metformin 
N (%)
P
Reduced appetite T2 2/26 (8) 12/26 (46) 0.004
T6 0/17 (0) 12/20 (60) 0.001
T12 0/16 (0) 6/18(33) 0.001
Nausea T2 7/26 (27) 6/26 (23) ns
T6 1/17(6) 5/20 (25) ns
T12 0/16 (0) 3/18(17) ns
Vomiting T2 2/26 (8) 2/26 (8) ns
T6 217(12) 0/20 (0) ns
T12 0/16 (0) 0/18 (0) ns
Diarrhoea T2 2/26 (8) 13/26 (50) 0.002
T6 1/17 (6) 9/20 (45) 0.01
T12 0/16 (0) 6/18 (33) 0.02
Headache T2 8/26 (30) 4/26 (16) ns
T6 3/17 (18) 2/20 (10) ns
T12 3/16(19) 3/18(17) ns
Breast tenderness T2 10/26 (38) 4/26 (15) ns
T6 6/17 (35) 6/20 (30) ns
T12 4/16 (25) 3/18 (17) ns
Depression T2 6/26 (23) 2/26 (8) ns
T6 4/17 (24) 4/20 (20) ns
T12 1/16 (6) 3/18(17) ns
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Figure 3.1
Randomisation and process of patients from recruitment to completion of 
treatment after 12 months with Dianette or metformin.
TO
T6
T12
Pregnant, 2Weight gain, 1
Dianette
Dianette
Dianette
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Metformin
Metformin
Metformin
Pregnant, 1 
G.I. side effects, 3 
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Weight gain, 4 
Blood pressure, 1 
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Chest pain, 1 
Lost TFU, 2
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Figure 3. 2
Responses of Ferriman Gallwey score to treatment with Dianette or metformin 
over 12 months. The broken line represents the upper limit of normal values.
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Figure 3.3
Mean terminal hair diameter values through the programme of treatment with 
Dianette or metformin over 12 months.
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Figure 3.4
Responses of self-assessment score to treatment with Dianette or metformin 
over 12 months.
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Chapter 4
To examine the effects of different 
doses of metformin in obese 
women with PCOS: roles in weight 
reduction and improvement in 
lipid profiles
4.0 Summary
The widespread use of metformin in the treatment of women with polycystic ovary 
syndrome (PCOS) is based upon a limited, but growing evidence base. There 
has been a widespread patient population examined in previous studies, from 
morbidly obese to lean patients with PCOS, and weight reduction has been 
reported in some, but not all reports. Some studies have suggested that most 
immediate benefits may be achieved with lean patients, but no examination of 
different doses in different body mass categories has been reported. The aim of 
this study was to determine whether different doses of metformin (1500 or 
2550mg per day) could have different effects upon clinical features associated 
with PCOS; specifically weight reduction, circulating hormone changes, markers 
of inflammation and lipid profiles.
Patients (n=82) categorised as obese (Ob, BMI 30 to<37 kg/m®; n= 40) and 
morbidly obese (Mob, BMI >37 kg/m®; n=42) started treatment and 68 (82%) 
completed the course with assessments at the start, and after 4 and 8 months 
treatment.
Both the degree of weight reduction and the degree of suppression of circulating 
androstenedione in obese women (the Ob group) were dose related, but no
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similar relationship was established for the Mob group. Although generally 
beneficial changes In cardiovascular risk markers were recorded, there was no 
relationship with either BMl category or metformin dose.
We conclude that weight loss and suppression of androgens are features of 
protracted metformin therapy in obese women with PCOS, with greater weight 
reduction, and more profound suppression of androgens potentially achievable 
with higher doses of metformin.
4.1 Introduction
Following the first publications of treatment of women with PCOS with ISAs, (6, 
25, 30, 31) there has been an enthusiastic subsequent exploration of effects. 
Recent objective reviews (16, 108) determined that the effects of metformin upon 
ovarian activity were beneficial, and that a number of other potential benefits 
were observable in appropriately controlled studies. These include 
improvements in lipid profiles, and reductions in the circulating concentrations of 
androstenedione, if not always testosterone. However, in the Cochrane database 
review (108), despite a number of reports observing weight loss during treatment, 
the meta-analysis of current studies did not confirm that weight loss was a 
significant factor. This contrasts with the comprehensive data provided by the use 
of metformin in patients with glucose intolerance in the Diabetes Prevention 
Program (DPP) (74), where significant and prolonged weight loss was recorded. 
Furthermore, there had been debate over whether some of the apparent 
improvement in ovarian function associated with metformin treatment, such as 
circulating androgen and lipid profiles, may be directly related to changes in body 
constitution (30).
98
One placebo controlled trial of metformin in women with PCOS (47) observed 
that the biochemical effects and reductions in body mass were more consistent in 
the lean and obese patients than in the morbidly obese group (Mob; body mass 
index, BMl > 37kg/m^). This paper suggested that such (Mob) cases are either 
refractory to the effects of metformin, or that they may require increased doses. 
One recent study (62) further substantiated the view that obesity may reduce the 
benefit of metformin treatment. Many of the studies with metformin in women 
with PCOS have included large proportions of obese and morbidly obese women, 
and this may be a confounding feature in the conclusion of the Cochrane 
database review (108). Furthermore, the relationships between metformin and 
dose, and weight changes, endocrine changes and cardiovascular risk factors 
such as lipid profiles (78) and C-reactive protein (CRP) (109) have only been 
sparsely examined.
The aim of this study was to examine the efficacy of metformin at 2 different 
doses (ISOOmg per day, and 2550mg per day) in obese and morbidly obese 
women. The primary endpoint was weight loss, with the secondary intent to 
examine effects of treatment or weight loss upon cardiovascular risk factors, as 
these latter measures may be an important part of the case for extended use of 
ISAs in women with PCOS.
4.2 Methods
4.2.1 study population
Women with PCOS (n=82) were recruited from the Reproductive 
Endocrinology/Assisted Conception clinic at the Royal Infirmary, Glasgow, UK, 
and surrounding hospitals. The diagnosis of PCOS was as described in methods
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(chapter 2) (3). Amongst the presenting symptoms were hirsutism, menstrual 
disturbance and weight gain. Women whose primary complaint was obesity were 
invited to take part in this study. Women taking medication known to affect weight 
loss, gonadal or adrenal function, or carbohydrate or lipid metabolism, were 
excluded. Women were also advised to use barrier contraception, and were 
excluded if interest were expressed in immediate pregnancy.
Informed consent was obtained from each woman, and the study was conducted 
at the Royal Infirmary, Glasgow, UK, following approval from the ethics 
committee of the North Glasgow Hospitals University NHS Trust. The study was 
passed by the hospital ethics committee and supported by a grant from the Chief 
Scientist Office (CZG/4/1/47).
4.2.2 Power calculation
This was based on the concept that the morbidly obese may respond to the 
higher dose of metformin in a similar way to patients with BMl <37kg/m% 
responded to 850mg bd in the study by Fleming et al (47). This precedent data 
showed that the effect upon weight loss was significant at p<0.02 (BMl declined 
from 29.4 to 28.5kg/m^, representing approximately 2kg reduction after 14 weeks) 
in 15 patients in whom the BMl <37kg/m^. There was no change in the weight of 
those whose BMl was >37kg/m^ (BMl from 42.5-42.3 kg/m^), while the placebo 
group showed a significant weight increase. Thus, it was calculated that efficacy 
should be detectable with 15 cases in each arm, requiring a total of 60 patients. 
The group in whom the BMl is >37kg/m* on the lower dose would be expected to 
show no change after 4 months, but the trial will determine whether changes at 8 
months can be achieved.
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4.2.3 Study design
The study was prospective, with dose block randomisation in 2 groups of patients 
with PCOS, defined as obese (Ob; BMl >30 <37kg/m=') and morbidly obese 
(Mob; BMl >37kg/m^). The patient number treatment codes were held by a third 
party and were allocated following individually written consent. Metformin 
(Glucophage; Merck, West Drayton, UK) doses were 500mg tds and 850mg tds. 
Patients were not blinded to treatment dose. Medication was commenced in a 
titrated fashion by taking one tablet a day for the first week, then one tablet twice 
a day for the second week, and then one tablet three times a day thereafter. 
Tablets were either SOOmg or 850mg. Study assessments were performed prior 
to treatment (TO), after 4months (T4) and 8 months (T8) and included 
anthropometric measurements (weight, BMl, waist-hip ratio), ovarian structure, 
circulating hormones, and fasting glucose.
All patients were given the same advice concerning the benefits of life-style 
modification through diet and exercise. No further advice or framework to assist 
weight reduction was given.
4.2.4 Assessment programme
At TO, T4, T8 all patients underwent clinical and hormonal assessments. These 
included anthropometric measurements of height, weight,BMl, waist and hip 
(WHR), and also blood pressure, menstrual cyclicity, and hirsutism using the 
modified Ferriman-Gallwey score (see Appendix) (82). Ultrasound assessments 
(all performed by the same observer, LH) were also performed at 0, 4 and 8 
month intervals to assess ovarian morphology and follicular growth (ovarian 
volume, numbers of follicles with diameter (FD) <10mm, and the diameter of the 
largest follicle.
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Circulating blood samples taken at each assessment point were analysed for 
fasting insulin, glucose, LH, FSH, estradiol (E2), testosterone, sex hormone 
binding globulin (SHBG), free androgen index (FAI), DHEAS, androstenedione,
17aOHProgesterone, high sensitivity C-reactive protein (CRP), total cholesterol, 
triglycerides, LDL-C, HDL-C, leptin, IGF-1 and IGFBP-3. Also performed were 
liver function tests, basic blood biochemistry and thyroid function tests.
Although there was no specific diet or exercise regime advice given as part of this 
trial, patients were asked to complete an exercise and dietary questionnaire at 
each time interval (TO, T4 and T8) (see Appendix). A side effect profile was also 
performed at 1, and 2 months (see Appendix).
4.2.5 Techniques
These were described in chapter 2.
4.2.6 Statistics
Where distributions were normal, group statistical evaluations were compared 
with unpaired t-tests, with Welch correction for unequal variances where 
necessary, and when distributions were non-Gaussian the Mann-Whitney U test 
was applied. Changes in variables during treatment within groups were 
evaluated using repeated measures ANOVA on values pre-treatment (TO) and at 
4 months and 8 months treatment. Simple linear correlation examinations were 
effected to examine relationships between changes in weight and other 
parameters. Statistical analyses were performed using GraphPad Prism (San 
Diego, CA) software.
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4.3 Results
The randomisation resulted in similar cross-sectional data within the body mass 
groups (nil significant difference between the dose categories), and table 4.1 
shows the characteristics of the Ob and Mob groups starting treatment on the 2 
doses of metformin (1500 mg/d and 2550 mg/d). They generally showed 
abnormal ovarian activity, with only 19% of the patients showing normal 
menstrual rhythm.
Of the 82 patients embarking on the study, 68 (82%) completed the course to the 
final 8 month assessment point. There was no difference in the proportions of 
patients completing the study in each group (0b500, 18/20; Ob850, 17/20; 
MobSOO, 18/21; Mob850, 15/21). Subsequent evaluations were effected on 
those patients completing the study.
Table 4.2 shows that the Ob and Mob groups differed in a number of the factors 
examined prior to treatment. The fasting insulin concentrations were significantly 
lower (p=0.025) in the Ob group, and the glucose/insulin ratios (p=0.003) were 
significant higher in the Ob group, while the HOMA-IR measure of insulin 
resistance was borderline lower (p=0.06) in the Ob group. The concentrations of 
IGF-1 were higher in the Ob group and leptin was significantly lower in the Ob 
group, as were circulating CRP and VEGF concentrations. The lipid profiles also 
differed between the groups, with the expected relationships: the Ob group 
showed significantly lower triglycerides and higher HDL-C concentrations, while 
there was no difference in the LDL-C between the groups. Broadly, table 4.2 
shows that the markers of insulin sensitivity indicated increased resistance in the 
Mob group. Markers of endothelial function, and chronic inflammation were 
increased, while the lipid profiles tended to indicate increased proportion of
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patients with undesirable balance of HDL to LDL and total cholesterol values in 
the Mob group.
4.3.1 Effects of metformin treatment
4.3.1.1 Weight loss
Figure 4.1 shows the analyses of the weight changes in all patients completing 
the 8 months metformin treatment (n=68). This revealed that there was a highly 
significant reduction from a mean BMl of 37.1kg/m^ with 95% confidence limits 
(CL) of 35.6 to 38.6 kg/m^ at the start (TO) to a mean BMl of 35.7kg/m^ (CL: 34.2, 
37.3 kg/m^). This was a considerable (3.8%) and highly significant reduction in 
body mass (repeated measures ANOVA, P<0.0001).
4.3.1.1.1 Dose of metformin. Table 4.3 examines the effects of the different 
doses of metformin on the body mass of the patients and reveals that both dose 
groups lost significant weight over the 8 month assessment period under both 
dosage regimes. At 8 months, the ISOOmg group (n=36) lost an average of
2.8 kg, (mean BMl from 37.9 to 36.8 kg/m '^), while the 2550mg group (n=32) lost
4.8 kg (mean BMl from 36.3 to 34.5 kg/m^). The higher dose of metformin 
appeared to have a more consistent effect upon weight loss as evidenced by the 
degree of significance in all cases and in both obesity categories. However, with 
all cases combined, there was no statistical difference between the 2 dose 
groups with respect to the total weight lost (1500 mg group = 2.84 kg, 2550 mg 
group = 4.70 kg: unpaired t test [Welsh correction for unequal variances];
p = 0.19).
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4.3.1.1.2 Obesity category. The Ob sub-group showed a statistically 
significant dose relationship with respect to weight loss, as those taking the 
higher dose lost an average of 4.2 kg (CL 3.4, 5.9) while those taking the lower 
dose lost an average of 1.6 kg (CL -0.2, 2.4). The difference between these 2 
values was significant (P= 0.03).
In contrast, the Mob group showed similar mean losses on both doses: 4.4 kg on 
the lower dose, and 5.3 kg on the higher dose.
Figure 4.2 shows that the percentage decline in weight for the 1500mg dose 
groups, both Ob and Mob groups, was around 2%, while it was greater than 5% 
for both high dose groups. However, the difference between the doses was 
statistically valid only for the Ob group (P=0.03). The error bars represent the 
standard error of the mean.
4.3.1.2 Ovarian function as represented by menstrual 
frequency
There was effectively a doubling of the frequency of menses during metformin 
treatment in those patients with oligomenorrhoea in both dosage groups, in the 
1500 mg group the mean frequency increased from 3.8 menses per year to 6.7 
(p<0.0001, paired t-test), and in the 2550 group the increase was from a mean of
3.8 to 6.8 menses per year (p<0.0001).
There was no difference apparent between either the dose or obesity sub-groups 
in the menstrual responses to treatment. The proportions of patients with 
oligomenorrhoea who achieved normal menstrual rhythm (>10 menstrual cycles 
per year) during treatment were 36% in the 1500 mg group and 48% in the 2550 
mg group (p = 0.41). There was also no difference between the Ob and Mob 
groups in the proportions attaining normal menstrual rhythm.
106
4.3.1.3 Blood analytes and metformin doses
Markers of insulin resistance (fasting insulin, glucose/insulin ratio and log HOMA- 
IR) revealed modest improvements associated with treatment in the high dose 
group only (table 4.4). Although there were significant changes in the 
glucose/insulin ratio and HOMA-IR in the 2550mg dose group, which were not 
observed in the 1500mg dose group, absolute values at 8 months did not differ 
significantly between the 2 dose groups (unpaired t tests: fasting insulin, p = 0.29; 
glucose/insulin ratio, p = 0.47; HOMA-IR, p = 0.15).
Table 4.4 also shows that circulating leptin concentrations indicated significant 
reductions in fat mass in both dose groups, and reductions in leptin and 
androstenedione appeared greater in the 2550 mg group (6.9 ng/ml) than the 
1500mg group (4.6 ng/ml). However, absolute values at 8 months did not differ 
significantly between the 2 dose groups (unpaired t test: leptin, p = 0.12 
androstenedione, p = 0.81). The increase in DHEAS recorded in the ISOOmg 
group was not replicated in the 2550mg group, and there was no difference 
between the groups in the final concentrations of DHEAS at T8 (p=0.37).
The circulating concentrations of LH showed no indication of change in either 
treatment group. This was despite the changes in ovarian activity evidenced by 
menstrual frequency noted above. Analysis of the LH values in those cases 
undergoing the change from oligomenorrhoea (<9 menses per year) to normal 
menstrual rhythm (>9 menses per year) revealed that these individuals (n = 21) 
showed marginal reduction in circulating LH (p = 0.042, paired t-test) with 
absolute values at TO (12.2 lU/L) evolving through 11.4 lU/L at 4 months down to 
7.6 lU/L at 8 months. This latter value would be considered to represent the ‘high 
/ normal’ range.
106
Table 4.4 also shows the changes in lipid and inflammatory marker profiles 
observed during treatment with the 2 doses of metformin. Significant reductions 
in total cholesterol and LDL-C were observed in both dosage groups, but there 
was no dose effect apparent. The changes in lipids, and leptin as a marker of 
total fat mass in both groups were not reflected in changes in circulating CRP 
which showed no significant change in either dose group, and reductions in 
VEGF were significant only in the 1500mg dose group.
4.3.1.4 The role of weight change
Changes in parameter values were examined in respect of weight change over 
the 8 month treatment period, irrespective of obesity category and dose of 
metformin. There were simple linear correlations between the change in weight 
(kg) and change in total testosterone (r  ^= 0.09, P = 0.01), androstenedione (r^  
=0.06, P = 0.04), SHBG (r  ^= 0.11, P = 0.006) and FAI (r^  = 0.10, P = 0.01), and 
also total triglycerides (r  ^= 0.19, P = 0.0002) and leptin (r  ^= 0.25, P < 0.0001). 
Changes in fasting insulin and HOMA-IR, as well as cholesterol, LDL-c, and 
HDL-C showed no relationship with weight change. There was also no correlation 
with CRP.
4.4 Discussion
We believe this is the first systematic, randomised study of the effects of different 
doses of metformin in obese women with PCOS. The data reveal that women 
with PCOS respond to metformin in a manner related to both the dose and their 
body mass. Both the degree of weight reduction and the degree of suppression 
of circulating androstenedione in obese women (the Ob group) were dose 
related, while neither showed such consistent changes in the morbidly obese
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(Mob) group. These observations imply that the degree of obesity impacts upon 
responses to metformin, and that maintained excessive obesity had a 
confounding effect upon responses to treatment. Notwithstanding this, ovarian 
function appeared to show general improvement in all sub-groups. It is 
interesting to record that although measures of insulin resistance changed only in 
the high dose group, some markers of cardiovascular risk showed apparent 
improvements with both metformin doses and both BMl groups, while others 
remained unchanged in all circumstances.
The recent Cochrane Library review and its summary (108) concluded that 
metformin treatment of women with PCOS was effective in increasing ovulation 
rates and suppressing androstenedione in women with PCOS, but it could not 
confirm effects upon weight reduction. Many of the studies quoted in the review, 
included relatively small numbers, were of generally short duration, and most of 
the primary end-points were related to ovarian function and fertility. All of these 
characteristics may reduce the validity of the conclusions with respect to the non­
ovulation end-points. That conclusion also contrasts with the finding of the 
diabetes prevention study (74), with large numbers of individuals (not PCOS) in 
whom weight loss was consistent and long lasting. The study reported here was 
designed to address weight loss during metformin treatment amongst PCOS 
patients given standard weight reducing advice, and it shows convincing 
evidence supporting a pharmacological effect.
The effects of metformin upon lipid profiles and markers or risk factors for 
vascular disease were complex, generally beneficial, and appeared to be 
unrelated to metformin dose, degree of obesity, or weight change. Total 
cholesterol showed a general decrease, mainly through a decrease in LDL- 
cholesterol, and there was a trend towards increased HDL-cholesterol. There 
appeared to be no dose differential in either BMl category. There was no
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consistent change in total triglycerides. A large series of women with PCOS 
treated with 3 doses of troglitazone similarly showed no change in circulating 
triglycerides (78), and furthermore only non-significant trends in reduction of LDL- 
cholesterol and increase in HDL-cholesterol were recorded. The review (108) of 
studies using metformin for variable duration revealed consistent changes in 
LDL-cholesterol only, in accord with the observations above.
It is acknowledged that the absence of a placebo group of patients limits the 
validity of observations of weight changes, but a previous study with placebo in 
similar patients given identical advice showed a modest but significant weight 
increase over 16 weeks (47).
Although relative insulin resistance, and its compensatory hyperinsulinaemia, or 
insulin hypersecretion, are thought to underpin the aetiology of PCOS, the origins 
of the ovarian disorder (excessive, primary and small antral follicular 
development) may be established at birth through excessive primordial follicular 
development at birth (110). An alternative explanation accounting for at least 
some cases include environmentally induced increased primary and more 
advanced follicular development. Correspondingly, until means of influencing the 
rate of initial follicle recruitment and survival to the antral stage can be elucidated, 
the prospect of a ‘cure’ for PCOS Is a distant concept. However, the effects of 
increasing body mass and hyperinsulinism appear to have a profound impact 
upon ovarian function and fertility in women with (and perhaps without) PCOS, 
and metformin appears to be defining a role for itself in this specific area. This 
study appears to suggest that the doses used hitherto in obese and morbidly 
obese women with PCOS may be sub-optimal.
It is likely that most of the immediate symptoms of PCOS will continue to be 
treated using a symptom-specific approach, but the role of insulin sensitising 
agents in the treatment of these disorders remains to be determined either alone
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or as an adjunctive medication. With the possible exception of fertility issues, the 
principle symptoms for considering treatment generally require protracted 
treatment, often in conjunction with other medications.
Optimal doses of metformin in these circumstances have not been elucidated, but 
the indication from this study is that more obvious benefit down stream from 
changes in hormones, lipids and weight change may be obtained with doses 
higher than those previously explored -  particularly in patients with excessive 
body mass.
We conclude that weight loss is a feature of protracted metformin therapy in 
women with PCOS, with greater weight reduction potentially achievable with 
higher doses of metformin. Correspondingly, future studies should examine 
whether higher metformin doses yield greater clinical benefit, although this study 
suggests that large numbers of patients will be required to show convincing 
differences in many parameters.
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Table 4.1
Profiles of the groups of patients (obese, Ob, and morbidly obese. Mob) with 
PCOS before treatment with metformin at 2 different doses. The doses were 500 
mg tds (1500 mg/d) and 850 tds (2550 mg/d). Standard deviations are in 
parentheses.
Group Ob Mob
Dose (mg/d) 1500 2550 1500 2550
N 20 20 21 21
Amen (n) 9 7* 6 8
Oligomenorrhoea (n) 8 9 10 10
Normal Menses (n) 4 4 4 3
32.9 32.1 42.6 41.2
Mean BMl (kg/m^) (2.7) (2.2) (5.3) ... (3.6)0.84 0.85 0.86 0.87
Waist/Hip Ratio (0.075) (0.048) (0.065) (0.043)
10.6 10.3 8.6 io.9
Ovarian Volume (ml) (4.9) (4.0) (2.6) (7.1)
14.7 14.4 12.3 12.9
Ovarian Follicles (FD2-9, n) (5.4) (5.3) (4.5)_ 1 (4.61 .
11.1 12.7 11.2 10.0
Androstenedione (nmol/L) (3.8) (5.5) (4.4)__ (4.1)5.2 6.8 5.8 5.8
Testosterone (nmol/L) (1.8) (3.2) (2.2) (2.9)
10.5 10.8 11.2 9.2
LH (lU/L) (5.1) (6.4) (6.6)_ (5.6)
8.9 11.5 11.8 9.9
FAI (6.6) (8.4) (5.3) (6.9)
15.9 14.1 19.2 22.1
Fasting Insulin (mlU/L) (13.1) (6.5) (7.0) (11.7)
0.45 0.41 0.31 0.28
Glucose/Insulin Ratio (0.25) (0.15)_ (0.16) (0.12)....3.8 3.1 4.4 4.8
HOMA-IR (3.8) _ (1.4) (1.9) (2.4)5.9 6.7 5.9 6.1
DHEAS (ktmol/L) (1.8) (2.7) (3.3) (2.8)
56.0 56.8 81.7 77.4
Leptin (ng/ml) (16.9) (34.4) (21.1) (25.2)
7.0 4.8 7.0 9.0
CRP (mg/L) (6.9) _Ï6.4) _ (5.1) (9.5)
*1 patient had a levonorgestrel intrauterine system in situ and could not provide a 
reliable estimate of her menstrual history.
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Table 4,2
The mean values (with 95% confidence limits) and differences in anthropometric, 
endocrine and circulating lipids of the Ob (n=42) and Mob (n=41) groups of 
women with PCOS determined prior to treatment.
Ob Mob P
BMl (kg/m^) 32.5 (31.7, 33.3) 41.9(40.5, 43.3)
Age (years) 30.5 (28.3,32.7) 30.5 (28.7, 32.3) NS
Fasting Insulin 
(mlU/L)
15.0 (11.5, 18.6) 20.5 (17.2, 23.8) 0.025
Glucose/Insulin 0.43 (0.36, 0.50) 0.30 (0.25, 0.35) 0.003
Homa-IR* 3.45 (2.46, 4.44) 4.61 (3.87, 5.36) 0.063
IGF-1 (ng/ml) 224(191,257) 158 (131, 184) 0.002
CRP (mg/L) 5.92 (3.63, 8.21) 7.92 (5.3, 10.5) 0.010
Leptin (ng/ml) 56.4 (47.3, 65.5) 79.8(71.7, 87.8) 0.0002
VEGF (pg/ml) 19.0 (9.1,28.8) 24.5(18.4, 30.6) 0.002
Triglycerides
(mmol/L)
1.46 (1.15, 1.77) 2.05 (1.65, 2,45) 0.0004
HDL-Cholesterol
(mmol/L)
1.16(1.05, 1.28) 0.91 (0.84, 0.97) 0.0002
LDL-Cholesterol
(mmol/L)
3.03 (2.77, 3.30) 3.50 (3.20, 3.80) 0.021
*Data log-transformed for comparative analyses 
Table 4.3
The mean BMl {kg/vcf) values before and after 8 months treatment with 2 doses 
of metformin (with standard deviations in parentheses). The changes 
(significance levels, P) were assessed using values taken at TO, 4 months and 8 
months using repeated measures ANOVA.
1500mg/d 2550mg/d
TO 8m P* TO 8m P*
All cases 37.9(6.5) 36.8 0.0022 36.3 34.5 <0.0001
(6.9) (5.6) (5.7)
Ob group 33.0 32.4 0.0577 31.9 30.4 <0.0001
(2.8) (3.5) (2.3) (3.0)
Mob group 42.7 41.3 0.0268 41.2 39.2 0.0027
(5.5) (6.7) (3.7) (4.1)
"repeated measures ANOVA of BMl values at TO, T4 and T8.
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Table 4.4
Changes in concentration of individual analytes during treatment with metformin 
in the 2 dose groups of patients (Ob and Mob patients combined) treated with 
1500mg or 2550mg per day. The absolute values are shown for pre-treatment 
(TO) and at 8 months (8m), and the statistical value (P) represents the repeated 
measures ANOVA assessment for values at TO, 4 months and 8 months. 
(Standard deviations are represented in parentheses.)
1500mg/d 2550mg/d
TO 8m P TO 8m P
Fasting Insulin 
(mU/L)
17.6
(10.5)
18.6
(16.1)
0.746 17.7
(10.0)
15.1
(10.9)
0.084
Glucose/Insulin
Ratio
0.38
(0.22)
0.39
(0.23)
0.644 0.35
(0.15)
0.43
0.25)
0.039
HOMA-IR 4.10
(3.0)
4.37
(4.3)
0.711 3.92
(2.1)
3.13
(2.3)
0.039
IGF1 (ng/ml) 187
(102)
186
(104)
0.856 197.0
(79)
183.1
(78)
0.373
Testosterone
(nmol/L)
5.54
(2.0)
5.83
(1.8)
0.57 6.40
(3.1)
6.05
(3.6)
0.078
Androstenedione
(ng/ml)
11.18
(4.2)
9.34
(2.7)
0.016 11.97
(5.0)
9.14
(4.1)
<0.0001
FAI 10.45
(6.3)
12.04
(8.7)
0.158 11.5
(8.1)
11.1
(8.4) -
0.870
LH (lU/L) 11.07
(5.7)
9.43
(7.2)
0.605 10.3
(6-4)
9.5
(5.6)
0.305
DHEAS (uml/L) 5.86
(2.7)
6.53
(3.4)
0.023 6.81
(2.9)
7.28
(3.4)
0.133
Triglycerides
(mmol/L)
1.63
(0.96)
1.54
(0.66)
0.684 1.87
(1.1)
1.70
(0.9)
0.374
Total Cholesterol 
(mmol/L)
5.16
(0.96)
4.82
(0.83)
0.0002 5.04
(0.90)
4.70
(0.87)
0.004
HDL-C (mmol/L) 1.09
(0.30)
1.15
(0.36)
0.072 0.99
(0.28)
0.99
(0.28)
0.807
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(Table 4.4 cont.)
1500mg/d 2550mg/d
TO 8m P TO 8m P
LDL-C (mmol/L) 3.33
(0.76)
2.97
(0.76)
<0.0001 3.17
(0.91)
2.88
(0.87)
0.003
Leptin (ng/ml) 68.9
(22.9)
57.1
(25.8)
<0.0001 66.5
(31.7)
48.3
(19.8)
<0.0001
CRP (mg/L) 7.02
(6.0)
5.51
(8.1)
0.15 6.74
(8.2)
5.71
(7.4)
0.485
VEGF (pg/ml) 26.0
(29.5)
16.6
(8.6)
0.016 16.8
(14)0
15.6
(8.0)
0.762
Figure 4.1
Weight changes in all patients completing the 8 months metformin treatment 
revealed that there was a highly significant reduction from a mean BMl of 37.1 to 
35.7 kg/m' (CL: 34.2, 37.3 kg/m').
Effects of metformin treatment 
weight loss
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Figure 4.2
Percentage weight changes during 8 months completed metformin therapy 
amongst the Ob and Mob groups of women taking 1 SOOmg and 2550mg doses 
per day.(Error bars represent the standard error of the mean.)
Ob Mob
Weight
Change
(%) -5-
1500 mg 2550 mg-KH
8 I TO 
Treatment months
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Chapter 5
The investigation of Mullerian 
Inhibiting Substance in obese 
women with PCOS, and 
determination of the effects of 
metformin treatment
5.0 Summary
The objective of this study was to assess the role of Mullerian inhibiting 
substance (MIS) in obese women with PCOS and investigate changes in 
response to metformin treatment. The study was a prospective element based 
upon the investigation into the effects of metformin upon body mass (chapter 4), 
whereby sample aliquots were stored for assessment of MIS. The study included 
randomization to 2 different doses of metformin treatment.
Eighty-two obese women with polycystic ovary syndrome (PCOS) were recruited 
to the trial at the Royal Infirmary, Glasgow, through the University Department of 
Obstetrics and Gynaecology. Markers of ovarian function were assessed at TO 
and after 4 and 8 months. The main outcome measures were reproductive 
hormone changes over time, primarily being those of androgens and MIS.
The results showed that there was no difference in the reproductive hormone 
changes between the doses of metformin (including MIS), and all data were 
combined for analyses.
Significant responses to metformin treatment were recorded for menstrual 
frequency (increased) and androstenedione (reduction) within the first 4 months
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of treatment. However, suppression of the elevated circulating MIS 
concentrations required protracted treatment, as no change was observed in the 
first 4 months -  only in the second 4 month assessment period. Thus the initial 
ovarian changes took place in the absence of changes in MIS.
In conclusion, women with PCOS show high concentrations of circulating MIS 
which are correlated with the number of small antral follicles in their ovaries. 
Metformin treatment of obese women with PCOS lead to rapid suppression of 
androstenedione and improved menstrual frequency, while suppression of MIS 
showed a delayed response. We may construct a hypothesis suggesting that the 
delayed effect may be secondary to the development of a cohort of follicles, 
which underwent initial recruitment in an environment of reduced insulin 
stimulation under the influence of metformin, and it takes in excess of 4 months 
for that cohort to be represented at the more advanced stages.
5.1 Introduction
Following the advances in the understanding of the metabolic / endocrine 
disturbances seen in polycystic ovary syndrome (PCOS) (111), recent work has 
addressed the ovarian abnormality seen in this common disorder. Webber et al 
(110) showed that the proportions of primitive follicular categories differed 
between normal and PCOS ovaries, also concluding that the number of 
primordial follicles present at birth was greater in PCOS. Jonard et al (112) 
showed that there are important differences in categories of antral follicles 
definable by their size. The number of smaller visible follicles (follicle diameter 
[FD] between 2 and 5 mm; FD 2-5), is significantly raised in PCOS compared 
with normal, and they represent the category responsible for the high circulating
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androgen concentrations, while the number in the larger category (FD 6-9) 
reflects the degree of insulin resistance, and is closely linked to the frequency of 
follicular maturation, ovulation and infertility. These 2 follicular categories 
represent later stages of development, prior to the pre-ovulatory stage, and 
whose development from the primordial stage requires many weeks growth 
(113). Thus in PCOS, rates of initial recruitment and progress through 
developmental stages appear to differ from normal. The raised androgens in the 
circulation of women with PCOS probably derive from the enlarged cohort of 
small follicles at the androgen secreting stage (112) as well as increased direct 
stimulation by insulin and LH, perhaps involving stromal tissue as well (114).
Mullerian inhibiting substance (MIS), a dimeric glycoprotein, also known as anti- 
mullerian hormone (AMH), is a member of the transforming growth factor beta 
super-family of growth and differentiation factors, and its concentration is raised 
in the circulation of women with PCOS (64, 115,116). MIS is believed to act in a 
paracrine fashion after birth to regulate granulosa cell and oocyte function (117), 
and it may be an important regulator of follicle recruitment (118). In humans, MIS 
is not seen in primordial follicles, but it Is expressed from the primary stage 
through to small antral follicles where maximal expression is seen (119). It is this 
latter category of follicle, with maximal granulosa cells, that is likely to be 
responsible for much of the MIS in the circulation.
A study by la Marca et al found higher serum MIS levels in women with PCOS 
compared with controls. They also found that the level of MIS was higher in those 
subjects with amenorrhea compared with oligomenorrhea, thus indicating a 
possible role for MIS in PCOS related anovulation. A simple measure of insulin 
sensitivity, the HOMA score, was found to positively relate to serum MIS levels. 
However, there exists no literature relating insulin and MIS levels (64).
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As discussed previously, women with PCOS show relative insulin resistance and 
compensatory hyperinsulinaemia (120), which may be critical to the underlying 
disorder. Treatment with ISAs in women with PCOS results in reduced 
androgenicity (suppression of total androstenedione) and increased frequency of 
follicular development and ovulation as described in Chapter 1. It is not known 
whether the reduced circulating androgen concentrations reflects simply reduced 
insulin driven secretion of androgens per follicle, or a reduced follicle cohort size 
(or both). The effect of ISAs on circulating concentrations of MIS in PCOS has 
not been explored, and its elucidation is important for furthering the 
understanding the ovarian effects of ISA treatment.
The aims of this study were to explore the relationship between MIS and other 
reproductive parameters in obese women with PCOS, and also to test the 
hypothesis that reducing the degree of insulin stimulation to the ovaries in these 
women, using protracted metformin therapy, would reduce the circulating 
concentrations of MIS. The relationships of changes in all parameters were 
explored and revealed some critical observations.
5.2 Methods
Most of the methods used were described in Chapter 2, but those specific to this 
study are described below. Details addressing study population, study design, 
assessment programme and techniques are provided in Chapter 4.
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5.2.1 Serum MIS assay
Serum MIS was measured by an enzyme linked immunosorbent assay as 
described in earlier studies (121). There is no cross reactivity with other 
members of the TGF beta gene family, and is specific for primate MIS. The intra­
assay coefficient of variation was 9%, the inter-assay coefficient of variation was 
15%, and the limit of sensitivity was 0.3 ng/ml. MIS values that fell below the limit 
of sensitivity for the assay (<0.3 ng/ml) were considered undetectable. Mean 
serum MIS values in female infants, ages two to twelve months, were reported to 
be 0.7 ng/ml (range <0.3-1.9 ng/ml), increasing minimally to prepubertal values of 
0.9 ng/ml (range <0.3-3.9 ng/ml) by 18 months. During the prepubertal years, 
MIS gradually increased to pubertal and adult values of 2.9 ng/ml (range <0.3- 
8.9 ng/ml). The upper limit of normal (95* centile) was taken to be 7ng/ml.
5.2.2 Statistical anaiyses
Comparison of variables between groups were effected using unpaired t tests 
where distributions were normal, and using Mann-Whitney U tests for analyses 
involving the glucose/insulin ratio and MIS concentrations which showed non- 
Gaussian distributions. Changes of variables within patients during metformin 
treatment, with values at TO and 4 and 8 months, were assessed using repeated 
measures ANOVA. In the cross-sectional analyses prior to treatment, correlation 
analyses were effected using Pearson correlation test where data showed normal 
distributions, and using the Spearman rank test when the data showed non- 
Gaussian distributions. The software package employed for these analyses, and 
the multiple regression model involving the factors shown to demonstrate 
significant correlations with MIS, was SPSS (version 8; SPSS UK Ltd,
Woking, UK).
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5.3 Results
5.3.1 Patients prior to treatment
Table 5.1 shows the characteristics of the patients participating in the study.
They were obese (BMl > 29 kg/m^) with indications of insulin resistance 
determined by high fasting insulin (laboratory normal maximum >13 nmol/dl), 
and a raised HOMA-IR. The total follicle number (TFN) was high (diagnosis of 
polycystic ovary demanded a minimum TFN of 10 follicles), and circulating 
androgen and LH concentrations were elevated. The mean circulating 
concentration of MIS was elevated, with a value of 7.9 ng/ml, which is above the 
laboratory normal upper limit described previously as 7.0 ng/ml.
Table 5.2 shows that there was no relationship between MIS and BMl or fasting 
insulin concentrations or HOMA-IR values. Of the clinical markers of ovarian 
function, ovarian volume showed no clear relationships with circulating MIS. 
However, there was a positive linear correlation between circulating MIS and 
TFN, and also between MIS and androstenedione and a negative correlation with 
age.
When the 3 variables (TFN, androstenedione and age) showing significant 
individual correlation with circulating MIS as the dependent variable, were 
entered into a multiple regression model, only TFN remained significant (p = 
0.022). The predictive capacity (r squared) for the model was 0.18, and the 
significance of the combined model was p = 0.011.
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5.3.2 Effects of metformin treatment
5.3.2.1 Ovarian function and MiS
During metformin treatment, there were numerous changes recorded over the 8 
month treatment period, but in respect of factors related to ovarian function, there 
was no significant difference between the 2 doses employed. Correspondingly, 
the data from both dose schedules were combined for further analyses.
There was an increase in the presumed ovulation rate, evidenced by an increase 
in the frequency of menstrual events. The mean frequency of menses per year 
increased from 5.6 (+/- 0.5, standard error) to 8.3 (+/- 0.5, standard error), which 
represents (paired data) a highly significant increase (p<0.0001) with 95% 
confidence Intervals of the difference between 3.7 to 1.7 events.
Analysis of all cases using repeated measures ANOVA showed a highly 
significant reduction in MIS during 8 months metformin treatment (p=0.0005, 
table 5.3). The absolute suppression of MIS concentrations in both dosage 
groups during 8 months metformin treatment were similar (1 SOOmg group, -1.98 
ng/ml +/- 6.3; 2550mg group, -1.60 ng/ml +/- 2.8: P=0.78, Mann-Whitney Test).
Table 5.3 also shows that there were significant overall (repeated measures 
ANOVA) reductions in circulating androstenedione and VEGF, and significant 
increases in DHEAS, while there was no change in total testosterone 
concentrations.
Table 5.3 also shows that there was no change in the total ovarian volume, which 
remained above the normal upper limit of 9 ml, and there was a negligible change 
in the TFN (P=0.07, repeated measures ANOVA) over the 8 month treatment 
period.
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Metformin treatment afforded limited change in markers of energy metabolism, 
with no significant change in fasting insulin or HOMA-IR. However, there was a 
highly significant reduction in BMI, representing a 4.3% reduction in weight in the 
8 month period. Correspondingly, there was a highly significant reduction in 
leptin.
5.3 2.2 The chronology of responses to metformin
Table 5.3 shows the sequences of changes during metformin treatment. The 
data were examined using repeated measures ANOVA for the whole treatment 
period and paired t tests for examination of differences between 2 time points. It 
was clear that some factors responded rapidly (within 4 months) whilst other 
factors appeared to be delayed to between the 4^  ^and 8^"^  month of treatment.
While fasting insulin and HOMA-IR showed negligible change during treatment, 
the BMI showed significant reductions in both intervals. In contrast the reduction 
in leptin was significant only over the first 4 months. Similarly, the increase in 
DHEAS was restricted entirely to the first 4 months. The main change in VEGF 
also appeared to be in the early stages of treatment, but statistical significance 
was achieved in neither individual time frame. Androstenedione showed a rapid 
decline over the first 4 months and a further, more moderate, decline between 
months 4 and 8.
In contrast to those ‘rapid’ effects of metformin treatment, although there were 
highly significant reductions in MIS, table 5.3 shows that the reduction in 
concentration was restricted entirely to the 4m to 8m interval. Figure 5.1 shows 
the contrast in responses between androstenedione and MIS. The TFN showed 
no changes overall, but they did show a significant reduction between 4m and
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8m. The apparent delayed reduction in LH concentrations (months 4 to 8) did not 
achieve statistical significance.
5.4 Discussion
These data demonstrate, for the first time, that treatment of women with PCOS 
with metformin results in a highly significant reduction in the circulating 
concentrations of MIS. Furthermore, they show that the suppressive effect 
occurs only after protracted treatment of the time scale suggestive of effects upon 
initial follicular recruitment. The changes in circulating MIS contrast with those of 
androstenedione whose suppression is rapid, and observed mainly within the first 
few weeks. Thus, the testing of the hypothesis that insulin resistance (HOMA-IR) 
and MIS are directly linked did not confirm any such relationship.
The cross-sectional data from these women with PCOS prior to treatment with 
metformin support the previous demonstrations (115, 116, 122) that women with 
PCOS have elevated circulating concentrations of MIS. In accord with previous 
observations, there was no relationship between circulating MIS and markers of 
insulin resistance, and there were positive correlations with TFN and circulating 
androgen concentrations and a negative correlation with age. The multiple 
regression model revealed that only TFN showed a significant relationship with 
circulating MIS. Conversely, in the trial by la Marca et al, a significant positive 
correlation was found between MIS and HOMA index. However, it should be 
noted that this trial was of small patient numbers (14 women with PCOS and 15 
women as controls), and there were no ultrasound parameters included as an 
outcome measure.
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The effects of metformin treatment on circulating concentrations of 
androstenedione, with an immediate suppression, and MIS, with no change 
within the first 4 months. Indicates a dissociation between the 2 follicular products 
and their specific sources and control mechanisms. Furthermore, the fact that 
metformin increases the ovulation rate, represented by menstrual frequency in 
the data above, and shortens the duration to first ovulation (47) within the first 4 
months of treatment during which there is no change in MIS, suggests that 
circulating MIS activity is not responsible for the blockade to follicular maturation 
commonly seen in PCOS.
The eventual suppression of MIS, occurring after 4 months therapy, suggests that 
follicular profiles change during protracted metformin therapy, in the absence of 
any indication that its secretion per follicle is promoted by any of the factors 
influenced by metformin therapy. The protracted delay in the suppression of MIS 
(approximately 4 months) indicates that the eventual change in follicle profiles is 
independent of short term changes in metabolic and gonadal steroid profiles.
These observations lead to the hypothesis that the critical ovarian factor being 
influenced by protracted metformin treatment, and represented by the delayed 
changes in MIS, is initial follicle recruitment, a key abnormality in PCOS (110). 
The data suggest that changes in MIS require the replacement by the whole 
follicle cohort present at TO by a cohort recruited under a reduced degree of 
insulin (and perhaps androgen) stimulation. The reduction in TFN between 
months 4 and 8 may provide some circumstantial support for this concept. 
According to previous observations (113), it requires approximately 3 months 
from initial recruitment to achieve the antral stage of follicular development ready 
to undergo final maturation, and it is not until a new cohort has grown and 
replaced the original cohort (recruited under conditions of insulin resistance and
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high androgen concentrations), that we see changes in MIS. This subsequent 
follicle cohort is smaller, because it was recruited under a “normalized” insulin 
(and perhaps androgen) drive, showing the importance of insulin metabolism at 
this early stage. The apparent discrepancy between the accepted 3 month 
interval and the minimum of 4 months observed above may also indicate a key 
difference in PCOS, or the delay between the antral stage and the MIS secreting 
phase, or alternatively, a weakness in the hypothesis. The results indicate that 
more detailed observations are required, including determination of whether the 
same effect is seen in lean women with PCOS.
This hypothesis would demand that all insulin resistant states, with compensatory 
hyperinsulinaemia, would lead to increased follicular initial recruitment, cystic 
ovaries and high concentrations of MIS. The cystic ovaries, and raised androgen 
levels have been observed in a case of an insulinoma prior to surgical removal 
(123), although the MIS concentrations under these circumstances are unknown. 
During adolescence, there is a recognized state of insulin resistance, and its 
abnormal ovarian morphology often observed at this time (124) may fit this 
criterion. It may be advantageous to explore further the link between PCOS and 
adolescence.
Other factors examined during metformin treatment revealed similar data to 
previous publications, as metformin treatment resulted in negligible change in 
fasting insulin concentrations or HOMA-IR, although weight loss and reductions 
in circulating leptin were highly significant. The metformin treatment resulted in 
significant reductions in circulating VEGF and a significant increase in DHEAS, all 
within the first 4 months, while there was no change in circulating total 
testosterone values. The pattern of changes in androgens (suppression of 
androstenedione and negligible effect upon testosterone) is consistent with the
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combined observations of Lord et al (15) and some other single studies (125).
This implies that improving insulin sensitivity in PCOS has a differential effect 
upon different follicle categories. The role of MIS in this context is complex, since 
previous evidence indicates that high MIS values should suppress androgen 
biosynthesis (126), and a reduction in MIS under the influence of metformin 
should lead to an increase in androgen production. Both predictions are 
contradicted by the present observations, suggesting that the change in follicle 
category and cohort size may be more important than the quantitative effect upon 
individual follicles studied in vitro.
Irrespective of the speculation over an active role for MIS in the pathogenesis of 
PCOS, evidence is accumulating supporting further investigations of MIS in 
women with PCOS. As a marker of ovarian follicular activity, knowledge of the 
circulating MIS concentrations may have important repercussions in a number of 
areas, including assisted reproduction where it may be used to predict the 
response of patients to ovarian stimulation in normal and poor responder patients 
(116, 127-129).
In summary, metformin treatment of women with PCOS resulted in rapid and 
maintained responses of ovarian function under direct insulin control, while 
circulating MIS concentrations required 4 months treatment before responding. 
This suggests that MIS reflects the cohort size of follicles undergoing initial 
recruitment approximately 4 months previously.
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Table 5.1
Mean background data of the women with PCOS (n=82) prior to treatment, set 
against laboratory normal data for reference.
Mean 95% Cl
Upper limit of 
laboratory 
normal range
Age (y) 30.2 28.7-31.8 -
BMI (kg/m=*) 37.1 35.6 -  38.6 «
Fasting Insulin (nmol/dl) 17.7 15.2-20.2 12.9
HOMA-IR 4.0 3 .4-4.6 3.8
Glucose / insulin ratio 0.37 0.32 -  0.41 0.4*
IGF-1 (ng/ml) 192 170-214 330
Menses per year (n) 5.5 4 .5 -6 .5 10*
TFN (n) 13.8 12.5-15.1 9
Testosterone (nmol/L) 5.9 5.3 -6 .5 4.9
Androstenedione (nmol/L) 11.6 10.4-12.7 8.9
LH (lU/L) 10.7 9.2-12.1 9.9
Inhibin-B (pg/ml) 200
VEGF (pg/ml) 20.2 16.1-24.3 55
MIS (ng/ml) 7.9 6.2 -  9.6 6.9
rthe limit of these factors is the lower value of the normal range
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Table 5.2
Correlation assessments between circulating MIS and anthropometric, metabolic 
and endocrine factors in obese women with PCOS.
R 96% Cl P
BMI (kg/mz) 0.037 -0.274 to 0.203 0.761
Fasting Insulin (nmol/dl) 0.006 -0.233to 0.245 0.959
HOMA-IR 0.002 -0.247 to 0.243 0.988
Age (years) -0.241 -0.454 to -0.003 0.047
Total Follicle Number (TFN) 
(n)
0.384 0.145 to 0.582 0.002
Ovarian Volume (cm )^ 0.006 -0.261 to 0.251 0.966
Androstenedione (nmol/L) 0.239 0.287 to 0.662 0.049
Testosterone (nmol/L) 0.000 -0.221 to 0.256 0.881
Table 5.3
Mean values of endocrine and other factors before treatment (TO) and after 4 and 
8 months treatment with metformin. The statistical evaluations refer to change 
throughout the period of examination (repeated measures ANOVA) and also for 
the individual 4 month intervals (paired t tests). Standard deviations are 
represented in parentheses.
Significance
Factor TO 4m 8m Repeated
Measures
Anova
Paired 
t-test 
TO -4 m
Paired 
t-test 
4m -  8m
Fasting Insulin 
(nmol/dl)
17.7
(10.2)
18.9
(12.1)
17.1
(13.9)
0.81 0.74 0.57
HOMA-IR 4.02
(2.6)
4.3
(3.6)
3.8
(3.5)
0.50 0.44 0.32
BMI
(kg/m^)
37.1
(6.1)
36.3
(6.2)
35.7
(6.4)
<0.0001 <0.0001 0.0002
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(Table 5.3 cont.)
Significance
Factor TO 4m 8m Repeated
Measures
Anova
Paired 
t-test 
TO — 4m
Paired 
t-test 
4m -  8m
Leptin (ng/ml) 67.7
(27)
58.6
(23)
53.0
(23)
<0.0001 0.04 0.160
DHEAS
(pmol/L)
6.31
(2.8)
6.94
(3.1)
6.88
(3.4)
0.005 0.002 0.77
Androstene­
dione (nmol/L)
11.6
(4.6)
10.1
(3.4)
9.3
(3.4)
<0.0001 0.003 0.017
Testosterone
(nmol/L)
5.9
(2.6)
5.5
(2.3)
5.8
(2.8)
0.15 0.10 0.46
VEGF (pg/ml) 20.2
(17)
16.8
(9.6)
16.1
(8.3)
0.03 0.08 0.55
MIS (ng/ml) 7.9
(7.1)
7.7
(5.3)
6.1
(5.7)
0.0005 0.79 <0.0001
TFN (n) 14.0
(5.0)
15.1
(5.6)
13.2
(4.8)
0.07 0.18 0.023
Ovarian volume 
(ml)
10.5
(5.4)
10.9
(4.3)
11.1
(4.0)
0.59 0.72 0.76
LH (tU/L) 10.9
(6.1)
11.7
(12.0)
9.5
(6.4)
0.24 0.48 0.12
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Figure 5.1
The changes in the mean concentrations of androstenedione and MIS during 
metformin treatment of women with PCOS. The significance values refer to 
changes between the start of treatment (TO) and at 4 months, and between the 4 
and 8 month intervals.
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Chapter 6
To determine if metformin directly 
influences adrenal androgen 
biosynthesis in women with PCOS
6.0 Summary
Raised androgen concentrations in women with PCOS may be a result of 
increased production by the ovary, adrenal gland, or both. It is hypothesised that 
the dysregulation of cytochrome P450 - 17a hydroxylase activity may be a factor 
in androgen production from not only an ovarian source but also from the adrenal 
gland. The activity of this enzyme, found in both ovarian and adrenal tissues, is 
influenced by insulin drive. Metformin treatment has been found to influence the 
ovarian production of 17ahydroxyprogesterone (170HP) through the activity of 
cytochrome P450 - 17a hydroxylase activity in women with PCOS. The aim of 
this study was to examine whether suppression of ovarian function using a 
gonadotrophin releasing hormone agonist (GnRHa), and provoking adrenal 
function in the absence and presence of metformin, may reveal an effect of 
metformin upon adrenal steroid output in 18 women with PCOS and 8 control 
patients. Our results suggest that GnRH-A suppression of ovarian activity had 
little effect upon the responses of 170HP to standard synacthen tests or upon 
basal circulating concentrations of 170HP of adrenal origin in controls or women 
with PCOS. However, In women with PCOS, combined GnRH-A and metformin 
induced reductions in both the 170HP__AUC and also circulating basal 
concentrations of 170HP. This implies that metformin treatment was responsible 
for suppression of both basal adrenal biosynthesis of 170HP and its responses
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to exogenous ACTH stimulation. This suggests that the activity P450-17a 
hydroxylase may be abnormal in women with PCOS in the adrenal as well as the 
ovary, and that excessive insulin stimulation is the underlying controlling factor.
6.1 Introduction
Polycystic ovary syndrome is a common cause of anovulation and infertility, and 
is associated with insulin resistance and hyperandrogenlsm. High circulating 
androgen concentrations may be produced by either the ovary or by the adrenal 
gland. About 25% to 60% of women with hyperandrogenlsm display excessive 
adrenal androgen levels (65, 66).
There is evidence that the insulin sensitising drug metformin can improve 
menstrual cyclicity and fertility in hyperandrogénie women with PCOS. One of the 
effects of metformin (in the majority of studies) is to reduce the circulating 
androgen concentrations. However, it is difficult to detect by analysing serum 
androgen levels whether metformin is exerting its effects at the level of the ovary 
or the adrenal gland, or both.
Studies have shown that metformin treatment can influence the ovarian 
production of 17 hydroxyprogesterone (170HP) through the activity of 
cytochrome P450 - 17a hydroxylase activity in women with PCOS (24, 67). 
However, these have been effected in women with different patterns of 
endogenous ovarian activity, and the possibility of a contributory effect of adrenal 
origin was not explored. It was considered that the investigation Into the role of 
the adrenal in these tests should be explored further, in the absence of ovarian 
activity, removing any influence of changes in ovarian androgens.
This study aimed to examine whether suppression of ovarian function using a 
gonadotrophin releasing hormone agonist (GnRHa), and provoking adrenal
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function in the absence and presence of metformin, may reveal an effect of 
metformin upon adrenal steroid output.
6.2 Subjects and methods
6.2.1 Study population
A total of 33 pre-menopausal women were recruited from the Reproductive 
Endocrinology and Assisted Conception Unit clinics at the Royal Infirmary, 
Glasgow, UK. Patients were recruited if they were found to have a diagnosis of 
PCOS (described earlier In chapter 2) and a raised free androgen index. Other 
characteristics of patients recruited included being of reproductive age (range 19- 
39 years; mean for PCOS patients 32 and for control patients 33 years), no 
limitation of weight (range 52-111 kg), BMI (21-44 kg/m ;^ mean for PCOS patients 
35 and for control patients 30 kg/m^), WHR (range 0.68-1.04; mean for PCOS 
patients 0.88 and for control patients 0.78), and variable severity of hirsutism, 
acne, alopecia and acanthosis nigricans. Twenty four of these women were 
diagnosed as having hyperandrogénie PCOS, and 9 were controls (women 
without PCOS). Eighteen women with PCOS and 8 controls completed all 3 visits 
(see Figure 6.1a/b). Exclusion criteria were: contraindications to metformin, or 
metformin within last 4 months. None had thyroid dysfunction, 
hyperprolactinaemia, diabetes mellitus, or late-onset congenital adrenal 
hyperplasia. Women taking medication known to affect gonadal or adrenal 
function, or carbohydrate or lipid metabolism were also excluded.
Informed consent was obtained from each woman, and the study was conducted 
at the Royal Infirmary, Glasgow, UK, following approval from the ethics 
committee of the North Glasgow Hospitals University NHS Trust.
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6.2.2 Study design
Recruitment patients were down regulated using a GnRH agonist (Prostap). Two 
weeks later they then underwent the first synacthen test. They were then 
randomised to either metformin or no metformin. The patients randomised to 
metformin commenced the medication at a dose of 500mg tds for two weeks. 
After treatment or no treatment for two weeks all volunteers then returned for the 
second synacthen test.
The study was a prospective randomised controlled trial and power was 
calculated to detect a 15% difference AUG. The PCOS patients and controls 
were randomly assigned a treatment number (computer aided random number 
generation) and patients (controls and PCOS) with odd numbers received 
metformin while those with even numbers did not.
6.2.3 Assessment programme
Assessments were performed at baseline (TO), two weeks (T2), and four weeks 
(T4). Obtained at baseline was clinical history, including the date of the last 
menstrual period, menstrual frequency, symptoms of hirsutism/ acne/ acanthosis 
nigricans/ alopecia, and anthropometric data including measurements of height, 
weight, waist and hip (WHR). Hormonal assessments at baseline included those 
of E2, progesterone, testosterone, SHBG, and LH. All patients (PCOS and 
controls) then received a depot injection of the GnRH analogue Prostap. Two 
weeks later they then underwent a Synacthen test (Tetracosactrin 250mcg IV) to 
assess their adrenal function (fasting; Test 1). Blood analytes were performed at 
half hourly intervals including baseline, for 90 minutes, for E2, testosterone, 
progesterone, androstenedione, 170HP, DHEAS, LH, FSH, and SHBG. Initial 
sample prior to Synacthen being given also included HbAIC, insulin, and
135
glucose. All patients were then randomised to receive metformin 500mg tds or no 
medication for 14 days. After this time interval the patients returned to have a 
repeat Synacthen test performed (Test 2). The same time interval blood analytes 
were obtained.
At each assessment (TO, T2, T4) a transvaginal ultrasound was performed for 
ovarian morphology, ovarian volume, and size of the largest ovarian follicle in 
each respective ovary.
6.2.4 Methods
In addition to those covered in Chapter 2 are:
Acne was assessed by the presence of inflammatory follicular sebaceous units at 
any one time.
Acanthosis nigricans was noted by the presence of flexural hyperpigmented skin 
thickening.
Alopecia was noted by the presence of balding of the head in a male pattern 
distribution.
6.3 Results
6.3.1 Limitations of the hormone analyses
Unfortunately, the GnRH-A suppression of ovarian function reduced the 
circulating concentrations of both testosterone and androstenedione to close to 
the limits of assay sensitivity, and it was decided to make no use of these data. 
Correspondingly, the analyses are restricted to the adrenal product 170HP and
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its responses to the synacthen tests before and after GnRH-A suppression, with 
and without metformin treatment.
6.3.2 Circulating 170HP concentrations prior to ovarian 
suppression
Table 6.1 shows that the circulating concentrations of 170HP were not 
significantly higher in the PCOS group prior to the first synacthen test, and that 
the greater response to stimulation (AUC) seen in the PCOS group was also not 
statistically significant (p = 0.06).
6.3.3 Influence of GnRH-A suppression and metformin 
upon responses of 170HP to synacthen
Table 6.2 shows that the AUC of 170HP following synacthen stimulation was not 
influenced by GnRH-A suppression of ovarian function as there was no difference 
in the 170HP_AUC between test 1 and test 2 for either Controls No Metformin or 
PCOS No Metformin. In contrast, there was a highly significant (p=0.005) 
reduction in the 170HP_AUC by combined GnRH-A and metformin 
demonstrated in the 170HP Metformin group. There were insufficient values for 
assessment of the responses of the control group to GnRH-A and metformin.
6.3.4 Influence of GnRH-A suppression and metformin 
upon circulating concentrations of 170HP.
Table 6.3 shows that although there appeared to be a suppression of circulating 
170HP (at TO) by GnRH-A in the small number of cases in the Controls No 
Metformin group, no effect was seen in the PCOS (p = 0.12). In contrast, the
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PCOS Metformin group showed a significant (P = 0.04) reduction in circulating 
concentrations of 170HP. There was no difference between PCOS no metformin 
and PCOS metformin baseline 170HP values prior to treatment.
There was no difference in the absolute concentrations of 170HP or 
170HP_AUC values between the PCOS and control groups afforded by GnRH-A 
treatment alone or combined with metformin. However, the results for the PCOS 
group treated with metformin showed a statistically significant result (see 
Figure 6.2).
6.4 Discussion
These data demonstrate that GnRH-A suppression of ovarian activity had no 
effect upon the responses of 170HP to standard synacthen tests or basal 
circulating concentrations of 170HP of adrenal origin in controls or women with 
PCOS. However, in women with PCOS, combined GnRH-A and metformin 
induced reductions in both the 170HP_AUC and also circulating basal 
concentrations of 170HP. This implies that metformin treatment was responsible 
for suppression of both basal adrenal biosynthesis of 170HP and its responses 
to exogenous ACTH stimulation. This suggests that the activity P450-c17 
hydroxylase may be abnormal in women with PCOS in the adrenal as well as the 
ovary.
‘Dysregulation’ of cytochrome P450c17a has been proposed to result in the 
exaggerated secretion of ovarian androgens in PCOS (130). Both 17a 
hydroxylase and 17, 20 lyase activity arise from the action of the enzyme 
P450c17a which is expressed in both adrenocortical and ovarian tissue (131). 
Thus, it has also been hypothesised that this ‘dysregulation’ of cytochrome 
P450c17a may also be occurring in the adrenal gland (4).
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Hyperinsulinaemia and subsequent raised androgen concentrations from either 
an ovarian or adrenal source have been found to be a prominent feature of the 
polycystic ovary syndrome. Lanzone et al demonstrated that hyperinsulinaemia 
in women with PCOS affects adrenal androgen production (132), and there are 
also in vitro and in vivo studies showing that insulin potentiates the response of 
adrenal steroidogenesis to ACTH. Moghetti et al found that insulin Infusion in 
hyperandrogénie women potentiates ACTH-stimulated 17-hydroxypregnenelone 
and 17-hydroxyprogesterone responses. This effect was likely due to stimulation 
of the P450c17a leading to an increase of the 17a hydroxylase and 17,20 lyase 
activity, with the former being enhanced markedly more than the letter (133). 
Martikainen et al also showed that the selective catheterisation of the adrenal 
gland in hyperinsulinaemic hyperandrogénie women resulted in significant 
correlations with insulin and androgen concentrations (134). Studies have shown 
that metformin treatment can influence the ovarian production of 17 
hydroxyprogesterone (170HP) through the activity of cytochrome P450c-17a 
hydroxylase activity in women with PCOS (24, 67). This raises the question of the 
potential for IS As to address adrenal androgen production possibly via the same 
route.
La Marca et al found that the administration of metformin to unselected women 
with PCOS led to a reduction in the adrenal steroidogenesis response to ACTH 
(37). This was in the form of reduced response of 170H and androstenedione to 
ACTH, equating to a reduction in adrenal cytochrome P450 activity. Metformin 
presumably brought about a reduction in 17a hydroxylase and 17,20 lyase 
activity by reducing insulin levels, however, proof of hyperinsulinaemia was not 
an inclusion criteria. This result was in agreement with the findings by Arslanian 
et al that found that metformin treatment of obese adolescents with PCOS and 
impaired glucose tolerance was beneficial in improving glucose tolerance and
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insulin sensitivity, in lowering insulinaemia, and in reducing elevated androgen 
levels (135). They found that metformin therapy was associated with attenuation 
of the adrenal steroidogenic response to ACTH with androstenedione, 170H, and 
17hydroxypregnenelone lower after metformin treatment. Recently, pioglitazone 
(an ISA) administration was found to reduce the response of 170H and 
androstenedione to ACTH, most likely due to an inhibition of cytochrome 
P450c17a (136).
Contrary to these findings 2 studies found that the dysregulation hypothesis of 
cytochrome P450c17a was unlikely to be a factor in adrenal androgen 
production. Azziz et al found that the steroidogenic profile in a population of 92 
hyperandrogénie women before and after ACTH stimulation was not consistent 
with dysregulation of cytochrome P450c17a. However, in this trial there was no 
diagnosis of PCOS made prior to inclusion, and no use of ISAs employed (137). 
Also, Unluhizarci et al also found that the treatment of insulin resistance with 
metformin did not improve adrenal cytochrome P450c17a enzyme dysregulation 
in PCOS with no reduction in 170H and androstenedione (138). This was a small 
trial (15 pts with PCOS and 10 controls) and only SOOmg BD was used possibly 
reflecting suboptimal dosing. Our results suggest that there may be an 
abnormality in the action of cytochrome P450c17a in the adrenal gland as well as 
the ovary. It should also be noted that in none of the trials in the literature did they 
employ down regulation of ovarian function in an attempt to decrease background 
ovarian androgen ‘noise’.
It is unknown if this proposed dysregulation of cytochrome P450c17a is genetic 
or acquired. A genetic defect in serine phosphorylation in PCOS may lead to 
enhanced 17,20 lyase activity in both the ovary and adrenal gland (139), a great 
deal further work in this area is required to elucidate if the ‘dysregulation’ of
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cytochrome P450c17a hypothesis may be correct, and if so, then the evolution of 
this abnormality whether it be genetic or acquired.
Table 6.1
The concentrations at TO and the AUC of 170HP at synacthen test 1 in controls 
and PCOS patients at the start of the experiment.
ITOHPatTO 170HPAUC
Test 1 Test 1
Mean
(ng/ml)
CLs Mean
(ng/ml)
CLs
Controls 
(All, n = 8)
1.08 0.46-1.69 10.7 7.58-13.8
PCOS 
(All, n = 18)
1.53 0.98 -  2.07 14.4 12.0-16.7
P (unpaired t test) 0.303 0.06
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Table 6.2
Responses of circulating 170HP (AUC) in the 3 groups of patients to their 2 
synacthen tests. The responses to the two tests were compared within groups 
using paired t tests.
Test 1 refers to the first Synacthen test prior to randomisation using metformin. 
Test 2 refers to synacthen testing after randomisation using metformin.
170HP_AUC
Test 1 Test 2 P
n Mean
(ng/ml)
CLs Mean
(ng/ml)
CLs Paired 
t test
Controls 
No Metformin
5 10.1 7.08-13.1 9.79 7.28-12.3 0.75
Controls
Metformin
3 11.7 11.4
PCOS
No Metformin
10 13.9 11.3-16.5 14.0 10.7-17.2 0.94
PCOS
Metformin
8 14.9 9.75-20.1 12.4 7.75-17.0 0.005
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Table 6.3
Mean concentrations of 170HP at the start of the 2 synacthen tests. Within 
group comparisons between test 1 and test 2 were effected using paired t tests.
17OHP_T0
Test 1 Test 2 P
n Mean
(ng/ml)
CLs Mean
(ng/ml)
CLs Paired 
t test
Controls 
No Metformin
5 0.81 0.28-1.34 0.57 0.18-0.95 0.02
Controls
Metformin
3 1.52 1.43
PCOS
No Metformin
10 1.36 0.75-1.97 1.06 0.61-1.52 0.12
PCOS
Metformin
8 1.73 0.58 -  2.88 0.96 0.38-1.54 0.04
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Figure 6.1a
Recruitment to the adrenal androgen trial for the patient group: PCOS
T4
TO n = 18
T2
Prostap given
Synacthen test 1
No Metformin Metformin
n=10 n=8
Synacthen
test
2
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Figure 6.1b
Recruitment to the adrenal androgen trial for the patient group: controls
T4
TO Controln = 8
T2
Prostap given
Synacthen test 1
No Metformin Metformin
n = 5 n = 3
Synacthen
test
2
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Figure 6.2
Comparisons of mean concentrations of circulating 170HP (AUC) and basal 
circulating 170HP for all three groups to their two synacthen tests.
17a-OH
Proges­
terone
(nmol/L)
P = 0,04Test 1
Test 2 P = 0.12
P = 0.02
P = 0.005
P = 0.94
P = (L75
Control
No Metformin 
Metformin
^  ♦   —  ' '♦
PCOS
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Chapter 7
Case Report:
Increased dosing of metformin treatment 
may result in greater weight loss in a 
woman with PCOS
The insulin sensitising agent, metformin has been used for many years in 
patients with glucose intolerance and has been associated with either weight 
reduction, or weight maintenance while control groups increase weight. Although 
weight loss is evident in a number of studies, many of which have been of short 
duration it is generally of a modest degree (42, 44-48). This is in contrast to the 
results presented in the metanalysis by Lord et al (15) that states that there is no 
significant reduction in weight using metformin.
In an attempt to determine whether the morbidly obese are refractory to 
metformin or whether they may respond to either higher doses or more protracted 
treatment we performed the trial described in Chapter 5. Generally, we found a 5- 
6% reduction in weight following treatment for 8 months. Azziz et al also found a 
dose response to weight loss using Troglitazone, another insulin sensitising 
agent (77). Some women show little or no weight loss, while others show clear 
and rapid responses.
Here we highlight a case of a morbidly obese woman treated with a high dose of 
metformin (2550 mg/d), which resulted in a dramatic reduction in weight. The aim 
was to attempt to determine why this case may have been exceptional, and 
whether there were other, perhaps endocrine, differences associated with this 
case.
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7.0 Case report
A 30 year old Caucasian female presented to the Reproductive Endocrinology 
Unit at the Royal Infirmary, Glasgow, UK, complaining of primarily morbid obesity, 
but also of menstrual disturbance and significant hirsutism. Table 7.1 shows that 
her weight was recorded asl 20.8kg, with a BMI of 44 kg/m^ and walst/hip ratio of 
0.871 (waist measurement 121cm, hip measurement 139cm). Gastric banding 8 
months prior to presentation had failed to result in any weight loss. She had a 
history of amenorrhea, her last menses being in 1995, and she had never 
conceived despite a lack of contraceptive use. At the time of the trial she was not 
sexually active. She was also severely hirsute (Ferrlman Gallwey score = 25). A 
reproductive hormone concentration screen in peripheral plasma revealed that 
she had a modestly raised free androgen index of 9.4 (upper limit of normal = 
7.9), low sex hormone binding globulin (18nmol/l), a normal total testosterone of 
1.7nmol/l and also a normal LH concentration of 6.8 lU/L. The patient had a 
classic appearance of POO on ultrasound scan, and a diagnosis of PCOS was 
made.
There was no evidence of thyroid dysfunction, diabetes mellitus, 
hyperprolactinaemia or congenital adult onset adrenal hyperplasia (DHEAS,
2.8 pmol/1; 17aOHProgesterone, 3.0 nmol/L). Not surprisingly, she was found to 
be significantly insulin resistant with a raised fasting insulin of 41 lU/ml 
(laboratory upper limit of normal = 13 lU/ml) with a fasting glucose of 5.0mmol/L 
(Table 7.2)
Table 7.2 also shows that other measurements prior to treatment including 
HOMA-IR, leptin, CRP, total cholesterol, triglycerides, HDL, LDL and VLDL were
148
unexceptional for an individual displaying such obesity. She was taking no 
medication at the time of commencement of metformin.
As part of the ongoing trial examining the weight reducing effects of metformin 
(Chapter 5), the patient was randomised to metformin 850mg tds following 
informed consent. It should be stressed that there was no specific instruction as 
to diet and exercise. The medication was found to be extremely well tolerated at 
one and two months follow up. However, interestingly, she complained of feeling 
constantly warm regardless of the ambient temperature, which was associated 
with significant sweating.
The patient re-presented at the scheduled intervals of 4 and 8 months. Table 7,1 
shows the changes in BMI, weight, WHR, waist and hip measurement at baseline 
(TO), 4 (T4) and 8 (T8) months. It shows that WHR showed negligible change as 
weight was lost at both the waist and the hips. At the 4 month clinic appointment 
her weight had undergone a dramatic reduction such that she had never 
previously experienced. Her weight had reduced by 21.8kg, and by the 8 month 
appointment she had lost a total of 27kg in weight. Accordingly, her BMI 
decreased 10 kg/m .^
Correspondingly, she showed changes in most other parameters at 4 months and 
then again at 8 months: Table 7.2 shows changes for endocrine, metabolic and 
lipid parameters. There was negligible change in LH, or LDL. Table 7.3 shows 
changes over the time points for ultrasound parameters.
An important observation throughout the trial was that this patient experienced 
significant and distressing diaphoresis. No attempt at objective measure was 
made of this however.
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7.1 Discussion
With a high dose of metformin treatment this morbidly obese patient underwent 
dramatic weight loss over 8 months. This was most marked in the initial four 
months. Associated with these changes was a negligible change in her waist hip 
ratio. The greatest reduction in her lipids was with triglycerides and VLDL. There 
was however, no change in her LDL level. HDL improved moderately. Weight 
loss was associated with a decrease in the inflammatory marker of CRP 
corresponding to an overall decrease in cardiovascular risk. Of note is that she 
had a resumption of menstruation once again most marked in the initial 4 months. 
Interestingly however, metformin showed significant improvement in the glucose / 
insulin ratio and the HOMA-IR, however, it had negligible impact upon circulating 
androgens. Also, an important observation in this individual case was the 
patient’s significant ongoing complaint of excessive sweating. Despite this trial 
being conducted over the Scottish winter the patient found this to the point of 
being extremely distressing and embarrassing, as she had not experienced 
significant diaphoresis prior to being commenced on metformin. In this case 
study, it may be that the side effects of sweating and reported heat are due to a 
normalisation of postprandial thermogenesis often described in women with 
PCOS. Robinson et al (140) found that PCOS subjects have a reduced 
postprandial thermogenesis that related statistically to the reduced insulin 
sensitivity. They also hypothesised that the decreased postprandial 
thermogenesis may predispose women with PCOS to weight gain. Brooks et al
(141) found that, in Type 2 diabetic patients given Acarbose, it improved energy 
expenditure and diet induced thermogenesis postprandially. However, Segal et al
(142) although confirming blunted thermogenesis in obese patients, failed to 
demonstrate evidence of altered resting metabolic rate or postprandial
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thermogenesis in women with PCOS compared with women of similar degrees of 
obesity. It should be noted however, that ail three of these trials were of small 
numbers (<15 PCOS, <15 controls).
This patient showed distinct improvements in circulating fasting glucose, and 
perhaps more significantly in the Glu/lns ratio. Before treatment she showed one 
of the poorest G/l ratios (marker of efficiency of insulin action) and she ended 
with one of the better one) -  so maybe there is something critical about this case 
in that metformin improved glucose uptake more than in others. Thus, it may be 
that the beneficial effects of weight loss appear to be mediated primarily through 
glycaemic metabolic pathways rather than effects upon circulating androgens, 
and it may be that women with morbid obesity may respond better to higher 
doses of metformin, as discussed in chapter 5.
Quite why this patient showed such remarkable weight loss is not clear, but there 
were a number of distinctive features about this case. Despite her multiple 
ovarian cysts and enlarged ovarian volume, she showed an unremarkable 
androgen profile. Her FAI was elevated more because of the low SHBG than the 
total androgens.
It is well known that PCOS is characterised by a great variety of symptoms, and 
this case appears to be one whose symptoms are more related to abnormal 
glucose / insulin metabolism than to hyperandrogenism: the latter being a product 
of excessive insulin secretion.
The ability of metformin to increase glucose uptake appears to have corrected all 
the manifestations, including reduced lipid production and deposition, and maybe 
produced her thermogenesis.
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It also supports the observation that metformin works best in women with least 
endocrine (androgen) disturbance.
Thus, it may be in this case, by correcting abnormal insulin metabolism rather 
than by significantly reversing hyperandrogenism, metformin resulted In this 
patient’s dramatic weight loss.
(see Appendix re patient letter)
Table 7.1
Changes in anthropometric parameters, FG score and menses over the three 
time intervals (TO, T4, T8).
TO T4 T8
Weight (kg) 120.8 99 93.8
Waist (cm) 121 112 108
Hip (cm) 139 127 121
WHR 0.871 0.882 0.893
BMI (kg/m^) 44 35.9 34
FG score 25 25 18
Menses (n) 0 3 4
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Table 7.2
Changes in endocrine, metabolic and lipid parameters over the three time 
intervals (TO, T4, T8).
TO T4 18 % Change 
(T4-T8)
% Change 
(T0-T8)
Testosterone
(nmol/L)
1.7 1.3 0.7 46 i 59 i
SHBG
(nmol/L)
18 19 22 16 Î 22 Î
FAI 9.4 6.8 3.2 53 i 66 4
Insulin
(lU/ml)
41 19 15 21 i 63 4
Glucose
(mmol/L)
5.0 4.7 4.6 2 i 84
HOMA- IR 9.0 4.0 3.1 22 i 66 4
Glu/lns Ratio 0.12 0.25 0.31 24 Î 58 T
IGF-1
(ng/mi)
85 188 195 4Î 29T
Leptin
(ng/ml)
59.4 27.8 36.2 30 T 394
CRP (mg/L) 8.8 4.88 3.8 22 i 57 4
Cholesterol
(mmol/L)
4.52 4.16 4.22 1 Î 74
TG (mmol/L) 4.14 2.02 1.42 30 1 66 4
HDL
(mmol/L)
0.53 0.86 0.98 14 T 85 t
VLDL
(mmol/L)
1.89 0.92 0.65 29 4 66 4
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Table 7.3
Changes for ultrasound parameters over the three times intervals.
TO T4 T8
Right ovarian 
volume (cm )^
14.7 12.2 16.3
Left ovarian 
volume (cm®)
14.9 12.0 9.6
Mean no. of 
cysts (n)
16 15 13
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C hapter 8
Case Report:
Metformin treatment may alter responses of 
mature follicles to the lutelnlsing signal In 
polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) Is a disorder of chronically abnormal ovarian 
function and hyperandrogenism affecting 5-10% of the female population of 
reproductive age (1). Insulin resistance I hypersecretion is an intrinsic feature 
underlying PCOS, particularly in obese individuals (5, 6, 120). The 
corresponding hyperinsulinaemia, in concert with increased LH exposure, is 
probably responsible for increased ovarian androgen secretion, and abnormal 
follicular development, which ultimately leads to dysfunctional follicular 
development and anovulation (143). We would presume that this primary function 
would be enacted through increased insulin/ LH drive to the thecal cells of 
follicles, since granulosa cells do not produce androgens. However, the 
granulosa cells of mature follicles acquire LH receptors in the latest stage of pre­
ovulatory development, but there is little evidence indicating whether insulin can 
influence these phenomena as well.
Treatment of women with PCOS with ISAs has been shown to promote follicular 
growth (16). Notable observations include i) that the interval from start of 
treatment to first ovulation is significantly reduced (47, 77) and ii) menstrual or 
ovulation cyclicity is increased with metformin treatment compared to placebo 
(16). The mechanism underwriting these changes is presumed to reflect a
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reduced insulin promotion of intrafoilicular androgen biosynthesis, an excess of 
which may induce follicular atresia. However, troglitazone (23) and recently 
metformin (144) have also been shown to influence ovarian steroid biosynthesis 
directly.
Metformin treatment of PCOS patients undergoing controlled ovarian stimulation 
(COS) for in vitro fertilisation with co-treatment with metformin may also improve 
outcome (40, 52). These studies are generally poorly controlled, with issues of 
variable exogenous gonadotrophin dose, but metformin pre-treatment may allow 
a more orderly follicular growth in response to stimulation. A recent prospective 
study in assisted conception found no change in the ovarian responses to FSH 
afforded by metformin. This shows that short term metformin treatment (<4 
months) failed to influence the number of follicles recruited by high FSH 
concentrations (145). The evidence pertaining to actions of insulin or 
hyperinsulinaemia is restricted to aspects of follicular growth and development -  
generally of immature follicles. We present here a case providing circumstantial 
evidence supporting the concept that the response to the luteinising signal may 
also be an area influenced by insulin or hyperinsulinaemia. Correspondingly, this 
would imply that the excessive insulin drive is acting at this stage through the 
granulosa cells.
8.0 Case report
A 30 year old female of Asian origin presented to the Assisted Conception Unit at 
the Royal Infirmary, Glasgow, UK, with a six year history of infertility. She had a 
history of oligomenorrhoea (cycle length; 6-20wk), and was severely hirsute 
(Ferriman Gallwey score = 34). A reproductive hormone concentration screen in 
peripheral plasma revealed that had a raised free androgen index of 13.0 (upper
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limit of normal = 7.9), low sex hormone binding globulin (16nmol/l), and an 
elevated LH concentration (10 lU/L). Her BMI was 30 kg/m^ with a weight of 
70kg, and she was found to be insulin resistant with a raised fasting insulin of 
25.8 lU/ml (laboratory upper limit of normal = 13 lU/ml. The patient had a classic 
appearance of PCO on ultrasound, and a diagnosis of PCOS was made. A 2hr 
fasting oral glucose tolerance test revealed a 2h glucose concentration of 
8.6mmol/L, consistent with glucose intolerance, not NIDDM. There was no 
evidence of thyroid dysfunction, hyperprolactinaemia or CAH (DHEAS,
3.9 jj.mol/L; 17aOHProgesterone, 8.0 nmol/L).
Her partner’s semen analysis showed a reduced sperm count, and the couple 
were recommended to undergo COS and intracytoplasmic sperm injection (ICSI) 
treatment.
The couple underwent 2 conventional cycles of COS with a standard long GnRH- 
agonist protocol (Chapter 2) for ICSI, using human menopausal gonadotropin 
(HMG) as the ovarian stimulant, and similar, but abnormal responses were 
observed. Table 8.1 shows that both treatment cycles progressed well with 
multiple follicular development and associated high estradiol (E2) concentrations. 
In the first 2 cycles the follicular phases were of 16 days and 14 days 
respectively, yielding circulating E2 concentrations of 9000 pmol/L and 6000 
pmol/L, associated with more than 6 follicles in each cycle whose follicular 
diameter was greater than 15mm at the time of HCG. However, in both cycles, 37 
hours after HCG, at the time of oocyte pick up, the large follicles had disappeared 
and no mature oocyte was recovered. A single immature oocyte was collected in 
the second cycle. There was no evidence of premature lutéinisation as evidenced 
by progesterone concentrations on the day of HCG administration <3.0 nmol/L 
prior to HCG in both cycles.
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At review, it was suggested that the use of metformin may reduce insulin 
promoted actions at the ovarian level, which may decrease androgen 
biosynthesis and allow normal follicular and oocyte maturation to proceed, 
perhaps avoiding precocious ovulation and follicular collapse.
The patient subsequently underwent COS as before (cycle 3 in table 8.1), except 
that on the same day as the GnRH-agonist was administered, daily metformin 
treatment was commenced at a dose of 500mg tds. After 2 weeks, HMG was 
commenced at a daily dose of 150IU/day (the same dose as previous cycles) 
until >3 follicles were observed at diameter >17mm. Table 8.1 shows that the 
responses through the follicular phase were broadly similar to the previous 2 
cycles except that the follicular phase was markedly reduced in length. This 
cycle required only 8 days HMG treatment, and HCG was administered as 
before. Metformin treatment was continued until the day of oocyte retrieval 
(discontinued after the morning dose). Oocyte retrieval was performed 35h after 
HCG administration, and serial ultrasound examinations to monitor follicle size 
and number revealed no shrinkage of the follicles prior to oocyte pick-up, when 5 
oocytes were obtained, 4 of which were deemed mature at ICSI. Two days 
culture resulted in 3 good quality embryos, 2 of which were transferred to the 
uterus. Unfortunately, the patient failed to conceive.
Table 8.1 also shows that fasting insulin concentrations at oocyte pickup were 
reduced (though still above the normal range) during the metformin treated cycle 
while circulating IGF-1 and IGF-BP3 were similar in all 3 cycles.
8.1 Discussion
Although the specific actions of insulin at the ovarian level are not clearly 
understood it is thought that insulin promotes androgen biosynthesis by direct
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action on thecal cells in the presence of LH (146), and it may also play a role in 
granulosa cell function (147-149).
Restriction of follicular maturation, leading to amenorrhoea, may be incurred by a 
premature induction of LH receptors in granulosa cells. Thus, hyperinsulinaemia 
may be associated with multiple small follicle development because of abnormal 
control of follicular maturation in an environment of relatively raised LH and 
modestly reduced FSH, leading to a clinical picture of estrogenised anovulation 
consistent with PCOS. Induction of follicular growth with exogenous FSH often 
results in multiple follicular development, with apparently normal responses to 
HCG.
The main effect of metformin on ovarian function is thought to be by dint of 
reducing the degree of insulin stimulation of thecal androgen biosynthesis, and 
modifying the control mechanisms of follicular growth and maturation.
This case suggests that insulin may have a further role in ovarian function, 
previously unrecorded. The excessive hyperinsulinaemia in this case appears to 
have influenced the response of mature sized follicles to the pre-ovulatory, 
lutéinisation signal, such that lutéinisation, ovulation and follicular collapse 
(corpus luteum formation) occurred more rapidly than normal. The process 
appeared to be normalised by reducing the exposure to excessive insulin 
concentrations after metformin treatment. This concept would support the 
hypothesis that insulin promotes the actions of LH in both follicular cell types.
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Table 8.1
Changes over the three treatment cycles for hormones, ultrasound parameters 
and responses to treatment and outcomes.
Cycle no. 1 Cycle no. 2 Cycle no. 3 
(with metformin)
Fasting insulin (lU/ml) 
(at oocyte pickup)
54 109 32
IGF-1 (ng/ml) 187 203 248
Follicular phase (days) 16 14 8
Estrogen (pmol/L) 9000 6000 4000
Follicles at HCG 
(diameter >15mm) (n)
7 8 9
Follicles at HCG 
(diameter = 12-14mm) (n)
6 5 2
Follicles at GPU 
(diameter >15mm) (n)
0 0 9
Oocytes 0 1
(immature)
5
IGF-BP3 (mg/L) 5.1 4.9 5.5
Embryos 0 0 3
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Chapter 9
Discussion
9.0 Introduction
To date in the literature ISAs have been shown to have effects in women with 
PCOS both clinical and biochemical. However, there are a great many questions 
that still remain to be answered. This thesis comprises a number of studies in an 
attempt to answer certain questions that have arisen from the literature. We used 
the agent metformin due to its ready availability, good safety record, lack of 
expense and previous experience. Metformin on the whole was well tolerated by 
the patient cohorts.
We believe that the studies presented in this thesis have not only answered some 
existing questions, but raise further possibilities for the future exploratory use of 
metformin in women with PCOS.
9.1 Hirsutism
Hirsutism in women with PCOS has significant psychosocial sequelae and 
traditionally poses a difficult management dilemma. The existing treatments for 
hirsutism are time consuming (eg waxing), expensive (electrolysis, laser 
treatment), or not especially effective (COCP). The underlying hormonal basis 
for the condition is complex, but accepted to be based upon either excessive 
androgen exposure and/or sensitivity.
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It has been hypothesised that by reducing circulating insulin concentrations, 
leading to decreased free androgen concentrations, ISAs may ameliorate 
hirsutism; and some trials have addressed their use in hirsutism. In none of these 
was hirsutism a primary outcome measure and in only one of these was an 
objective measure of hirsutism used. These trials also tended to be of too short a 
duration, the longest being 6 months and the patients were only mild to 
moderately hirsute. Thus, we determined there was a need to perform a simple, 
comparative randomised trial of significant power and sufficient duration where 
not only semi-subjective but also objective measures were employed, and 
hirsutism was a primary outcome measure.
In this trial, we attempted to compare the efficacy of metformin with the ‘gold 
standard’ treatment, Dianette (ethinylestradiol and cyproterone acetate). Dianette 
has been shown, however, to have only limited efficacy in women with severe 
hirsutism, thus there is a place for an acceptable and hopefully more efficacious 
treatment in the management of women troubled by this condition.
In this trial we found that there was a clear benefit of a standard dose of 
metformin treatment on moderate to severely hirsute women with PCOS. 
Metformin reduced hirsutism on both objective and semi-subjective measures. 
The objective measure of hair diameter however was modest and comparable 
with Dianette. However, the FG score reduced dramatically and patients’ 
perception of an improvement in hirsutism was also positive. The medication was 
found to be tolerable to the majority of patients thus hopefully aiding compliance. 
The decrease in FG score was also independent of changes in BMI.
Hirsutism occurs as a result of end organ sensitivity and direct androgen 
stimulation. Tissue sensitivity is also controlled by insulin and IGF-1 activity, 
possibly through reduced IGF-BP’s.
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Contrary to the existing literature we did not see a significant decrease in 
androgenicity. Metformin treatment did however show significant improvement in 
the glucose/ insulin ratio and the logHOMA-IR, but no change in 1GF-BP1, IGF- 
BP3 or IGF-1. Thus, addressing insulin sensitivity, possibly at the local tissue 
level may be a more effective approach to hirsutism in women with PCOS.
This trial has raised further questions for future work.
Combined therapies: given that hirsutism is a result of androgen stimulation and 
insulin metabolism influences androgens and growth factors, there is a role for a 
randomised placebo controlled trial that addresses different therapies and the 
combinations. Possibilities are ISA’s including the biguanides and 
thiazolidinediones, the COCP +/- cyproterone acetate and the direct androgen 
blockers ie Flutamide and/or Finasteride.
Tissue level insulin metabolism: based on the results from this trial there is the 
suggestion that local tissue factors may play a role in the amelioration of 
hirsutism. Thus, a study to examine IGF’s at the tissue level may further clarify 
this issue.
Reduction of 019 steroid 5a reductase: a recent paper by Tsilchorozidou et al 
(150) found that insulin seems to enhance 5a reduction of steroids in PCOS in 
vivo. They found that the increased 5a reductase activity in women with PCOS 
may be secondary to hyperinsulinaemia. Thus, potentially by decreasing 
hyperinsulinaemia there may be a reduction in 5a reductase activity and thus in 
turn reducing the conversion of testosterone to the more potent DHT, thereby 
ameliorating hirsutism. A placebo controlled trial addressing insulin metabolism in 
relation to 5a reductase would be appropriate.
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9.2 Weight loss
Obesity is an extremely common feature of PCOS. This, like hirsutism, not only 
has significant psychosocial consequences, but also those of adverse 
reproductive and cardiovascular outcomes. The Cochrane database review did 
not confirm that weight loss was a significant factor in the use of metformin for 
weight loss in women with PCOS. This is contrary to a number of reports in the 
literature that note modest weight loss with metformin. It may be that significant 
obesity may reduce the benefit of metformin treatment and thus greater doses of 
metformin are required to observe an effect.
In this trial the aim was to determine whether different doses of metformin could 
have different effects upon features associated with PCOS, notably, weight 
reduction, circulating hormone changes, markers of inflammation and lipid 
profiles.
We found that women with PCOS respond to metformin in a manner related to 
both the dose and their body mass. Firstly, weight loss was a feature of 
protracted metformin therapy. Both the degree of weight reduction and the 
degree of suppression of circulating androstenedione in obese women were dose 
related, however, the morbidly obese group showed no such changes. This 
finding implies that the degree of obesity impacts upon responses to metformin. 
The effects of metformin upon lipid profiles were generally beneficial and 
appeared to be unrelated to metformin dose, degree of obesity, or weight 
change. Effect of metformin upon CRP showed a trend towards benefit without 
reaching statistical significance.
Our results raise the question as to why we did not see any significant results in 
the morbidly obese group. It may be simply that an even greater dose of 
medication is required given the degree of obesity. Alternatively, it may be that
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the nature of insulin metabolism is more complex in the morbidly obese which 
requires further elucidation. Regardless, given the pharmaceutical restriction of 
maximum dosing (3g/day) there is scant leeway for further increasing the dose, 
especially in light of a lack of licensing for use in women with PCOS. Thus, it may 
be that the pathway for future work in this area should be directed towards other 
means of achieving weight loss in conjunction with metformin treatment.
Lifestyle modification: this must remain the mainstay of weight loss 
programmes with or without metformin treatment. This dogma was reinforced by 
the UKPDS study as mentioned previously, and the results from our study 
reiterate this. It may be that further weight loss medications may need to be 
added to the regime in an attempt to decrease weight by whatever means 
possible. By enabling weight loss we would expect a greater benefit on lipids as 
in our study we saw no significant benefit of a dose response with differing doses 
of metformin, and we would also expect an improvement in CRP levels thus 
reflecting a reduction in the long term risk of cardiovascular compromise.
9.3 MIS
Ovarian function in PCOS is characterised by an Increased ratio of growing 
follicles to primordial stage follicles: the rate of initial recruitment of ovarian 
follicles and progress through developmental stages appears to differ from 
normal and result in excessive antral follicles. MIS is a product of granulosa cells 
and because there are excessive follicles present in PCOS, it has been found to 
be raised in women with PCOS. Its potential role in regulating follicular 
recruitment and growth has yet to be determined in humans. Prior to this study, 
the effect of ISAs on circulating concentrations of MIS In PCOS had not been 
explored. The aims of this study were to explore the relationship between MIS
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and other reproductive parameters in obese women with PCOS, and also to test 
the hypothesis that reducing the degree of insulin stimulation to the ovaries in 
these women, using protracted metformin therapy, would reduce the circulating 
concentrations of MIS. This trial was undertaken as a result of sample aliquots 
stored from the weight loss trial and eventually the availability of a suitable assay 
for circulating MIS.
The results show that the treatment of women with PCOS with metformin resulted 
in a highly significant reduction in the circulating concentrations of MIS. They also 
show that the suppressive effects occur only after protracted treatment of the 
time scale suggestive of effects upon initial follicular recruitment. Thus, within the 
first 4 months, despite a rapid reduction of androgen concentrations, possibly as 
a result of the reduced insulin stimulation of the existing thecal cells, there was no 
observed effect on the number of ovarian follicles present or on the circulating 
MIS. However, when we continued treatment beyond the 4month time interval in 
an environment of continued insulin metabolism normalisation, there was a 
decrease in the number of ovarian follicles. This may represent a reduction in the 
total mass of granulosa cells, secondary to a reduction in the number of FSH 
responsive follicles evident at the 8 month point. There was some evidence of a 
reduction in the number of small follicles at this stage, although there was no 
change in ovarian volume, perhaps indicating that the existing follicles were 
growing to more advanced stages. It was not evident from our study if the 
emphasis was on reduction of androgen concentrations or on the normalisation of 
insulin metabolism to achieve these results, however, as it has been shown in the 
literature that hyperinsulinaemia facilitates raised androgen concentrations then 
by ameliorating hyperinsulinaemia we can attempt to achieve the same result. 
These results suggest that the existing literature of the effect of ISAs on ovarian 
function are too short in duration. Only after 4-8 months should the effects of
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metformin on the underlying ovarian function be examined. Thus, longer trials 
are required to elucidate this further. Perhaps this also indicates a role for longer 
treatment of women with PCOS undergoing assisted conception cycles. A recent 
prospective study in assisted conception (145) found no change in the ovarian 
responses to FSH afforded by metformin. This shows that short term metformin 
treatment failed to influence the number of follicles recruited by high FSH 
concentrations. Correspondingly, the patients remained at risk of ovarian 
hyperstimulation. Our data imply that to achieve improved safety in this area, the 
metformin pre-treatment should be more of the order of 6 months.
9.4 Adrenal androgens
High circulating androgen concentrations may be produced by either the ovary or 
by the adrenal gland, and metformin has been shown to reduce androgen 
concentrations in women with PCOS. However, it is difficult to detect by 
analysing serum androgen levels whether metformin is exerting its effects at the 
level of the ovary or the adrenal gland, or both. Metformin treatment can influence 
the ovarian production of 17ahydroxyprogesterone (170HP) through the activity 
of cytochrome P450 - 17a hydroxylase activity in women with PCOS. It has been 
found that the activity of this enzyme, found in both ovarian and adrenal tissues, 
is influenced by insulin drive. It was considered that this hypothesis of 
dysregulation of cytochrome P450 - 17a hydroxylase activity may also be a factor 
in hyperandrogenaemia from an adrenal source. It was decided that this should 
be explored further, and that this should be tested, as far as possible, in the 
absence of ovarian activity, removing any influence of changes in ovarian 
androgens.
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This study aimed to examine whether suppression of ovarian function using a 
gonadotrophin releasing hormone agonist (GnRHa), and provoking adrenal 
function in the absence and presence of metformin, may reveal an effect of 
metformin upon adrenal steroid output. Despite the fact that this work remains 
incomplete (as we intend performing DHEA and DHEAS assays on the stored 
samples) this trial showed some very interesting results pertaining to 170HP.
The data suggest that GnRH-A suppression of ovarian activity had little effect 
upon the responses of 170HP to standard synacthen tests or upon basal 
circulating concentrations of 170HP of adrenal origin in controls or women with 
PCOS. However, in women with PCOS, combined GnRH-A and metformin 
induced reductions in both the 170HP_AUC and also circulating basal 
concentrations of 170HP. This implies that metformin treatment was responsible 
for suppression of both basal adrenal biosynthesis of 170HP and its responses 
to exogenous ACTH stimulation. This suggests that the activity P450-17a 
hydroxylase may be abnormal in women with PCOS in the adrenal as well as the 
ovary, and that excessive insulin stimulation is the underlying controlling factor. 
Adrenal gland trials: as the adrenal gland is a less complex organ compared 
with the ovary, there may exist a role for the adrenal gland to help us examine the 
dynamics of PCOS and efficacies of different treatments in an attempt to develop 
alternate therapeutic approaches. If this were to occur then it would be advisable 
to perform a trial in which ovarian down regulation is compared with non ovarian 
down regulation. The changes observed in basal levels of 170HP may not have 
been evident in the absence of ovarian down regulation, because mature follicles 
and corpora lutea secrete significant quantities of 170HP.
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9.5 Conclusion
Widespread use of metformin in PCOS is based upon a broad consensus 
with a poor evidence base in a broad clinical environment. Perhaps 
because of the multiple symptoms of PCOS, there are many and complex 
reasons for actively treating women with ISAs in general and metformin in 
particular. Unfortunately, the evidence supporting this widespread use is 
playing catch-up with clinical practice, and alternative strategies such as 
exercise driven weight reduction appear to have less appeal, but may be 
more beneficial in the long run. Or perhaps there is a role for combined 
therapies.
We have been able to show that for women with moderate to severe 
hirsutism, metformin may provide a better treatment modality than the 
standard OCP Dianette. However, the main recommendation from this work 
would be that future studies should explore combined therapies. 
Concerning the long term health indications of women with PCOS, the 
comparative dosing examination revealed that higher doses of metformin 
may be more beneficial in weight reduction and suppressing androgen 
concentrations under some circumstances, but the modest effects upon 
indicators of cardiovascular and diabetic risk would not support a high 
dosing regime.
Most of the original work with metformin in PCOS explored effects upon 
ovarian function. These studies, by dint of their duration, tended to be 
examinations of the effects of insulin upon the functions of LH (or thecal 
cells) in the excess of established follicles. We present novel information 
suggesting that prolonged treatment with metformin may result in a degree 
of correction of the principle underlying factor in PCOS -  the excessive
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incidence of initial recruitment and survival of ovarian follicles. Of course 
this is speculative, but it would be interesting to examine further.
The dysregulation of P450- 17o hydroxylase activity may also be a factor in 
hyperandrogenaemia from an adrenal source. Our study implies that 
metformin treatment suppressed basal adrenal biosynthesis of 170HP and 
its responses to exogenous ACTH stimulation. This also requires further 
elucidation.
Thus, the studies presented in this thesis have not only answered some 
existing questions but also raise further possibilities for the elucidation of 
the use of metformin treament in women with PCOS.
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APPENDIX
THE ROLE OF ISAs IN PCOS
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Name
^ cru itm cm  visit -  p a n  J
M je t fo r m iw  s t u d y
Hospital number
Address Date of birth
Date of recruitment
Consent signed: Y N
GP informed: Y N
Inclusion criteria:
Diagnosis of PCO Ÿ N
Hirsutism. FG score >8 Y N
Exclusion criteria:
Contraindications to metformin: hepatic or 
renal impairment, heart failure, severe infection 
ui Uauuia, ttiooiiol dependence, pregnancy, 
breast feeding
Contraindications to Dianettc: risk factors for 
arterial disease, arterial or venous thrombosis, 
aged > 35 and a smoker
BMI > 35
Use of COCP or metformin within last 3 
months
Presenting complaint 
Hirsutism 
Oligomenorrhoea 
Amenorrhoea
Previous obstetric history
Y
Y
Y
N
N
N
Y
Y
N
N
N
N
Previous medical history
Drug history (within the last 6 months)
Social history
Smoker ?
Contraceptive use
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Treatment allocation Return visit • 6 /  Î2  after starting
Name
Date
Weight Height
BMI Waist
BP Hips
Woman’s perception of hairiness
Very bad 
Acne
normal
Ferriman Galwey score (fill in on accompanying sheet)
Menstrual cycle over last 3/12 
(Menstrual diary Y / N)
Blood results LH
LNMP
FSH
Testosterone
Finer Hair Y N
SHBG
FAl
i Rate Growth Y N
7DHAS 717 OH?
j Need Cosmesis Y N
?HbAl
7 random glucose
Improved Appearance Y ^
Insulin
Lipids
î Confidence Y N
Hair removed from following areas and placed on slide (with base to frosted end) Chin - C
Abdomen - A Sebum Anterior midthigh - T 
Forearm - F Side effects:
Loss appetite Y NNausea Y NVomiting Y NDiarrhoea Y NHeadache Y NBreast tenderness Y NChange in body weight Y NDepression Y NSkin reaction Y N
Patient happy to continue? If so, review 6 / 1 2  months
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CenQ'e number:
Study number:Panem identirlcaiion number for this trial:
CONSENT FORM
Title of project: A randomised trial to determine the efficacy of metfonnin in the 
treatment of hirsutism
Name of researcher: Dr Jane Norman / Dr Helen Lyall
(Please imuai each statement)
1. I confirm that I have read and vmdcrstand the information sheet dated February 
20ÜÜ. version I for the above study and have had the opportunity to ask questions.
2.1 understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being 
affcctecj.
3. I understand that sccuons of my medical notes may be looked at by responsible 
individuals from regulatory authorities where it is relevant to my caking pan in 
researcn. 1 give permission for cnesc individuals to have access to my records.
4.1 agree to take pan in the above study.
Name of patient Date Signature
Name of person taking consent Date Signature
Researcher Dace Signature
192
DAVID FERRIMAN ANC. J.O. CALLüJEY 
TABLE 1. Œ7i:flT10l Œ HAIR GRP0IM5 AT EXH.Œ.JT. SITES  ^
{CRfŒ 0 at a li sites indicates absence of temânel haïr,)
SHE GRACE CEFMnCW
1. LtPer Lip 1 1 A feu noirs at outer norgla
2 1 A srtall ircuEtcche at cuter nurgin.
3 1 A mxstacne extendLnq halfway fron oucer nergin.
û I Arnxstacre excending to nickiire.
2. Oûn 1 A few scattered hairs.
2 Scattered heirs with smaH coxsntratiorts.
3 it 4 CoTplete oxer, iig it  and heavy.
3. 0~est 1 Circumreolar hairs.
c ü&th mid-line hair in addition.
J Fusion of tlese arees, with three quarter oxer.
4 Ccnplete oxer.
4. Lbper Back 1 A feu scattered hairs;
2 Rather mare, stiU  scf.’.ttsred.
3 4 4 Corplete cc-er, lic fit and heavy.
5. LoiET Beck 1 A sacral tuft or" hair.
2 UÜth sore lacerai extension.
3 Three-qjETdir. o x e r .
r.-np.‘ ocy r *  / r .
6. Itper. Ptxtnen. 'l A few, mid-line hairs.
2 Fbther nore', s t ill mid-lire.
3 a u Half and fu ll ocxer.
7. Ucuizr AbcDiEO 11 A few mid-lire hairs.
2 A mid-lire streek of hair.
3 • A mid-line bend of hair.
4
1
An irxerted V-sneppd nrouth.
8. Arm 1 ' ScQTse crcwth affecting rot more then a qjBitsr
of the lifltJ sucfscs.
2 1 Mare then this; cover stiU  ircoiplete.3 4 4 i Ccnplete cover, light and heavy.
9. Foraacm 1:2 3.4 î • 1Corolets oxer of dorsal surfacs, 2 grades of
! liant and 2 of heavy grewth.
10. TVûgr 1 7 .3 ,ü ;( HS for arm.
n .  Leg l> 5 - 4  j As for arm
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Name
Address
Return visit 1 (2 /J2 after recruitmentj
M e t f o r m in  study
Hospital number 
Dale of birih
Dale of recruitmeni
Side effects:
Loss appetite Y N
Nausea Y N
Vomiting Y N
Diarrhoea Y N
Headache Y N
Breast tenderness Y N
Change in body weight Y N
Depression Y N
Skin reaction Y N
Waist
Hips
BP
Weight
Any problems 
Review in 4 /  12
194
Patient information sheet, version 1.2
A randomised, triai to determine the efficacy of metformin in the
trea tm en t o f  h irsu tism
You are Deing invited to caJce pan in a research study. Before you decide, it is 
important for you to understand why the research is being done, and what it w ill 
involve. Please take time to read the follow ing information carefully and discuss it 
with fnends, relatives and your GP i f  you wish. Ask us i f  there is anything that is not 
clear o f i f  you would like more information. Take time to decide whether or not you 
W ish to take part.
We are doing a study to compare a new treatment for body and face hair (Metformin) 
w ith the standard treatment (Dianette). We believe the new treatment may be as good 
or better than the old treatment, out we need to do this study to find out if  we are 
correct. We are asking you to help us because you have asked for treatment for face 
and / or bodv hair.
It IS up to you CO decide whether or not to take pan. I f  vou do decide to take pan. you 
w ill be given this information sheet to keep and be asked to sign a consent form. If 
you decide to take pan you arc still tree to withdraw at any time and without giving a 
reason. This w ill not affect the standard of care you receive.
I f  you are w illing to take part you w ill be ailocated either to the new treatment 
(metformin), or to the standard treatment (Dianette). Neither you nor the doctor 
looking after you w ill be able to chose which treatment you have. The new treatment 
is in tablet form, and will involve taking one tablet three times each dav. We w ill 
examine you and take 10 ml ( a small tube) o f blood from you immediately before 
you start on the treatment. 6 months after you start on the treatment, and 12 months 
after you start on the treatment. We w ill also take a sample of  hair at the beginning.
middle and end o f treatment to see if the thickness of the hair has changed. We will
also ask you about any side effects which you experience. Possible side effects of 
metr'oimin (the new creacmeni) include: decreased apoetite. nausea, vomiting and
di an huea
We hope that the treatment w ill help you. However, this cannot be guaranteed. The 
information we get from this study may help us to treat future patients with hirsutism 
(excess hair growth) better.
Sometimes during the course of a research project, new information becomes 
available about the treatment/ drug that is being studied. I f  this happens, your research 
doctor w ill tell you about is and discuss with you whether you want to continue in the 
study, i f  you decide to withdraw, your research doctor w ill make arrangements for 
your care to continue. It you decide to continue in the study, you w ill be asked to sign 
an updated consent form.
AJso on receiving new informauon. your research doctor might consider it to be in 
your best interests to wundraw you from the study. He / she w ill explain the reasons 
and arrange for you care to continue.
I f  you are harmed oy taxing part in this research project, there are no signal
cümpensauon arrangements. If you are harmed due to someone's negligence, then 
you may have grounds for a legal action, but you may have to pay for it. Regardless 
of this, if you- wish to complain about any aspect of the way you have been 
approached or treated during the course of this study, the normal National Health 
Service complaints mechanisms may be available to you.
All information which is collected about you during the course of the research will be 
kept strictly confidential. Any information which leaves the hospital will have your 
name and ildress removed so that you cannot be recognized from it.
Your GP will normally be informed that you are participating in this research. If you 
do not agree to your GP being informed, you should decline to participate in this research.
The results of the research will be submitted for publication at the end of the study. If 
you wish to obtain a copy of these results you should inform the research doctor. You 
will not be identified in any report or publication.
The study is being organised by Glasgow Royal Infirmary. The study lias been 
reviewed by the Ethics Committee at Glasgow Royal Infirmary.
If you wish tuixher information, please contact your research doctor. Dr Jane Norman 
or Dr Helen Lyall at the Department of Obstetrics and Gynaecology, Glasgow Royal 
Infirmary, 10 Alexandra Parade, Glasgow, 031 2ER, telephone 0141 211 4702
Thank you for taking part m this study, 
informauon sheet, version 1.2, prepared March 2000
You will be given a copy of this information sheet and a signed consent form to keep.
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Metformm for Weight Loss Study
Name
Address
Date o f recruitment
Consent signed Y  N
GP informed Y N
Hospital number
DOB
Inclusion criteria
BM I 29-36.9 Y  N
>37 Y N
Oligomenorrhea Y  N
Amenorrhea Y  N
PCO on U/S Y  N
FAI Y  N
Exclusion criteria
Contraindications to Metfonnin Y N
Desire to conceive Y N
Metformin in last 4 months Y N
COCP in last 2 months Y N
N il CAH; Thyroid; N ID D M Y N
Previous obstetric history 
Previous medical history 
Drug history (within last 6 months) 
Smoker
Average daily caloric intake 
Average weekly exercise
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Date
Weight
Height
BMI
Waist
Hips
BP
FG Score
Menstrual diary LNMP K
Blood Results 
1) Main Lab
-Red- Test/ SHBG/ FAI/ DHEAS/ 170HP/ Andros/ TFT 
-Grey- Glucose
-Yellow-U&EÆJFT/GGT/urate
GynLab 
-Green- Insulin 
-Red- CRP/ Leptin etc 
-Purple- Lipids
Ultrasound (TVS) 
Ovarian volume L 
FDMax
No. follicles <10mm
W x L x D W x L x D
R
Average daily caloric intake
Average weekly exercise
PPARS
NEXT VISIT DATE: 
DOSE:
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Organising body
The study is being organised by the Glasgow Royal Infirmary. The study has been 
reviewed by the Ethics Committee at Glasgow Royal Infirmary.
If you wish further information, please contact your research doctor, Dr Lyndal 
Harbome at the Department of Obstetrics and Gynaecology, Glasgow Royal 
Infirmary, 10 Alexandra Parade, Glasgow, G31 2ER,
Tel.: 0141 211 4000. Page No. 2262
Dr Richard FIeming_at the Department o f Obstetrics and Gynaecology, Glasgow 
Royal Infirmary, 10 Alexandra Parade, Glasgow, 031 2ER, Tel.: 0141 211 4703.
Thank you for volunteering to take part in this study.
You will be given a copy of this information sheet and a signed consent form to keep. 
CONSENT
1. I confirm that I have read and understood the information sheet dated 29* August 2001 (version 
1.2) for the above study and have Iwd the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am fiee to withdraw at any time, witliotil 
giving reason, without my medical care or legal rights being afiTectcd.
3. I understand tirat sections of any of my medical notes may be looked at by reqxinsible individuals 
from regulatory authorities where it is relevant to my taking part in research. I give permission for 
these individuals to have access to my records. ■
4. I agree to take part in lire above study
Name of Patient Date Signature
Name of Person taking Consent Dale Signature
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Patient in fo rm a tio n  sheet: version  3 13/09 /2 0 0 !
A trial to determine the efficacy of metformin in the treatment 
of weight loss in women with poiycystic ovary syndrome
P ag e  1 o f  3
You are being invited to take part in a research study. Before you decide, it is 
important for you to understand why the research is being done, and what it w ill 
involve. Please take time to read the following information carefully and discuss it 
with friends, relatives and your GP i f  you wish. Ask us i f  there is anything that is not 
clear or i f  you would like more information. Take time to decide whether or not you 
wish to take part.
The study
Metformin, a drug normally used in diabetes, has been shown to improve ovarian 
function, aid weight loss, and improve the profiles o f fats (cholesterol) circulating in 
the blood in women with polycystic ovaries. Women who were above average weight 
did not respond as well as those w ith normal weight. We are now carrying out a study 
to find out i f  a higher dose o f metformin, or i f  a longer course o f treatment is effective 
for weight loss and blood cholesterol levels. We think that heavier women may need a 
higher dose than used previously, but we need to find out i f  we are correct. We are 
asking you to help us find out if, and i f  so. how much, weight you w ill lose by taking 
the treatment.
Conditions
It is up to you to decide whether or not to take part. I f  you do decide to take part, you 
w ill be given this patient infomiation sheet to keep and be asked to sign a consent 
form. I f  you decide to take part you are still free to withdraw at any time and without 
giving a reason. This w ill not affect the standard o f care you receive.
Details about the study
I f  you are w illing to lake part you w ill be allocated to either the higher or lower dose 
o f Metlbrmin. Neither you nor the doctor looking after you w ill be able to choose 
which dose you w ill have. The treatment for both dosages is in tablet form and w ill 
involve taking one tablet three times a day. We w ill examine you and take 30ml o f 
blood from you immediately before you start on the treatment, 4 months after you start 
on the treatment, and 8 months after you start on the treatment. We w ill also measure 
your blood pressure, height and weight, and you w ill be asked to keep a diaiw o f your 
menstrual periods for the 8 months. We w ill also ask you about any side-effects o f 
Metformin that you may experience. This w ill involve phoning you each month for 4 
months. Possible side effects include: decreased appetite, nausea, vomiting and 
diarrhoea.
We hope that this treatment w ill help you. However, this cannot be guaranteed. The 
information we get from this study may help us revise how we treat women for weight 
loss in the future.
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Developments during the study
Sometimes during the course o f a research project, new infonnation becomes 
available about the treatment/ drug that is being studied. I f  this happens, your research 
doctor w ill tell you about it and discuss with you whether you want to continue in the 
study. I f  you decide to withdraw, your research doctor w ill make arrangements for 
your care to continue. I f  you decide to continue in the study, you w ill be asked to sign 
an updated consent form.
Also on receiving new information, your research doctor might consider it to be in 
your best interests to withdraw you from the study. He/ she w ill explain the reasons 
and arrange for your care to continue.
Risk
Metformin has been used extensively to sensitise people to insulin as in diabetes. It 
has been shown to be a safe drug in practice. It does not lead to abnormal circulating 
sugar levels. It has not been implicated in the development o f liver dysfunction as 
have some other insulin sensitising agents.
Complaints
I f  you are harmed by taking part in this research project, there are no special 
compensation arrangements. I f  you are harmed due to someone's negligence, then you 
may have grounds for a legal action, but you may have to pay for it. Regardless o f 
this, i f  you wish to complain about any aspect o f the way you have been treated or 
approached during the course o f this study, the normal National Health Service 
complaints mechanisms may be available to you.
Confidentiality
All information that is collected about you during the course o f the research w ill be 
kept strictly conlldcntial. Any information which leaves the hospital w ill have your 
name and address removed so that you cannot be recognised from it.
Your GP w ill normally be informed that you are participating in this research. I f  you 
do not agree to your GP being informed, you should inform us o f this fact.
On completion
The results o f the research w ill be submitted for publication at the end o f the study. I f  
you wish to obtain a copy o f these results you should inform the research doctor. You 
w ill not be identified in any report or publication.
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O rgan ising  body
The study is being organised by the Glasgow Royal Infirmary. The study has been 
reviewed by the Tlhics Committee at Glasgow Royal Infirmais.
I f  you wish further information, please contact your research doctor. Dr Lyndal 
Harbornc at the Department o f Obstetrics and Gynaecology. Glasgow Royal 
Infirmary, 10 Alexandra Parade, Glasgow, G31 2ER,
Tel.: 0141 211 4000. Page No. 2262
Dr Richard Fleming_at the Department o f Obstetrics and Gynaecology, Glasgow 
Royal Infirmary, 10 Alexandra Parade, Glasgow, G31 2ER, Tel.; 0141 211 4703.
Thank you for volunteering to take part in this study.
You w ill be given a copy o f this information sheet and a signed consent form to keep. 
CO N SEN T
I . I confirm that 1 have read and understood the information sheet dated 29'*’ August 2001 (version 1.2) 
for the above study and have had the opportunity to ask questions.
2. f understand that my participation is voluntary and that I am free to withdraw at any time, without 
giving reason, without my medical care or legal rights being affected.
3. 1 understand that sections o f any o f my medical notes may be looked at by responsible individuals 
from regulatory authorities where it is relevant to my taking part in research. I give permission for 
these individuals to have access to my records.
4. 1 agree to lake part in the above study
Name o f Patient Date Signature
Name o f Person taking Consent Date Signature
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Synacthen Study in PCOS: Laboratory Data Sheet
Sheet 1
Pi. Sticky Label
PCOS (20; 10,10) / C O N TR O L (20; 10,10) Random: YOB,odd=Rx, even=NoRx
Visit 1 (Prostap Day) Date: Last Menstrual Period:
Ultrasound Scan:
Largest Follicle: R: L : Ovarian Volume:
PCO appearance R: V / N L : V / N
ANTHR O PO M ETRIC  DATA
Kgs: Hi: Waist (cms): Hip (cms):
HIRSUTISM / ACNE / ACANTHOSIS NIGRICANS / ALOPECIA 
M ENSTRUAL FREQUENCY K:
NMR OLIGOMENORRHOEA POLYMENORRHOEA
START Prostap: DATE:
Gyn.Lab. E2
Progesterone
Testosterone
SHBG
LH
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Synacthen Study in PCOS: Laboratory Data Sheet
Sheet 2
V ^ i s i t  2  (1 4  days post prostap) Date:
Ultrasound Scan: Largest Follicle: R:
PCO appearance R: Y / N L : V / N
Last Menstrual Period:
Ovarian Volume:
Haematology HbIC
Biochemistry Insulin,
Glucose
Gyn.Lab. E2
Testosterone
Progesterone
Androslenedionc
170HProg
DHEAS
LH
FSH
SHBG
S y n ^ C t h c n  T e s t  1 (ZSOug leiracosaclnn iv)
Time E2 T A4 170HP DHEAS
TO
T30
T60
T90
START M ETFO R M IN  [SOOmg Ids] (or NOT): V / N
V i s i t  3  (14 days post starting metformin) Date:
Ultrasound Scan: Largest Follicle: R: L:
PCO appearance R: V / N L: V / N 
S y n S C t h c n  T e s t  2  (250ug tetracosactrln iv)
Last Menstrual Period:
Ovarian Volume:
Time i E2 1 T | A4 I70HP DHEAS
, TO ............. . ...........
'T3Û .......................„ , .4 „ _ ______ i ............ ..... iT6p ............. ..............................1.................... j
T90 i !
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Study to investigate the influence of metformin on adrenal androgen 
output.
CONSENT
I. (Name)....................................................
of (Address)....................................................
agree lo take pan in the Research Projcct/Sludy Programme described above.
Dr/Mr.......................................................has explained to me what I have to do. how it might affect me
and the purpose of the Research Projcct/Sludy Programme.
Signed Date *
Witness..............................................................  Dale...
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Study to investigate the influence of metformin on adrenal androgen 
output.
Polycystic ovary syndrome (PCOS) is a common cause of failure to ovulate 
(produce an egg) each month. This may lead to difficulties in achieving a pregnancy. 
The cause of PCOS is poorly understood, but many women with PCOS have 
increased levels of androgens (the male type of hormone) in the blood. Androgens arc 
produced normally in the ovary and also the adrenal gland (a gland which lies above 
each kidney).
Insulin (a hormone) in our body as well as other actions, controls our blood 
sugar (glucose). PCOS may be associated with resistance to the actions of Insulin, 
which means the body is less sensitive to insulin. Metformin is a drug which has been 
widely used in the treatment of diabetic patients as it helps the body to use glucose 
and therefore helps insulin to work. There is evidence that metformin can improve 
menstrual cycle regularity and fertility in women with PCOS who have high blood 
levels of androgens by improving the action of insulin.
One of metformin’s effects is to rapidly reduce the level of testosterone (one 
specific androgen hormone) in the blood. However it is impossible to detect by 
measuring androgen levels in the blood whether metformin is exerting its effect on the 
ovary or the adrenal gland. We aim to test whether androgens from the adrenal gland 
may be affected by metformin treatment. Metformin may cause you to feel off your 
food and may cause nausea, vomiting and diarrhoea, but these are usually short-lived.
In order to answer our question, we will suppress the function of the ovary 
using an injection (gonadotrophin releasing hormone analogue, GnRHa) which 
temporarily stops the ovaries producing hormones. This is similar to the buserelin 
(snuff) which you take during the course of your treatment. We will then stimulate 
the adrenal gland using a test widely used in medical practice. This is called a 
Synacthen test. You will have a blood sample taken then receive a small (250 
microgram) injection of Synacthen (Tetracosactrln). Thirty and sixty minutes later 
further blood samples are taken. As this is such a small dose problems associated with 
the injection are very unlikely. However rarely, Synacthen can be associated with an 
allergic reaction.
We will ask you to attend the hospital for an injection of the GnRH analogue 
Prostap (leuprorelin acetate). Two weeks later you will have a Synacthen lest. This 
involves a blood lest then a small injection. Two further blood tests will then be taken 
30 and 60 minutes after the injection.
Some of you (whether you have PCOS or are a person with a regular menstrua! 
cycle) will then be asked to take metformin 500 mg three times daily for 14 days. A 
second synacthen test will then be performed which will be the same as previously.
Please note that if you agree to take part, this Research Project may be of little 
or no benefit to you but the results may help other patients in the future.
If you do not want to take part in the Research Project or if at any time you 
wish to stop taking part you may do so. The care which you arc presently receiving 
will not be affected in any way.
If you do agree to take part in the Research Project, your own General 
Practitioner will be told and will be given details of information about any care which 
you are to receive.
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PH Y SICA L A C LI ViTY QUESTI ONNAI RE
rac laUomac quoUoiiuairc u «juplc >rny of uicajMjriiig Uic aiiiouiii of pJiv«ical activiiy you 
have done over ;uc l;wl ircdc TJic qwcaUonnairc b «iriclJy confidciiti^l ao try and ««jucr aJi 
<lucsUoiu sw honatJy us you cuiu Obviously, lUc ovcraJI accuracy dc|>cud.i on ilic accuracy of 
individual aiuwcr». The questionnaire is not a test so tlicrc is no pass or fail.
May I taltc this opportunity to (iiaiik you for taking tUe time to fill out tlic questiomiairc
(1) Do you consider voursclfio be icgutarly aciivc now Y YES j | NO 1 1
\
(Plciic nek one box;
If YES go lo question (2). If NO, were yon regniarly physically active.
Î months ago ? YES I 1 NO 1 1
t'l miatllis ago ■' ;YES | i NO 1 1
Now go to question (2)
(2) Please raid Uiroitgli all U>c ciicgoncs listed bdow and Uck 0N5 oos lor the ctiicgoo’ wtncli 
best describes how physically active yon lutvc been ova titc last si.s inontlis.
(!) 1 am not regularly active and do not iiiicnd to be so in the next six nionlhs {
(ii) I :un not regularly physically active but ant Ututking aboui "Parting to do so 
in ilic next six niuntlu.
(iii) I do some physicil activity but not uiough to meet liic description of 
fcguLif physical activity given above.
(iv) I  a m  r c g n t a r l y  p h y s i a d l y  a c t i v e  b u t  o n l y  b e g a n  i n  liic l a s t  s i x  i n o n i i i s .
(V ) I am rcgiitarly pliysicilly active and liavc beat for six iiionttis or longer.
I 1
i I
1 I 
I 1
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(4) Wivjk Iasi weci» (ypicaJ of the iitiiuuiil o f  pliysical ;icllvi(jr you usuuily do 7 
(Please (icK one box)
\'ES I I
NO-I USUALLY DO MORE | |
NO-1 USUALLY DO LESS ( j
ir you usually do more, uoraiuUy how mucii more (iti iiiinulct) and of which activity 7
If you usually ao less, nurnlally how much less (in minutes) and of which acliviCy ?
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{V) Cycling lur plcaxurc ui lu work '!
MON TU1ÙS WKI) r i i u R S  1 K id  1 .Sa T SUN TOTAL j
. L ..... 1 I 1
(vi) ParticipalJitg in a .spori, leisure activiiy ui' iranung
hv uictudc E.g. exercise classes. Iboilxdl, swimming, golf, jogging. aUiiciics. cic.
Do not inciutlc E g. dufls. siiookcr/pooi. fisliiiifi. playing a musical iusinmicni. c;c.
MON TUGS WEI) i THÜKS 1 l-'KI .SAT SUN TOTAL 1
___ ____ ...... - 1 ..........1...., _ !-----------
(vii) Any oUicr pliysieal activiiy if uol aircmly covered ? (please >vn(c in)
Please nil in below how many minutes you spent each day doing these olhec physical activiiio
MON I'UES 1 WKI) i THUUS KKl ' SAT Si(,N. total !
1 I 1 1.......... I_________1
(3) Plcîisc nil in below liow many caloncs you burn I cacli day wJiilsi nearing llic C.illrac 
device.
MON TIJES \ WED ) TIUIRS FRl SAT t SUN TOTAL'
........ . , . . j 1 ! ~------- !------------ 1....... .. ... ______ — J !L _ _  . . ] f
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( 3 )  111 ( h e  p a M  w e e k  h v w  m a n } ’ i i i i i i i U o '  U i u  y o u  a j i o i U  c a d )  d a y ;
(!) WaJkini; a l wui1v ?
E g . wnlKiug up or down «(airs, walking (o and from your d c i k .  "doing (lie l O n n c I s " .  etc.
iMON TUKS : WED ! T1IUK.S KUI SAT ! SUN I TOTAL '! !
!.. ‘ . J .J__L .
l>‘i Walking ouiwiili »orU 7E.g walking lo I lie shops, walking your dog, walking lo work. Iniiwalkmg. walking for 
pleasure, walking up and down sians. cic.
MON TUES 1 WED ( THURS KRI SAT SUN ! TOTAL 1
; ..
i l l.1 . 1 . . ! . 1
i ’M) Doing active homework ?
Do Include g. hoovering, scrubbing floors, bed makmg lunging vn( nashmg. uc. 
Dll not include /*.' g. sewing, dusitng. washing dislics.4)rcparing food. cic.
! MON TUES 1 WED ! THURS KRl SAT j SUN 1 TOTAL Ii. L..j__________............! ! i
( j v )  D a n c i n g  7
E.g. disco, line. cotnn;y c(c.
1 MON TUES WEI) 1 THURS KRl SAT . SUiN 1 total :
1— ..........
i ! 
1
: 1 i :
-----------------!-----------------i-----------------!----------------J
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P E R S O N A L D E T A IL S
NA M L:
TE LE P H O N E  NUiVlDER
ACE IN YEARS :
TODAY'S PATE:__________ _________________ _
( I )  Arc you currcniJy employed ' VES 1 ] NO
(please lick one box)
(2) If NO. aid of qucsUomuirc.ylf YES. 
tuivc you clinitgcd your employme:x 
or ihc kind of work you do iu die Iasi
mondi Y YES | | NO | j
(please Uck one box)
(.1) i f  NO , ciicl of questionnaire. I f  YES. Itas 
this resulted in an increase in lUc amonni
of physical activily you do V YliS I j NO 1 |
If NO. end of qucsiiotiiuurc. If YES. how and by how much V
ENÜ OF q u e s t io n n a ir e  -  THANK YOU
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Surnam e........
First Name(sj 
Address . , ,
Phone No.
Date ot Birth
FOOD INTAKE QUESTIONNAIRE FOR OFFICE USE O N Li
Subject ID
Questionnaire No 
Group Code 
Sur.rey No 
Male / Female
Data of Survey.
The following questions are about the foods you USUALLY eat.
Please indicate the number of days per week mat you eat each item on 
average. Ring the answer as m these examples;
If you eat tne food every day. ring 7 7 6 5 4 3 2 1 F R
If you eat the food three days/week, ring 3 7 6 5 4 3 2 1 F R
If you ea tlhe  food once a fortnight, ring F 7 6 S 4 3 2 1 F R
If you rarely or NEVER eat the food, ring R 7 6 5 4 3 2 1 F R
P L E A S E  A N S W E R  E V E R Y  Q U E S T I O N
ll-U
14-15
r r n
ie -18/1flS -lC3
I 120-21
122-23□ T E J
24.Z»164-165
I BREAD _______ ________ _________________________
H o w  o f t e n  d o  y o u  e a t  t h e  f o l l o w i n g  b r e a d s  a n d  h o w  m a n y  s l i c e s  d o  y o u  h a v e  p e r
d a y ?
No days/w eek No. slices or Size of
ro lls p e r day slices or rolls
White or high fibre / 6 5 4 3 2 1 F K    rhick/medium/thin
Large/small
Brown nr wheatgerm 7 S 5 4 3 2 1 F R   Thick/medium/thin
Large/small
Wholemealfchapatis 7 6 b 4 3 2 l F R................ ...................  ThicWmedium/thm
Largefsmaii
Chapatis
Bread rolls / h b 4 3 2 t F R Whitabrown/
wholemeal
Crispbread, Ryvita /  ü b 4 3 2 i F R ..................
Of cream crackers
H o w  o f t e n  d o  y o u  e a t  j a m .  m a r m a l a d e  o r  h o n e y  7 6 5 4 3 2 ' t F R
on bread?
26-28
--- - j-----
WvHBml i|i».iMiiim»aBiJ 32
□ □
I 1
—I I- ..J  40
38-39
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BREAKF AS I CEREALS___________ ___
FOR OFFICE USE Q N l Y
H o w  often do  you  e a t  t h e  f o l l o w i n g  c e r e a l s ?
I CornnakKS or Froslies / 6 5 4 3 2 1 F R
2. Sugar Puffs, Special K. R icicles or Rice Cnspies 7 6 5 4 3 2 1 F R
3. IWuesli or Fruif n'Fibre 7 S 6 4 3 2 1 F R
4. Weetabix, Advantage or Shredded W heat 7 6 5 4 3 2 1  F R
b Bran Flakes or Sultana Bran 7 6 5 4 3 2 1  F R
6 Pcrndge or Ready Brek 7 6 5 4 3 2 1 F R
7 All Bran 7 6  5 4 3 2  1 F R
Other Cereal 7 6 5 4 3 2 1 F R
Please specify brand ...............
H o w  m a n y  t e a s p o o n s  o t  s u g a r / h o n e y  d o  y o u  a d d ?  . . . . . . . . . . . . . . . . .
How often do you have wheat bran? 7 6 5 4 3 2 1 F R
! MEATS           ""
Sausages 7 6 S 4 3 2 1 F R
What type of sausages ao you iiave? i Pork
2 Beef
□  a
□□ 4 5
H o w  o f t e n  d o  y o u  h a v e  t h e  f o l l o w i n g  m e a t s ?
I n c l u d e  a l l  f o r m s  o f  e a c h  m e a t ,  e g  u s e  i n  s t e w s ,  c a s s e r o l e s ,  l a s a g n e ,  c u r r y  e t c .
Beef 7 6 5 4 3 2  1 F R  ) ]
Lamb 7 6 5 4 3 2 1  F R  , I'__ lee
Pork 7 6 5 4 3  2 i F R  | |i----149
Bacon 7 6 5 4 3 2 1 F R
Iso
Ham 7 6 5  4 3 2  1 F R  ,----- 1
Chicken or other poultry 7 6 5 4 3 2 1 F R
Canned meat (e g comeo beef) 7 6 5 4 3 2 1 F R  Z Z z j
3 Pork and Beef
4 Turkey ] 55
5 Low Fat
M eal pies/pasties - shop bought 7 6 5 4 3 2 1 F R Issfdeat pies/pasues - home made 7 6 5 4 3 2 1 F R ---------------------- ;------- 1
Liver/kidney/hean 7 6 5 4  3 2 1 F R
Do you usually eai the fat on meat Yes / No
□ ,
L ] «
- - - - - - - j
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How often do you eat Uie following fish? 
White fish {cod/haddock/plaice/fish fingers) 76  5 4  3 2 1 F R □ „
□«
Kipper/herring/mackerel/trout (including canned) 7 6 5 4 3 2 1 F R
Pilchards/sardines/salmon (including canned) 
7 una (including canned)
7 6 5 4 3 2 1 F R 
7 6 5 4 3 2 1 F R
VEGETABLES & SAVOURY DISHES J
How often do you have the following vegetable» or dishes?
Potatoes - boiled oi mashed 7 6 5 4 3 2 1 F R □«
Potatoes - jacket 7 6 5 4 3 2 1 F R □ „
Chips - shop buughi or oven chips 7 6 5 4 3 2 1 F R 1— 1 J w
Chips " homecooked 7 6 5 4 3 2 1 F R • 1 1 ... J  47
Potatoes - roast 7 6 5 4 3 2  1 F R □  „
Peas 7 6 5  4 3 2 1 F R
Other green vegelables/salads 7 6  5 4 3 2  1 F R
Carrots 7 6 5 4 3 2 1 F R □  n
Par snips/swedes/luinips 7 6 5 4 3 2 1 F R O .
Baked beans 7 6 5 4 3 2 1 F R
Butter Deans or broad beans 7 6 6 4 3 2 1 F R LJ„
Lentils, Chick peas or üahi 7 5 5 4 3 2 1 F R □ „
Onions icooked/raw/ptckled) ? G 5 4 3 2 1 F R U n
Spaghelli/olher pusla 7 6 5 4  3 2 1 F R
Rice (NOT pudding nee) 7 6  5 4 3 2  1 F R Î--1
i— iTB
Quiche 7 6 5 4 3 2 1 F R
Pizza '6 5 4  3 2 1 F R ,----
Vegetaiian pasties 7 6 5 4  3 2  'F R 1--1
w - J s i
j BISCUITS, CAKES &  PUDDINGS 1
How often do you eat the following items?
Digestive btscuits/piain biscuits 7 6 5 4 3 2 1 F R : 1
Other sweet biscuits 7 6 5 4 3 2 1  F R IÉI .fcejl 13
Chocolate 7 6 5 4 3 2 1 F R r - 1
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Sweets 7 6 5 4 3 2 1 F R
Cnsps 7 Ü 5 4 3 2 1 F R
Nuts 7 6 5 4 3 2 1 F R
ice cream 7 6 5 4  3 2  1 F R
Low fat yogurt 7 6 5 4  3 2  1 F R
Low calone yogun (eg Shapej 7 6 5 4 3 2 1 F R
Other yogurts 7 6 5 4 3 2 1 F R
Fruitcake/sponge cake - shop bought 7 6 5 4 3 2 1 F R
Fruitcake/sponge cake • homemade 7 6 5 4 3 2 1 F R
Fruit tart/jam tart - stiophought 7 6 5 4 3 2 1 F R
Fruit tan/jam tart - home made 7 6 5 4 3 2 1 F R
Milk pudding (eg nce/lapioca/macaroni| 7 6 5 4 3 2 1 F R
W hat type of milk do you use lor milk pudding?
1 Ordinary/wfiole
2 SemFskimmed
3 Skimmed
4 Canned milk pudding • ordinary
5 Canned miik pudding - low fat
FRUIT . ............. ........... J
How often do you have fruit canned m syiup’’ 7 6 5 4 3 2 1 F R
How often do you have fruit canned ir luice? ■/ 6 5 4 3 2 1 F R
How many apples do you have per week?
How many pears do you have per week?
How many oranges/grapefruit do you have per week?
How many bananas do you have per weex?
EGGS Si MILK PRODUCTS |
□□□□
a
□ «
□ «
□ «
I—i___ »7
□□□
□
GI— I
I____ I
91
W
100
101
102
103
How m any eggs (Jo you usually eat per week?
104-105
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Roughly how  m uch milk do you drink In a day in te«/coffeWmJ(ky drink»/c*r«al«?
1 None
2 Half a pint or less
3 Between half and one pint
4 One pint or more G It»
what type of milk do you have? 1 Whole
2 Semi-skimmed
3 Skimmed
A More than one type
How m uch cream do you use per week?
(1 tabiespoon=20g. small cartons  ^150g; large carton-300g) .............
How m uch cheese (excluding cottage cheese) do you 
usually eat per week?
(Suggestion; divide amount bought foi household by number of people m house) 
How often do you eat cottage cheese? 7 6 5 4 3 2 1 F R
iFATS
W h a t  d o  y o u  u s u a l l y  s p r e a d  o n  b r e a d ? 1 B u t t e r
2 Itflarganne ■ polyunsaturated
3 Margarine - other soft (tub)
4 Margarine - hard (block)
5 Low fat spread • polyunsaiurated 
0 Low fat spread • other
7 Laro. dripping, solid vegetable oil
8 Very low fat spread (25% fat)
0 Bread eaten dry
Brand name & description on packeLtuS
How much butter/margarlne/sprcad du you usually eat par week?..
(One block or small tub *  250g. Spread on one slice of bread: Thinly» 5g. Mcdium-Ôg; 
rhickty=13g.)
G 107
3GG,».,
x n
G 1 1 4
G O 115-116
 ^ L J 117.119
H ow often do you have food which is shallow fried?
(e.g ., fish/onions/mushrooms/tomatoes/eggs) 7 6 5 4 3 2 1 F R G 1 3 0
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W h a t  B R A N D S  o f  f a t  d o  y o u  u s e  i n  c o o k i n g ?
S h a l l o w  F r y in g  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
^^ hips . ...  .....
R o a s t  P o t a t o e s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Home made cake ..............................................
Home made pastry.............................................
solid/UquiO 
solid/i tquia 
sotid/Irquid/eaten out
□□□□□
121
122
123
124
Idrxnics'
H o w  m a n y  c u p w  o f  t e a  d o  y o u  h a v e  p e r  d a y ?  
H o w  m a n y  t e a s p o o n s  o f  s u g a r / i i o n e y  p e r  c u p ?
H o w  m a n y  c u p *  o f  c o f f e e  d o  y o u  h a v e  p e r  d a y ?  
H o w  m a n y  t e a s p o o n s  o f  s u g a r f h o n s y  p e r  c u p ?
H o w  O f t e n  d o  y o u  h a v e  f r u i t  J u i c e / s q u a s h / r p z y  
d r i n k s  ( N O T  l o w  c a l o r i e ) ?
W h i c h  o f  t h e s e  d o  y o u  u s u a l l y  h a v e ?
H o w  o f t e n  d o  y o u  h a v e  d r i n k s  c o n t a i n i n g  a l c o h o l ?
W h e n  y o u  d r i n k ,  h o w  m a n y  d o  y o u  h a v e ?
7 6 5 4 3 2 1  F R
1 Natural Juice
2 Squash
3  F i z z y  D r i n k
4 More than one
7 6 5 4 3 2 1  F R
r  n  
□
121F12Ï
1120
□ Z ] 129-130
G
G
G
132
133
194
please specify now many drinks ot each type per occasion. 
Beer/stout/cider Number of pints
Wine Number ot glasses
Sherry/port/vermouth Number ot glasses
Spirits No. of Single measures
r 1 3 S -1 3 6!----1
I____ IGG
1 3 7
13A
139
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HEIGHT, WEIGHT & ACTIVITY
W h a t  i s  y o u r  h e i g h t ?   f t
W h a t  i s  y o u r  w e i g h t ?   s t
H o w  p h y s i c a l l y  a c t i v e  i s  y o u r  o c c u p a t i o n ?
H o w  p h y s i c a l l y  a c t i v e  i s  y o u r  l e i s u r e  t i m e ?
Q u e s t i o n s  f o r  w o m e n  o n l y .
A r e  y o u  p r e g n a n t ?
A r e  y o u  b r e a s t  f e e d i n g ?
i n s  O R  . . .
l b s  O R
iADPrflONAL QUESTIONS
cm
K g
1 N o t  v e r y  a c t i v e
2 Moderately active
3 Very active
4 Not working
1 Not very Active
2 Moderately active
3  V e r y  a c t i v e
Y e s  /  N o  
Y e s  I N o
140-1*3
[ Z E T O Q
iz m jG
1*4-147
□
□
1*4
14»
□□ ISO161
L U E J m .,.
O O Luna,».lSS-157 ISO
t h a n k  y o u  v e r y  m u c h  k o r  y o u r  h e l p
D i e t  C o d e 141
218
\■ - ' , "Y
■:
EXAMPLE OF FACIAL HIRSUTISM
EXAMPLE OF ABDOMINAL HIRSUTISM
219
EXAMPLE OF MALE PATTERN BALDING
EXAMPLE OF CENTRAL OBESITY 220
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